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SUMMARY.
Herpes simplex virus type 2 (HSV-2) has been associated 
with cervical cancer for many years and certain regions of 
both the HSV-1 and the HSV-2 genome can induce 
transformation of tissue culture cells. However, no virus 
transforming protein has yet been identified and no region 
of viral DNA appears to be stably retained in transformed 
cells or tumours. This implies that continued expression of 
a virus protein is not required and has resulted in the 
proposal that HSV transforms cells by a "hit and run" 
mechani sm.
HSV infection can generate chromosomal breaks together 
with amplification and rearrangement of cellular genes. 
Additionally, infection of permissive cells with 
UV-inactivated HSV-1 and of non-permissive cells with HSV-2 
leads to an increase in the mutation frequency of the 
cellular hypoxanthine-guanine phosphoribosyltransferase 
gene. HSV-1 was also found to increase the mutagenic 
frequency of a plasmid-based gene located on the shuttle 
vector pZl89. These mutagenic effects resemble changes 
produced by chemical carcinogens and may represent a 
mechanism for transformation which would not require the 
retention of viral sequences.
The cause of mutations occurring in HSV-infected cells 
is unknown but could be connected with the destabilization 
of doxyribonucleoside triphosphate (dNTP) pools seen in 
infected cells as studies of both prokaryotic and eukaryoti 
systems have stressed the importance of dNTP concentrations 
in mediating base substitutions and misincorporations. The 
HSV enzyme ribonucleotide reductase has a potential role in 
the destabilization of cellular dNTP pools since, unlike it 
cellular counterpart, it is not allosterically regulated. 
This is supported by results which show that a mutant 
cellular enzyme, which was deficient in allosteric control, 
raised the cellular mutation rate in transfected cells.
In order to study the effect of HSV-2 ribonucleotide 
reductase on mutagenesis, expression vectors were 
constructed which contained the large (RRl) and small (RR2) 
subunits of the HSV-2 ribonucleotide reductase under the 
control of the inducible mouse metallothionein promoter,
which responds at the transcriptional level to heavy metals 
such as zinc and cadmium. These constructs were used in 
mutagenesis assays which involved monitoring the mutation 
frequencies of the cellular adenine
phosphoribosyltransferase gene (aprt) in Chinese hamster 
ovary (CHO) cells and of the plasmid-based suppressor tRNA 
gene (supF ) in human cells. Increasing the amount of enzyme 
expression by zinc-induction did not increase the 
mutagenesis of the marker genes in either assay suggesting 
that virus ribonucleotide reductase expression may not be 
mutagenic in HSV-infected cells. Experiments using the HSV-1 
mutant viruses tsl207 and tsl222, which are temperature 
sensitive (ts) for RRl and RR2 respectively, support this 
finding since these viruses were as mutagenic as wild type 
HSV-1 at both the permissive (P) and the non-permissive 
(NPT) temperatures.
Although expression of the viral ribonucleotide 
reductase does not appear to be the cause of increased 
mutagenesis in infected cells, the possibility that enzyme 
activity is capable of producing a mutagenic effect cannot 
be ruled out. The mutagenesis assays described above 
involved only the transient expression of the viral enzyme 
and the lack of any mutagenic effect might be due to 
inefficeincies in the transfection procedure and/or 
insufficient expression of the viral genes. The cellular 
enzyme would also be present and might counteract dNTP pool 
imbalances brought about by viral ribonucleotide reductase 
expression. To address these problems, NIH3T3 and CHO cell 
lines were constructed using HSV-2 ribonucleotide reductase 
expressing plasmids that contained the G418-resistance gene 
(neoR). Mutations causing morphological transformation were 
assayed in NIH3T3 cells while in CHO cells the aprt gene was 
assayed. None of the G418-resistant cell lines tested were 
found to express RRl or RR2 and further lines will be 
screened for expression before repeating the experiment.
The ribonucleotide reductase constructs were used to 
generate transgenic mice to determine the effect of enzyme 
expression in an animal model. The mice did not appear to be 
affected by the presence of a large number (50+) of viral 
ribonucleotide reductase sequences. Viral ribonucleotide 
reductase RNA was detected in these animals, however, it did
not appear to be inducible and protein could not be 
detected.
Both HSV-1 and HSV-2 increase the spontaneous mutation 
frequency of the plasmid based supF gene by around 6-fold 
which is in agreement with values obtained by others in 
similar studies. Of the induced mutations, roughly 30% are 
due to large structural changes which result in plasmids 
which have altered restriction maps. The remaining mutations 
are presumably caused by small changes and point mutations. 
Such changes could be examined in future studies, by 
sequencing.
Experiments were performed to identify the mutagenic 
agent in infected cells using a range of HSV-1 mutant 
viruses, UV-inactivated HSV-1 and incomplete HSV-1 virus 
particles in the pZl89 mutagenesis assay. The mutagenic 
effect on the supF gene was still apparent following 
infection with the mutant virus tsK at the NPT, with d!1403 
and in!814 at low multiplicities of infection and with 
UV-inactivated HSV-1. This suggests that viral gene 
expession is not required. The virus tysl204 was not 
mutagenic at the NPT, when cell penetration does not occur, 
and this observation together with the apparent lack of 
requirement for viral gene expression, indicates that the 
mutagenic effect may be caused by some part of the incoming 
virion. L-particles, which do not contain HSV DNA or capsid 
proteins, but which do enter the cell, were not found to be 
mutagenic, implying that the effect may be caused by one of 
these components. Transfected, non-infectious, cleaved HSV 
DNA is mutagenic in cells which suggests that the HSV DNA 
itself may be the mutagenic agent. HSV DNA could exert a 
mutagenic effect by integrating into the cellular genome 
causing disruption of a gene sequence or by exerting some 
promoter/enhancer function. Alternatively, the HSV DNA, 
which is nicked, could trigger an error-prone DNA repair 
mechanism. The sequencing of mutations occuring following 
HSV infection may cast light on this. Future studies might 
also include experiments to determine the effect of capsid 
proteins on mutagenesis.
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1SECTION A; INTRODUCTION.
The aim of this introduction is to give a summary of 
herpes simplex virus biology followed by a more detailed 
account of two relevant areas of study, namely,
HSV-transformation and the HSV enzyme ribonucleotide 
reductase.
1. THE HERPESVIRUSES.
1.1. Classification.
The family Herpesviridae comprises more than 80 species 
which infect a wide range of higher eukaryotic hosts 
(Roizman and Batterson, 1985) . The family is defined by 
certain morphological features which are listed below:
(i) The core is an electron dense fibrillar spindle that 
is surrounded by the double-stranded DNA of the viral genome 
(Epstein, 1962; Furlong et al., 1972; Nazarian, 1974).
(ii) The capsid surrounds the core and is in the form of 
an icosahedron, approximately lOOnm in diameter, which is 
composed of 162 capsomeres (Wildy et al., 1960).
(iii) The tegument is a layer of proteinaceous material 
between the capsid and the envelope (Schwartz and Roizman, 
1969; Morgan et al., 1968; Roizman and Furlong, 1974).
(iv) The envelope surrounds the capsid and tegument. It 
is derived from budding through the nuclear membrane and 
harbours numerous virus-encoded glycoprotein spikes (Morgan 
et al., 1959; Wildy et al., 1960; Asher et al., 1969; Spear 
and Roizman, 1972).
All the herpesviruses also exhibit the ability to 
persist in a latent state in their hosts and they have been 
classified into three sub-families based on host range, 
duration of the reproductive cycle, cytopathology and 
characteristics of latent infection (Matthews, 1982;
Roizman, 1982).
Alpha herpesviruses may have a wide or narrow host range 
in tissue culture. The reproductive cycle is short (less 
than 24 hours) and causes destruction of infected cells, 
however, latent infection is frequently established in
2neuronal cells. Members of this sub-family include the human 
herpesviruses HSV-1, HSV-2 and VZV.
Beta herpesviruses have a narrow host range in tissue 
culture. Viral replication and lytic progression are slow 
with replication resulting in an enlargement of cells.
Latent infections are usually established in secretory 
glands, lympho-reticular cells and kidneys. An example of a 
member of this sub-family is HCMV.
Gamma herpesviruses also have a limited host range, 
replication occurs only in T- or B-lymphocytes in vivo and 
latent infection is frequently established in lymphoid 
tissue. This sub-family includes EBV.
The herpesviruses have also been classified on the basis 
of characteristic repeated DNA sequences within their 
genomes (Roizman, 1982; Figure 1).
1.2. Pathogenicity of the Human Herpesviruses.
Herpesviruses cause a range of clinical disorders, some 
of which are described below:
HSV-1 causes vesicular lesions of the mouth, lips and 
nasal membranes, ocular keratitis and occasionally more 
severe symptoms such as encephalitis, particularly in 
immunocompromised individuals (Smith et al., 1941; Gallardo, 
1943; Rawls, 1985).
HSV-2 is the agent of sexually transmitted genital 
herpes. It is closely related to HSV-1 and some overlaps in 
their clinical manifestations occur (Whitley, 1985). HSV-2 
has also been implicated in the aetiology of cervical cancer . 
(see section A.1.5.).
HSV-1 and HSV-2 often establish latency in trigeminal 
and sacral ganglia respectively, with periodic recurrence of 
lytic infection leading to outbreaks of lesions at 
peripheral sites (Klein, 1982; Knox et al., 1982; Hill,
1985) .
VZV is the causative agent of chickenpox (varicella), a 
disease resulting from primary infection normally found in 
children, and of shingles (herpes zoster), a localized 
vesicular condition occuring in adults which appears to be 
caused by reactivated, latent VZV (Weller, 1958; Gelb,
31985) .
HCMV infections can cause complications in 
immunosuppressed individuals and in patients with aquired 
immune deficiency syndrome (AIDS). It is also sometimes 
associated with neurological damage in neonates (Alford and 
Britt, 1984) . Infection of the vast majority of the human 
population, however, results only in a mild, sub-clinical 
condition. HCMV has been implicated in the development of 
cervical carcinoma (see section A.2.2.) since HCMV DNA has 
been detected in a small proportion of biopsies from 
patients with cervical intraepithelial neoplasia (Fletcher 
et al., 1986).
EBV infects B-lymphocytes and is the causative agent of 
infectious mononucleosis. It is also associated with 
Burkitts lymphoma, nasopharyngeal carcinoma and lymphomas of 
immunosuppressed individuals (Neiderman et al., 1976;
Miller, 1985; section A.2.1.3.).
HHV6 was first isolated from immunosuppressed patients 
but it can infect T-cells in vitro. It is linked to specific 
childhood illness (Salahudin et al., 1986).
HHV7 has been recently isolated from CD4+T cells 
purified from peripheral blood mononuclear cells under 
conditions promoting T-cell activation (Frenkel et al., 
1990). The role of HHV7 in human disease is, as yet, 
unknown.
1.3. The Structure of Herpesvirus Genomes.
The genomes of herpesviruses consist of linear duplex 
DNA molecules (Becker et al., 1968) which have molecular 
weights ranging from 80-150x10^ depending on species 
(Roizman and Furlong, 1974). The basic composition of the 
genome varies considerably; VZV has a G+C-content of 46%, 
pseudorabies virus (PRV) 73%, and HSV-1 68.3% (Ben-Porat and 
Kaplan, 1962; Kieff et al., 1971; Ludwig et al., 1972; 
McGeoch et al., 1988). Members of the herpesvirus family 
have been grouped according to the pattern of repeated 
sequences in their genomes (Roizman, 1982) although these 
structural criteria do not correlate with the biological 
classification (section A.I.I.). Figure 1 shows the genome 
arrangement of representative members of the Herpesviridae.
Figure 1 . Arrangement of sequences in herpesvirus genomes. 
Examples of genomes types A to F are channel catfish virus 
(CCV), herpesvirus saimiri (HVS), Epstein-Barr virus (EBV), 
varicella zoster virus (VZV), herpes simplex virus (HSV) and 
murine cytomegalovirus (MCMV) respectively. Lines represent 
unique sequences and arrowed lines show possible inversions. 
Open boxes are large Olkb) repeats and shaded boxes are 
repeats of small reiterated sequences; arrowheads above 
boxes denote whether repeats are direct or inverted. The 
small terminal direct and internal inverted repeats of HSV 
a" sequences) are indicated, the number of isomers of each 
..i-decule are also given. The genome type according to the 
system of classification defined by Roizman (1982) is shown.
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1.3.1. Structure of the HSV-1 Genome.
The HSV DNA molecule is composed of two covalently
linked segments designated long (L) and short (S). Each
segment contains unique (U„ or UT ) sequences flanked by a
o Li
pair of distinct inverted repeat sequences (R) of which one
is terminal (TR or TRC ) and the other is internal (IRT or 
Li O Li
IRg ), (Sheldrick and Berthelot, 1974). The molecule also 
exhibits terminal redundancy due to the presence of a short 
(400bp) terminal direct repeat termed the "a" sequence. One 
or more copies of this sequence are located internally at 
the joint between the L and S segments, but in the opposite 
orientation to the terminal "a" sequences (Wadsworth et al., 
1975; Wagner and Summers, 1978). Preparations of HSV virion 
DNA contain equivalent amounts of 4 isomers which differ in 
the relative orientations of L and S segments about the 
joint (Delius and Clements, 1976; Wilkie, 1976). The isomers 
appear to be functionally identical (Davison and Wilkie, 
1983), and one has been designated as the prototype for 
purposes of genomic map representations (Roizman et al., 
1979, Figure 1). As the "a" sequence contains signals for 
cleavage and packaging of concatermeric DNA, the presence of 
internal copies provides alternative sites for these events 
and would account for half the isomerization events.
Together with recombination of sequences dispersed 
throughout R and Rc, this arrangement provides the means to
Li O
generate the 4 genome isomers. In addition to the "a" 
sequences and inverted repeats, HSV-1 DNA contains a number 
of small tandemly reiterated sequence elements that vary in 
copy number (McGeoch et al., 1988).
1.3.2. The Nucleotide sequence of HSV-1.
The complete nucleotide sequence of HSV-1 (strain 17)
has now been determined (Davison and Wilkie, 1981; Murchie
and McGeoch, 1982; McGeoch et al., 1985, 1986, 1988). Other
herpesviruses whose genomes have been completely sequenced
are VZV (Davison and Scott, 1986) EBV, (Baer et al., 1984),
CCV (Dr. A. Davison, personal communication) and HCMV (work
peformed in Barrell's laboratory). The U region of theb
HSV-2 genome has also been sequenced (Dr. D. McGeoch, 
personal communication) and although the full genome
5sequence is, as yet, unknown, it seems to closely resemble
that of HSV-1 albeit with a slightly higher G+C-content
(Roizman, 1983). The HSV-1 genome comprises 152260 residues
although the exact length varies due to small reiterations
and "a" sequence copy number. It is estimated to encode 7 0
unique genes (2 are repeated), 56 in UT , 12 in Uc and 1 in
Li O
each of TRg and IRg (McGeoch et al., 1988, Figure 2, Table 
1). The genes are quite densely packed and it is clear from 
the close apposition and overlap of adjacent coding regions 
that in many cases transcriptional control elements must 
overlap with the polypeptide coding regions of adjacent 
genes.
The overall G+C-content of the genome is 68.3% and some 
regions are extremely G+C-rich. For example, the coding 
sequences of IE genes 1 and 3 have a G+C-content of 75.4% 
and 81.5% respectively. This is due to a large amount of 
G+C-rich codons and a notable bias towards a G or C in the 
redundant third position. High G+C codon usage, which 
results in restricted amino acid utilization, is thought to 
have arisen independently of protein functional demands 
(McGeoch et al., 1986; Perry et al., 1986).
1.4. The Lytic Cycle.
After entering the cell, HSV replication is co-ordinated 
by temporal control of gene expression. There are three 
groups of genes based on their kinetics and expression in 
the absence or presence of metabolic inhibitors of 
replication and translation (Jones and Roizman, 1979; Kozak 
and Roizman, 1974). These groups are named immediate-early 
(IE), early (E) and late (L, Clements et al., 1977) or 
alpha, beta and gamma (Honess and Roizman, 1974). Expression 
of these genes after infection leads to viral DNA 
replication, the assembly of new virus particles, and 
release of these particles from the cell. This process is 
called the lytic cycle and generally results in cell death.
1.4.1. Cell Penetration.
HSV particles adsorb to cell surfaces and penetrate by 
fusion of the virion envelope with the cellular membrane in 
a process that requires glycoprotein B (gB) which is present
Figure 2 . Layout of genes in the genome of HSV-1. The HSV-1 
genome is shown on four successive lines, with unique 
regions represented by solid lines and major repeat elements 
as open boxes. The sizes and orientations of proposed 
functional ORFs are shown by arrows. Locations of the 
origins of replication are indicated. In the UT region, on
Xj
e first three lines, the genes ULl to UL56 are labelled.
.n the Uc region, on the bottom line, genes USl to US12 areb
labelled. The location of introns in the coding regions of 
gene UL15 and the two copies of the IE110 gene are 
indicated.

Table 1 . Properties of HSV-l-encoded Proteins (taken from 
McGeoch et al., 1988, 1989).
HSV-1 PROTEIN AND/OR FUNCTION
GENE
IE110 IE transcriptional regulatory protein 
ULl Unknown
UL2 Uracil-DNA glycosylase
UL3 Unknown
UL4 Unknown
UL5 DNA replication: probable helicase component
UL6 Presumed virion protein: possible role in DNA
packaging 
UL7 Unknown
UL8 DNA replication: function unknown
UL9 DNA replication: origin-binding protein
UL10 Possible membrane-inserted protein
ULll Unknown
UL12 Deoxyribonuclease
UL13 Predicted protein kinase
ULl4 Unknown
UL15 Unknown
UL16 Unknown
ULl7 Unknown
ULl8 Unknown
UL19 Major capsid protein
UL20 Unknown
UL21 Unknown
UL22 Glycoprotein H
UL23 Thymidine kinase
UL24 Unknown
UL25 Virion protein
UL26 DNA packaging
UL27 Glycoprotein B
UL28 Probably structural
UL29 DNA replication: ssDNA binding protein
UL30 Replicative DNA polymerase
UL31 Unknown
Table 1 continued.
HSV-1 PROTEIN AND/OR FUNCTION
GENE
UL32 Probably structural
UL33 Structural! involved in packaging DNA
UL34 Possible virion protein
UL35 Unknown
UL36 Very large tegument protein
UL37 Unknown
UL3 8 Required for capsid assembly
UL39 Ribonucleotide reductase large subunit
UL40 Ribonucleotide reductase small subunit
UL41 Presumed virion protein
UL42 DNA replication:^DNA binding protein
UL43 Unknown
UL44 Glycoprotein C
UL45 Unknown
UL46 Unknown. May modulate UL48 activity
UL47 Unknown. May modulate UL48 activity
UL48 Major tegument protein. Transactivates IE genes
UL49 Unknown
UL50 Deoxyuridine triphosphat . aS£-
UL51 Unknown
UL52 DNA replication: function unknown
UL53 Possible membrane protein
UL54 IE transcriptional regulatory protein
UL55 Unknown
UL56 Unknown
IE175 IE transcriptional regulatory protein
US1 IE protein: function unknown
US2 Unknown
US3 Protein kinase
US4 Glycoprotein G
US5 Unknown: possible glycoprotein
US6 Glycoprotein D
US7 Glycoprotein I
US8 Glycoprotein E
Table 1 continued.
HSV-1 PROTEIN AND/OR FUNCTION.
GENE
US9 Virion protein
US10 Virion protein
US11 Function unknown: localizes in nucleolus 
US12 IE protein: function unknown
in the envelope (Sarmiento et_al., 1979; Little et al.,
1981). The viral capsids then migrate to the nuclear pores 
where they disassemble and DNA is released into the nucleus. 
The HSV mutant tsB7 is blocked at the stage of DNA release 
indicating that this process requires a viral-encoded 
protein (Knipe et al., 1981; Batterson et al., 1983).
1.4.2. Immediate-Early Genes.
The immediate-early (IE) genes are the first to be
transcribed and unlike early (E) and late (L) genes their
expression does not require de novo protein synthesis
(Honess and Roizman, 1974; Clements et al., 1977). IE gene
expression peaks about 2-3 hours after adsorption but IE
mRNAs can still be detected in the cytoplasm at L times
(Harris-Hamilton and Bachenheimer, 1985; Godowski and Knipe,
1986). During infection in the presence of cycloheximide,
which blocks protein synthesis, large quantities of IE mRNAs
accumulate (Preston, 1979a) and there is no transcription of
E and L genes as IE polypeptides are required for the switch
to E and L mRNA synthesis. There are five IE genes (Clements
et al., 1979, Figure 3). IE genes 1 and 3 are located within
the IR and IR respectively and there are therefore two 
Li b
copies of each (Watson et al., 1979; Anderson et al., 1980; 
Mackem and Roizman, 1980; Rixon et al., 1982). The promoter
and 5 1-untranslated leader sequences of IE genes 4 and 5 are
located within the short repeat and are thus common to both, 
but the coding sequences differ since they are located in 
the Ug short region of the genome (Watson et al ., 1981;
Rixon and Clements, 1982). IE gene 2 is located in the U .
Li
IE transcription does not require de novo protein
synthesis of viral or host proteins (Kozak and Roizman,
1974; Clements et al., 1977) but it is stimulated 5-10-fold
by the product of gene U 48, a virus-encoded transinducing
Li
factor (TIF, Mackem and Roizman, 1982a,b,c; Cordingley et 
al. , 1983; Preston et al., 1984; Lang et al., 1984; O'Hare 
and Hayward, 1985b) which was later identified as the major 
tegument protein of the infecting virion, Vmw65, (Campbell 
et al. , 1984). Results suggest that vmw65 consists of two 
functional regions. The carboxy-terminal 78 amino acids 
function as as activating region (Sadawski et al., 1988; 
Triezenberg et al., 1988; Greaves and O'Hare, 1989), while
the amino-terminal 413 amino acids are required to form 
complexes with TAATGARAT motifs in a sequence specific 
manner (Triezenberg et al., 1988; Ace et al., 1988; Greaves 
and 0 1 Hare, 1989).
The consensus A+T-rich sequence 5'-TAATGARAT-3' (where R 
is a purine residue) is present in one or more copies, in 
either orientation, upstream of all HSV-1 and HSV-2 IE genes 
and is essential for their stimulation although flanking 
elements, such as SPl binding sites and G+A-rich elements 
resembling enhancer sequences, also modulate transcriptional 
activity (Preston et al., 1984; Mackem and Roizman, 1982a; 
Cordingley et al., 1983; Kristie and Roizman, 1984; Lang et 
al., 1984; Bzik and Preston, 1986; O'Hare and Hayward,
1987), although the G+A-rich elements were not found to 
mediate independent transcriptional activity. Similar 
results were reported by Triezenberg et al. (1988), who
placed moe emphasis on the importance of the G+A-rich 
sequences, which, they suggested, would mediate stimulation 
by the virion factor in the absence of the TAATGARAT motif. 
Further studies will be needed to resolve this conflict.
The presence of a cis-acting regulatory sequence 
upstream of the IE promoters was suprising as the TIF is not 
a DNA binding protein (Marsden et al., 1987). However, a 
virus induced protein/DNA complex, called the 
immediate-early complex (IEC), which contains the TIF, forms 
at, or immediately surrounding the TAATGARAT element. This 
complex requires 2 cellular factors for its formation and it 
has been suggested that the cellular factor(s) may recognize 
a sequence homologous to the common eukaryotic octamer 
element 5 1-ATGCAAAT-31 (Falkner and Zachau, 1984; Parslow et 
al., 1984) which is found 5'- to and overlapping the 
TAATGARAT elements of IE genes 1 and 2. The sequence is not, 
however, found in the IE genes 3, 4 and 5 (Pruijn et al., 
1986; O'Hare and Goding, 1988; Gerster and Roeder 1988; 
Preston et al., 1988). The cellular factor required for the 
virus-induced complex has been identified as the octamer 
binding transcription factor 0TF1 or 0CT1 (Gerster and 
Roeder, 1988), which is probably identical to nuclear factor 
III (O'Neill et al., 1988).
Many aspects of IE target sequence binding remain 
unresolved but the available evidence suggests that Vmw65
Gene Polypeptide Alternative
Nomenclature
IE-1 VtawllO ICPO
IE-2 Vmw63 ICP27
IE-3 Vtawl75 ICP4
IE-4 Vlnw6 8 ICP22
IE-5 Vmwl2 ICP47
Figure 3. A representation of the HSV-1 genome showing the 
location and orientation of the five IE genes. The positions 
of the spliced regions are indicated. Also shown is a table 
showing the polypeptides expressed from the IE genes.
(TIF) mediates transinduction by associating with cellular 
factors including 0TF1 and at least one other protein to 
form a novel transcription complex which recognizes 
octame r\TAATGARAT elerne nt s.
1.4.3. Immediate-Early Polypeptides.
The IE genes 1-5 code for the polypeptides VmwllO (whose 
alternative nomenclature is ICPO), Vmw63 (ICP27), Vmwl75 
(ICP4), Vmw68 (ICP22) and Vmwl2 (ICP47). The proteins are 
all phosphorylated and are located within the nucleus, with 
the exception of Vmwl2 (Pereira et al., 1977; Marsden et 
al., 1978, 1982; Preston, 1979b; Fenwick and Walker, 1979; 
Ackermann et al., 1984). The functions of the polypeptides 
are described below:
Vmwl75 is critical for HSV replication. Various 
conditional HSV-1 mutants containing lesions within IE gene 
3 (eg. tsK) fail to synthesize E and L proteins at the NPT 
and cannot replicate viral DNA (Marsden et al., 1976; 
Preston, 1979a; Dixon and Schaffer, 1980; Watson and 
Clements, 1978, 1980). The protein is continuously required 
for E and L gene expression (Watson and Clements, 1978,
1980; Preston, 1979a; Dixon and Schaffer, 1980) and is 
involved in turning off its own synthesis and that of other 
IE proteins (Preston 1979a; Dixon and Schaffer, 1980). 
Transient expression assays using cloned IE gene 3 also show 
that E and L genes can be activated by Vmwl75 (Everett, 
1984b; DeLuca and Schaffer, 1985; Gelman and Silverstein, 
1985; O'Hare and Hayward, 1985a,b; Quinlan and Knipe, 1985; 
Mavromara-Nazos et al., 1986) and that IE genes can be 
repressed (DeLuca and Schaffer, 1985; Gelman and 
Silverstein, 1987a,b). During infection, however, the 
products of later genes may also be involved in the turn-off 
of IE gene expression (Godowski and Knipe, 1986). 
Transactivation and repression of HSV promoters has also 
been demonstrated in vitro using partially purified Vmwl75 
(Beard et al., 1986; Pizer et al., 1986).
Vmwl75 binds specifically to the target consensus 
sequence 5'-ATGCTG-3' located at the transcriptional start 
site of its own gene, IE gene 3 (Beard et al., 1986; Faber 
and Wilcox, 1986; Kristie and Roizman, 1986; Muller, 1987)
9and it is thought that this process mediates autoregulation 
(Gelman and Silverstein, 1987b; Muller, 1987; Roberts et 
al., 1988). A highly conserved amino-terminal region of the 
polypeptide is important for both transactivation and 
autoregulation (DeLuca and Schaffer, 1987, 1988; Paterson 
and Everett, 1988a,b). Paterson and Everett (1988b) propose 
a model whereby Vmwl75 mediates transactivation by 
association with cellular factors (eg.TFIID) at promoter 
sequences. Repression might then occur if this complex were 
in the vicinity of a high affinity Vmwl75 binding site which 
may block the progression of the transcription machinery.
Recently, Batchelor and O'Hare (1990) have shown that 
Vmwl75 may repress LAT promoter activity by a mechanism 
similar to that involved in autoregulation and have 
identified a putative Vmwl75 binding site. This, however, 
contrasts to studies performed by Zwaagstra et al. (1989) 
who suggested that Vmwl75 induced LAT transcription, s
VmwllO is a potent activator of viral and cellular 
genes, either by itself, or in combination either additively 
or synergistically, with Vmwl75 (Everett, 1984b; O'Hare and 
Hayward, 1985a,b; Quinlan and Knipe, 1985; Gelman and 
Silverstein, 1985; Mavromara-Nazos et al., 1986). As yet, no 
ts mutants in IE gene 1 have been isolated but a HSV-1 
mutant dll403 with a large deletion in the gene gives a 
protein which is inactive in transient assays (Stow and 
Stow, 1986; Perry et al., 1986). At low moi this mutant grew 
inefficiently whereas at high multiplicities normal amounts 
of viral proteins were expressed and replication was the 
same as with the wt virus. It appears then, that VhiwllO is 
not absolutely essential in tissue culture, but at low moi 
viruses that lack the polypeptide exhibit a defect that can 
be overcome by increasing the number of infecting viruses. 
VmwllO may therefore ensure that sufficient gene expression 
for lytic infection can occur at low multiplicities when 
Vmwl75 alone is not enough to commit the cell to the lytic 
cycle. Similar conclusions have been reached using other 
mutants of the IE 1 gene (Sacks and Schaffer, 1987).
A mutant expressing little or no Vtnwl75 is unable to 
grow in normal cells suggesting that VmwllO fails to 
activate E gene expression in the absence of Vmwl75 during 
infection (DeLuca et al., 1985). The synergism between
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Vmwl75 and VmwllO seems to depend on the integrity of the 
carboxy-terminus of the polypeptide whilst mutations in this 
region do not greatly affect the ability of the protein to 
activate by itself (Everett, 1987, 1988). Thus, two 
different mechanisms of activation may operate and synergy 
may require an association between the two proteins. As yet, 
there is no information regarding the DNA binding properties 
of VmwllO, although the coding region does contain a 
consensus "metal finger binding domain" (Berg, 1986) which 
is essential for the activity of VmwllO in the absence of 
Vmwl7 5.
Vmw63 is an essential regulatory protein. Mutants that 
are ts in Vmw63 overproduce Vmwl75 and VmwllO at the NPT 
(Sacks et al., 1985) whilst synthesizing normal levels of E 
proteins and allowing replication to occur. However, the 
mutants exhibited a severe reduction of L gene expression, 
notably of gB (Rice and Knipe, 1988). Vmw63 can activate 
expression of the promoter of the L gene encoding Vmwl55 
(the major capsid protein) above levels obtained with Vmwl75 
and VmwllO but only when all three proteins are present, 
having no effect on its own or in combination with other 
promoters such as those of TK and gD (Everett, 1986). Vmw63 
also activates and represses a variety of HSV promoters in 
transfection assays when VmwllO and Vmwl75 are present (Rice 
and Knipe, 1988; Sekulovich et al., 1988). Using viruses 
encoding truncated forms of Vmw63, Rice and Knipe (1990) 
suggested that Vmw63 has four regulatory effects during 
infection, stimulation of leaky L gene expression (section 
A.1.4.4.), induction of true L gene expression, down 
regulation of E and IE genes late in infection and 
stimulation of viral DNA replication. They also suggest that 
Vmw63 possesses two genetically separable transactivating 
functions. One stimulates, but is not reqired for expression 
of leaky L genes, while the second activity is required for 
true L genes.
Vmw68 may have a role in L gene expression as a 
deletion mutant which lacks the carboxy-terminus of the 
protein (Post and Roizman, 1981) exhibits poor growth and 
reduced expression of at least one L gene in some cell lines
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(Sears et al., 1985). In addition the mutant was not 
neurovirulent in mice.
Vmwl2 does not seem to play an important role during 
infection in tissue culture as viable mutants which lack the 
whole gene have been isolated (Longnecker and Roizman, 1986; 
Umene, 1986; Brown and Harland, 1987).
1.4.4. Early Genes.
Peak expression of E genes occurs 4-6 hours 
post-adsorption although there is more variation in the 
kinetics of their expression than for IE genes. For example, 
some genes, including gD, are detected at E times but are 
not fully expressed until after the onset of DNA replication 
(Gibson and Spear, 1983; Johnson and Everett, 1986a). Such 
genes, whose expression is moderately dependent on DNA 
replication have been described as early-late (EL), leaky 
late (beta gamma) and gamma (Roizman and Batterson, 1985;±j
Wagner, 1985; Harris-Hamilton and Bachenheimer, 1985). The 
large subunit of ribonucleotide reductase (RRl) also has 
predominantly early kinetics but can still be detected in 
the presence of cycloheximide and in ts-Vmw!75 mutants that 
fail to express E genes at the NPT (Preston, 1979a; DeLuca 
et al., 1985).
Early promoters contain upstream sequences necessary for 
full expression, such as a CAAT box, G+C-rich Spl sites (for 
TK) and A+G-rich regions (for gD). However, the TATA box of 
these promoters is probably the main factor involved in the 
response to viral products (McKnight et al., 1981; McKnight 
and Kingsbury, 1982; Everett, 1983, 1984a; ElKareh et al., 
1985; Coen et al. 1986).
The rabbit beta globin gene was also found to be 
transactivated by HSV infection, but only when integrated 
into the viral genome (Everett, 1983, 1984a) which shows 
that the gene responds differently to transactivating 
factors depending on whether it is chromatin associated or 
extrachromosomal. It also suggests that E gene promoter 
activity is not exclusively dependent on viral-specific 
sequences (Smiley et al., 1987).
1.4.5. HSV Enzymes.
12
Many of the E proteins have enzymic activity and play 
roles in the metabolism or synthesis of viral DNA. For 
example, TK, (Kit and Dubbs, 1963; Jamieson et al., 1976; 
alkaline exonuclease (Morrison and Keir, 1968; Moss et al.,
1979), DNA polymerase (Keir et al., 1966; Chartrand et al., 
1979, 1980), ribonucleotide reductase, (Cohen, 1972; Dutia,
1983), dUTPase (Wohlrab and Franke, 1980; Preston and 
Fischer, 1984), uracil DNA glycosylase (Worrad and 
Caradonna, 1988; Mullaney et al., 1989) and protein kinase 
(McGeoch and Davison, 1986; Purves et al., 1986; Frame et 
al. , 1987) . , . | ,/)
The DNA polymerase (Chartrand et al., 1980)vand the 
ribonucleotide reductase (A.3.3.) are essential for growth 
in tissue culture whereas the dUTPase, uracil DNA
glycosylase, protein kinase and alkaline exonuclease are not 
(Dubbs and Kitt, 1964; Fischer and Preston, 1986; Mullaney 
et al., 1989; Purves et a l ., 1987).
The HSV DNA polymerase differs from most eukaryotic 
polymerases by virtue of its 3 1- to 5 ’-exonuclease (proof 
reading) activity (Knopf, 1979). In addition, the HSV enzyme 
is sensitive to phosphonoacetic acid (PAA), a pyrophosphate 
analogue (Leinbach et al., 1976).
1.4.6. Late genes.
L gene products, many of which are structural components 
of the virion, accumulate maximally by 10-16 hours 
post-adsorption which is roughly 2 hours after the peak of 
viral DNA synthesis (Munk and Sauer, 1964; Roizman, 1969; 
Wilkie, 1973). Indeed, it has been shown that L gene 
expression requires DNA replication (Swanstrom and Wagner, 
1974; Honess and Roizman, 1974; Powell et al., 1975; Marsden 
et al., 1976; Jones and Roizman, 1979; Holland et al., 1980; 
Conley et al., 1981; Pederson et al., 1981).
L genes can be "leaky" L (gamma ), for example, the
Li
Vmwl55 major capsid protein, whose expression is reduced but 
still detectable in the absence of DNA replication, or true 
late (gamma), like USll, whose expression is very hard to 
detect under such conditions (Wagner, 1985; Roizman and 
Batterson, 1985; Johnson and Everett, 1986a, b; Johnson et 
al., 1986).
Unlike E promoters, which contain upstream sequences
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necessary for full expression, the TATA box region (Johnson 
and Everett, 1986b) and sequences downstream from this 
(Mavromara-Nazos and Roizman, 1989), are involved in the 
regulation of L genes, and the E promoter of gD is regulated 
as a true L promoter in the absence of its upstream region 
when linked to an HSV origin of replication in transfection 
assays (Johnson et al., 1986). The L promoter regulatory 
sequences are either at the transcription initiation site or 
downstream of this (Mavromara-Nazos and Roizman, 1989).
The reason why viral replication leads to L gene 
induction is not understood. It is unlikely to be due, 
simply, to an increase in copy number of promoters, since E 
genes would also be expected to be dependent on DNA 
synthesis. Replication could possibly cause a change in the 
DNA template and provide a switch for L gene expression, or 
perhaps part of the replication machinery is needed in situ 
to initiate L gene transcription. However, IE gene products 
Vmw63 and Vmw68 seem to be involved in L gene induction 
(Sears et al., 1985; Sacks et al., 1985) and L gene 
promoters, like those of E genes, are activated by IE 
proteins in transfection assays (Dennis and Smiley, 1984; 
DeLuca et al., 1985; Mavromara-Nazos et al., 1986; Everett,
1986). It has been proposed (Mavromara-Nazos and Roizman,
1989), that the L promoter regulatory sites are blocked in 
the absence of viral DNA replication and that this block 
does not affect the upstream regulatory sequences of E and 
IE genes.
1.4.7. Structural Polypeptides.
HSV virions are thought to contain between 15 and 33 
polypeptides (Spear and Roizman, 1972; Heine et al., 1974). 
These can be grouped into glycoproteins, tegument proteins 
and capsid proteins.
(i ) Glycoproteins.
HSV encodes at least 7 glycoproteins (gB, gC, gD, gE, 
gG, gH and g l ), (Spear, 1976; Bauke and Spear, 1979; 
Buckmaster et al., 1984; Spear, 1985; Frame et al., 1986; 
Richman et al., 1986; Ackerman et al., 1986; Longnecker et 
al., 1987; Johnson et al., 1988). A further ORF, whose 
protein is as yet unidentified, has characteristic
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glycoprotein amino acid sequences (McGeoch, 1985). The 
glycoproteins are located within the membrane that comprises 
the viral envelope and are probably exposed on the surface 
of the virion. The glycoproteins gB, gC and gD have been 
implicated in cell surface adsorption (Johnson et al.,
1984), gB, gD and gH play essential roles in the ability of 
HSV to fuse with plasma membranes and penetrate cells 
(Sarimento et al., 1979; Little et al., 1981; Minson et al., 
1986; Desai et al., 1988; Cai et al., 1988), gD is thought 
to be an essential cell surface receptor-binding polypeptide 
(Johnson and Ligas, 1988) and gE and gl interact 
specifically with the Fc domain of immunoglobulin G (IgG, 
Bauke and Spear, 1979; Johnson et al., 1988). Thus it 
appears that several glycoproteins participate in the entry 
of HSV into cells as well as being structural proteins 
(Addison et al., 1984).
(ii) Tegument Proteins.
These proteins can be identified when released from 
virions in the presence of non-ionic detergents (Lemaster 
and Roizman, 1980; Roizman and Furlong, 1974; Spear, 1980). 
The major tegument protein is Vmw65. This protein is 
required for transactivation of IE genes (A.1.4.3.) and 
hence for lytic infection. It is, however, dispensible for 
the establishment and reactivation from latent infection 
(Steiner et al., 1990).
(iii) Capsid proteins.
Bnpty capsids (ie. capsids which do not contain HSV DNA) 
are made up of at least 5 proteins including Vmwl55, the 
major capsid protein. Mature nucleocapsids contain 2 
additional polypeptides, one of which is VP22 (p40, Gibson 
and Roizman, 1972, 1974; Heilman et al., 1979; Preston et 
al., 1983) .
1.4.8. DNA Replication.
Linear herpesvirus DNA molecules circularize upon 
infection (Jean et al., 1977; Jacob and Roizman, 1977) by 
direct ligation at the termini (Jean and Ben-Porat, 1976; 
Davison and Wilkie, 1983; Poffenberger and Roizman, 1985). 
During the initial stages of replication, loops and eyes can
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be seen in the DNA molecule at multiple, widely separated 
loci (Friedman et al., 1977). Newly replicated molecules are 
found in large concatemers, in a head to tail configuration, 
which probably arises by a rolling circle replication 
process (Jacob and Roizman, 1977; Ben-Porat and Tokazewski, 
1977) .
HSV DNA contains three origins of replication, two lie
within the R segment (ori ) and one within U (ori , 
t> O Li Li
Frenkel et al., 1976; Jean et al., 1977; Rixon and
Ben-Porat, 1979; Vlazney and Frenkel, 1981; Spaete and
Frenkel, 1982). The locations of origins of replication can
be seen in Figure 2. Deletion of ori or one copy of oricLi O
has little or no effect on viral replication in cultured 
cells (Longnecker and Roizman, 1986; Polvino-Bodnar et al.,
1987) .
Orig consists of a 90bp fragment containing a 45bp
palindromic sequence featuring 18 centrally located A or T
residues flanked by G+C-rich tracts, and is located between
the 5'-ends of IE mRNAs 3 and 4/5 (Stow, 1982; Stow and
McMonagle, 1983) .
Ori , located in the centre of U , between the genes 
L Li
encoding DNA polymerase and the major DNA-binding protein 
(MDBP), contains a 72bp palindrome which has 85% homology to 
orig (Gray and Kaerner, 1984; Quinn and McGeoch, 1985;
Weller et al., 1985). Both orig and oriL appear to be 
functionally identical in transient complementation assays 
(Wu et al., 1988), and it is thought that the potential 
ability of the origins to form cruciform structures 
containing a stretch of low melting point (A+T-rich) DNA may 
facilitate strand separation in these areas of the genome 
(Stow, 1985).
1.4.9. Genes Required for DNA Replication.
Seven genes, based on predicted ORFs, were found to 
be required for HSV DNA replication using the plasmid 
replication assay of Challberg (Challberg, 1986; Wu et al.,
1988) . Two of these genes, encoding DNA polymerase and the 
MDBP, were already known to be essential for viral 
replication by genetic analysis of mutants (Hay and 
Subak-Sharpe, 1976; Chartrand et al., 1979; Conley et al., 
1981; Weller et al., 1983; Coen et al., 1984; Gibbs et al.,
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1985) .
The MDBP is an E gene product. It is a single-stranded 
DNA binding protein which may reduce the melting temperature 
at poly(dA)/poly(dT) tracts (ie. at origins of DNA 
replication) thereby facilitating strand separation (Powell 
et al., 1981). The MDBP also has a role in gene regulation 
since ts mutants overexpress gC and a functional MDBP is 
involved in the repression of IE3 and Vmwl55 genes (Godowski 
and Knipe, 1983, 1985, 1986).
Other genes that were found to be required for 
replication were UL5, UL8, UL9, UL42 and UL52. The product 
of UL42 is a DNA binding protein (Marsden et al., 1987) and 
the polypeptide encoded by UL9 binds specifically to ori DNA 
sequences (Olivo et al., 1988; Weir et al., 1989). There is 
also evidence that UL5 encodes a helicase (Zhu and Weller, 
1988). The remaining gene products might be expected to 
include a primase, a topoisomerase and accessory factors 
that might improve the processivity and efficiency of DNA 
polymerase, in analogy with prokaryotic systems (Wu et al., 
1988) .
1.4.10. HSV Transcript Processing.
The mechanism by which HSV DNA is transcribed and mRNAs 
processed is fundamentally similar to that for cellular RNA 
polymerase II genes. HSV mRNAs are transcribed in the 
nucleus by the host RNA polymerase II (Ben-Zeev and Becker, 
1977; Costanzo et al., 1977). The transcripts are capped at 
the 5 '-terminus, polyadenylated at the 3 '-terminus and 
internally methylated (Bachenheimer and Roizman, 1972; Moss 
et al., 1977; Silverstein et al., 1973; Bartoski and 
Roizman, 1976). In vitro and in vivo analysis of HSV poly(A) 
site sequences has shown that efficient formation of mRNA 
3'-termini requires a poly(A) signal, AAUAAA and other 
sequences downstream of the mature 3' end, in particular a 
G+U-rich element (Cole and Stacey, 1985; McLauchlan et al., 
1985, 1988, Zhang and Cole, 1987). These sequence motifs are 
important for processing at other cellular and viral poly(A) 
sites (Skolnik-David et al., 1987). In addition, sequence 
specific complexes formed at these HSV poly(A) sites 
(McLauchlan et al., 1988), within which RNA processing 
occurs in vitro, resemble those formed at other eukaryotic
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poly(A) sites (Zarkower and Wickens, 1987, 1988). The 
sequences required for efficient 3'-processing are not 
identical for all poly(A) sites (Hales et al., 1988) and 
thus usage of certain poly(A) sites may be a regulated 
event. McLauchlan et al. (1989) have identified an activity 
induced in HSV infected cells that increases the 3' 
processing specificity at a L but not an E HSV-1 poly(A) 
site.
Splicing of HSV mRNAs is rare (Frink et al., 1981,1983; 
Watson et al, 1981; Costa et al., 1985), unlike many 
viruses, including HCMV and EBV, which undergo economic use 
of template DNA by generating multiple individual mRNAs with 
common 5'- and 3 '-termini. HSV-1 IE mRNAs 4, 5 (Watson et 
al., 1981; Rixon and Clements, 1982) and 1 (Perry et al.,
1986) are spliced as is UL15 (Costa et al., 1985; McGeoch et 
al., 1988). The LAT (section A.1.4.2.) is also spliced but 
only a tentative ORF has been designated (Wechsler et al.,
1988). The purpose of these splicing events does not seem to 
be related to gene compression since the introns do not lie 
within overlapping reading frames. Indeed, only US10 and 
US11 (Rixon and McGeoch, 1984) overlap in the U region of
u
the genome and there are 11 proposed overlaps in U (McGeoch
X j
et al., 1988). Many HSV transcripts, although not spliced, 
do overlap by having unique 5'- and common 3'-ends, as is 
the case for US10, 11 and 12 (Hall et al., 1982; Costa et 
al., 1983; Rixon and McGeoch, 1984).
1.4.11. HSV Polypeptide Synthesis.
One-dimensional SDS PAGE has identified about 50 novel 
polypeptides following infection of cells with HSV-1 (Honess 
and Roizman, 1973; Marsden et al., 1976). Two-dimensional 
PAGE increases this figure to around 230 virus-induced 
polypeptide species, a number presumably being related forms 
of the same polypeptide (Haar and Marsden, 1981).
The failure of some HSV polypeptides, synthesized in 
vitro, to co-migrate on SDS polyacrylamide gels with their 
in vivo counterparts suggests that modifications occur in 
vivo (Preston, 1977). There are four main types of
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modification (Marsden et al., 1982);
(i) Phosphorylation. Catalyzed by the enzyme protein 
kinase, this reaction involves the addition of phosphate 
groups to a serine or threonine residue. Roughly 16 HSV-1 
and 18 HSV-2 polypeptides are phosphorylated (Pereira et 
al., 1977; Marsden et al., 1978). In some of these 
phosphoproteins, namely Vmwl75, Vmw6 8, Vmw63 and Vmwl36, the 
phosphate can cycle on and off (Wilcox et al., 1980) and 
phosphorylation of Vmwl36 has been shown to decrease its 
affinity for double-stranded DNA.
(ii) Glycosylation. In this process, oligosaccharides 
are covalently attached to the polypeptide chain. Seven 
HSV-1 induced polypeptides are glycosylated (section 
A.I.4.7.).
(iii) Sulphation. This is a process which occurs at L 
times and involves the addition of inorganic sulphate to the 
major glycoprotein species (Hope et al., 1982; Hope and 
Marsden, 1983).
(iv) Proteolytic Cleavage. Several HSV polypeptides 
undergo specific proteolytic cleavage which does not occur 
in the presence of protease inhibitors. Vmwl36 gives rise to 
products of 100,000 and 90,000 mw which are found in the 
nucleus of infected cells while the polypeptide itself is 
predominantly cytoplasmic (McDonald, 1980). Similarly, 
Ingemarson and Lankinen (1987 ) reported that Vtnwl36 is 
proteolytically digested to products with molecular weights 
of 110,000, 93,000 and 81,000.
1.4.12. DNA Packaging and Virion Assembly.
Concatemeric DNA resulting from HSV DNA replication 
undergoes cleavage at the "a" sequence which is present at 
the termini of standard molecules (Davison and Wilkie, 1981; 
Mocarski and Roizman, 1982; Varmuza and Smiley, 1985;
Nasseri and Mocarski, 1988). The cleaved molecules are then 
encapsidated into virus particles in a process which also 
involves the "a" sequence (Kaerner et al., 1981; Vlazney and 
Frenkel, 1981). Cleavage of concatemeric DNA molecules into
unit length genomes is a prerequisite for, or occurs 
concomitantly with, packaging (Vlazny et al., 1982).
Analysis of the HSV mutant ts!201 revealed that packaging of 
DNA requires the processing of a structural protein p40 
(VP22a) to a form of lower electrophoretic mobility (Preston 
et al. , 1983). Another mutant, _tsl204, which belongs to 
another complementation group, was also unable to 
encapsidate DNA indicating that other polypeptides are 
involved in the process (Addison et al., 1984).
1.5. Interaction of HSV with Cellular Functions.
1.5.1. Alteration of Host Macromolecular Synthesis.
Infection of permissive cells with HSV-1 or HSV-2 
results in changes to many host cell functions. Cellular DNA 
and RNA synthesis is inhibited (Roizman and Roane, 1964), 
mitosis ceases (Wildy et al., 1961) and there is a rapid 
shut-off of host polypeptide synthesis (Sydiskis and 
Roizman, 1966, 1967) accompanied by a general degradation of 
cellular mRNAs (Nishoika and Silverstein, 1977, 1978; Schek 
and Bachenheimer, 1985). In general, HSV-2 appears more 
efficient than HSV-1 in causing host protein synthesis 
inhibition (Powell and Courtney, 1975; Pereira et al., 1977; 
Fenwick et al., 1979; Schek and Bachenheimer, 1985).
Shut-off of host protein synthesis seems to be mediated 
by one or more virion components as UV-irradiated virus in 
the presence of actinomycin D produces the same effect. 
Complete shut-off, however, requires the expression of E and 
perhaps L genes indicating that there is a secondary 
shut-off event in addition to the virion-associated 
mechanism (Honess and Roizman, 1974; Marsden et al., 1976; 
Nishioka and Silverstein, 1978; Stenberg and Pizer, 1982). 
This secondary event may be mediated by a virus-encoded 
protein or might be the result of virus promoters competing 
with cellular promoters for host transcription factors. 
Mutants of HSV-1 have been isolated for virion-associated 
host shut-off (vhs mutants) and the gene responsible has 
been identified as UL41 (Read and Frenkel, 1983). Some 
cellular promoters, possibly including those of the genes 
encoding the heat shock proteins and ubiquitin, are 
stimulated early in infection (Notarianni and Preston, 1982;
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La Thangue et al., 1984; Macnab et al., 1985; Patel et al., 
1986; Latchman and Kemp, 1987), and Kemp et al. (1986) 
implicated the involvement of virion components, including 
the HSV-1 Vmw65. Such alterations in cellular gene 
expression during the initial stages of infection could 
ultimately determine the fate of an infection, whether it be 
lytic, latent or transforming.
1.5.2. Activation of Cellular Genes.
It has been shown that a number of cellular RNAs are 
induced by a mechanism which requires IE gene expression 
(Patel et al., 1986), while others may be induced by 
mechanisms that parallel activation of the IE genes by 
Vmw65, or simply by adsorption of the virus to the cell 
surface (Kemp et a l ., 1986).
Certain cellular promoters are activated by HSV IE gene 
products in transfection assays, for example the rabbit 
beta-globin gene promoter (Everett, 1983), but the 
endogenous gene is not activated by virus infection. It is 
thought that this may be due to a densely packed chromatin 
configuration making the promoter unavailable for viral 
transactivation (Everett, 1985). Many other cellular genes 
may fail to be activated on viral infection for the same 
reason.
Infection of human embryo fibroblasts with HSV-2 induces 
the synthesis of a minor cellular stress protein of 57kDa mw 
(La Thangue et al., 1984) and the induction of stress 
proteins may represent an attempt by the cell to protect 
itself. Alternatively, it might result from the viral 
induction of cellular functions which facilitate viral 
multiplication (Patel et al., 1986).
Heat-shock proteins are also induced in chick embryo 
fibroblasts (CEF) by tsK at the NPT (Notarianni and Preston,
1982) due to the presence of an abnormal Vmwl75 protein 
(Russel et al., 1987). Natural isolates of HSV-1 frequently 
show mutations in the gene encoding Vmwl75 (Knipe et al., 
1981; Post et al., 1981). Thus, the induction of heat-shock 
proteins may be important in vivo. Heat-shock proteins might 
be induced to mediate the repression of cellular 
biosynthesis which is seen in heat-shocked cells (Peterson 
and Mitchell, 1981).
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The induction of heat-shock proteins also occurs in 
cells infected with the DNA tumour viruses adenovirus 
(Nevins, 1982), polyoma virus and SV40 (Khandjian and 
Turler, 1983) which has lead to the suggestion that the 
activation of such genes might be involved in 
transformation.
Western blotting studies have shown that TG7A (an 
antibody raised against affinity purified DNA binding 
proteins from HSV-2 infected cells) recognizes 2 
polypeptides of mw 35-40,000 and 90,000 which are induced on 
HSV-2 infection (La Thangue and Latchman, 1988) . Cellular 
polypeptides investigated in this way have been 
immunoprecipitated from HSV-2 transformed cells but not from 
untransformed cells, using the same monoclonal antibody and 
have similar molecular weights to both HSV-induced 
polypeptides (Macnab et al., 1985a). These proteins might be 
an important step in the initiation of oncogenic 
transformation by the virus.
1.5.3. Latency.
HSV can establish latency and coexist with its host in a 
non-infectious state (Stevens and Cook, 1971? Baringer and 
Swoveland, 1973; Galloway et al., 1979; McLennan and Darby,
1980). HSV-1 travels intra-axonally down nerves to 
ganglionic neurones after infection at peripheral skin 
sensory nerve cell sites. The latent state is characterized 
by the prolonged association of the viral genome in host 
neuronal tissue, during which time no infectious virus can 
be isolated (Hill, 1985).
Puga et al. (1978) were the first to detect HSV specific 
DNA in sensory ganglia from latently infected mice. Latent 
HSV genomes exist in a form other than unit length, linear 
DNA and it is unclear whether the viral molecules are 
maintained in circular or concatemeric forms (Rock and 
Fraser, 1983; Efstathiou et al., 1986). It does, however, 
appear that the latent DNA exists in an episomal rather than 
an integrated state (Mellerick and Fraser, 1987).
The HSV-1 genome is not completely inactive during 
latency and HSV-specific transcripts have been detected in 
ganglia of seropositive patients (Croen et al., 1987;
Steiner et al., 1988; Stevens et al., 1988) and in
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experimentally infected mice (Deatly et al., 1987; Puga and 
Notkins, 1987; Spivak and Fraser, 1987; Stevens et al.,
1987; Wagner et al., 1988) and rabbits (Rock et al., 1987; 
Wechsler et a l ., 1988). At least three latency associated 
transcripts (LATs) of 2.0, 1.5 and 1.45kb are present during 
HSV-1 latency and these map to a 3.0kb region contained 
within the BamHI b and e framents in the R region. These 
RNAs partially overlap the 3'-terminus of the IEl gene but 
are transcribed in the opposite direction (Rock et al.,
1987; Spivak and Fraser, 1987; Stevens et al., 1987; Deatly 
et al., 1988; Steiner et al., 1988; Wagner et al., 1988; 
Wechsler et al., 1988).
The DNA of this region does not contain any convincing 
protein coding sequences, apart from IEl (Perry and McGeoch,
1988) and most of the transcripts present during latency are 
not polyadenylated (Wagner et al., 1988). The LATs may 
modulate latency via control of IEl gene expression, 
possibly by interacting with the DNA sequence of the gene or 
with IEl mRNA (Croen et al., 1987; Rock et al., 1987;
Stevens et al., 1988) but latency competent HSV deletion 
variants have been isolated which lack all or part of the 
LATs (Javier et al. , 1988, Sedarati et al., 1989, Steiner et. 
al. , 1989) suggesting that these transcripts are not 
essential for the latency process.
Using HSV mutants in an in vitro latency system (tissue 
culture cells harbouring non-replicating HSV) Russell and 
Preston (1986) demonstrated that only limited gene 
expression, probably of the IE genes, is necessary for the 
latent state to be established and reactivated in vitro. 
VmwllO has been directly implicated in reactivation since 
super-infection with dll403 (a mutant containing a deletion 
in IEl) fails to reactivate HSV-2 in vitro (Russell et al.,
1987) .
Further work (Harris et al., 1989), has also implicated 
VmwllO in reactivation. An adenovirus recombinant expressing 
an HSV-1 mutant VmwllO, containing a deletion in the carboxy 
terminus, reactivated latent HSV-2 in vitro whereas a 
similar recombinant containing a deletion in the second exon 
of VmwllO did not, suggesting that VmwllO alone is required 
for reactivation of latent HSV-2 in vitro. Contrary to this, 
Clements and Stow (1989) have shown that dll403, which has
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reduced virulence in mice, is able to establish a latent 
infection in the sensory ganglia of mice following footpad 
inoculation. This latent virus can be reactivated from 
explanted ganglia suggesting that the IEl gene product is 
dispensible for establishment and maintenance of latency and 
reactivation from the latent state.
Vmwl75 may also affect transcription from the LAT 
promoter (section A.I.4.3.), although the significance of 
this is not known.
Reactivation of latent HSV can be triggered by trauma, 
nerve damage or various stimuli to the neurone or dermatome 
(Stevens, 1975; Wildy et al., 1982; Hill, 1985). There is 
also some evidence from experiments using TK deletion 
mutants that the viral TK gene has a role in reactivation 
(Tenser et al., 1989; Leist et al., 1989).
1.5.4. Transformation.
The effect of HSV on cellular transformation will be 
discussed in the following section.
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2. HSV TRANSFORMATION.
2.1. Transforming Viruses.
Both DNA and RNA tumour viruses are capable of causing 
tumours in animals. RNA tumour viruses are restricted to one 
genus (Leukovirus) and are the causative agents of natural 
leukaemias, carcinomas and sarcomas in a large number of 
animal species.
T . Some of the oncogenic DNA viruses
will now be briefly described.
2.1.1. Transformation by SV40 and Polyoma virus.
SV40 and polyoma virus are members of the Polyomavirus 
genus. Both are oncogenic in rodents and transform cells in 
culture (Fenner et al., 1974). An infection in cells 
permissive for viral multiplication leads to cell death 
whereas in a non-productive infection, cells may become 
stably transformed (Sambrook, 1972). Cells transformed by 
SV40 or polyoma virus invariably contain a functional early 
region integrated into the chromosomal DNA (Sambrook et al., 
1968; Basilico et al., 1980; Lania et al., 1980a) and 
transformation seems to be due to the addition of a specific 
viral oncogene rather than to the integration event itself 
(Lania et al., 1980b).
SV40 expresses two tumour antigens in transformed cells, 
large T antigen (90K) and small T antigen (19K),
(Livingstone and Bradley, 1987), whereas polyoma virus 
expresses three, large T (90K), middle T (50K) and small T 
antigen (19K), (Ito, 1980). The expression of SV40 large T 
or polyoma middle T antigen induces cell DNA synthesis and 
cell division (Stoker and Dulbecco, 1969; Fried, 1970) and 
the integration of these viral genes into cellular DNA could 
result in cancer cells which would continue to divide under 
conditions where normal cell division is inhibited (Fried 
and Prives, 1986).
These antigens are discussed in more detail below.
(i ) SV40 Large T Antigen.
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The large T antigen of SV40 is one of the most intensely 
studied eukaryotic proteins because it performs a large 
variety of functions including ATPase activity, regulation 
of cellular gene transcription, control of its own synthesis 
and viral replication and initiation of cellular DNA 
synthesis (Livingston and Bradley, 1987).
Little is known about the molecular role that the large 
T antigen plays in transformation. An important functiom 
might be its ability to associate with cellular proteins. De 
Caprio et al., (1988) described the interaction of T antigen 
with the protein encoded by the retinoblastoma 
susceptibility gene (pRB) which is believed to be involved 
in the negative regulation of cellular proliferation 
(reviewed in Murphree and Benedict, 1985; Weinberg, 1988). 
The protein, pRB, forms complexes not only with SV40 large T 
antigen but also with the adenovirus E1A protein (see below) 
and human papilloma virus E7 protein (Whyte et al., 1988;
De Caprio et al., 1988; Munger et al., 1989). Mutational 
analysis of the viral proteins has shown that the regions 
needed for interaction with pRB are also required for 
transformation (De Caprio et al., 1988; Whyte et al., 1989; 
Munger et al., 1989). This suggests that the pRB is a 
cellular target for transformation by these viral 
oncoproteins. By binding to pRB the viral proteins might 
interfere with its normal function thus mimicking the loss 
of pRB seen in tumour cell lines (Whyte et al., 1988).
Another cellular protein, p53, binds to a different 
region of large T antigen. Numerous reports suggest that 
this protein, which is overproduced in a variety of 
neoplastic cell types (Jenkins and Sturzbecher 1988), is an 
oncogene product directly involved in malignant 
transformation (Rovinski and Benchimol 1988) and may actas a 
tumour suppressor ( reviewed by Levine, 1990). The large T 
antigen of SV40, the E1B protein of adenovirus (see below) 
and the papilloma E6 protein form tight complexes with p53 
(reviewed by Levine, 1990) which seems to become 
metabolically stabilized in SV40-transformed cells leading 
to an enhanced level of p53 (Crawford, 1983). This, however, 
does not seem to be caused directly by the binding of large 
T antigen and p53 (Deppert and Steinmayer, 1989) .
Large T antigen is sufficient for both immortalization
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and transformation of primary rat cells but the efficiency 
of transformation caused by SV40 large T antigen is probably 
increased by the presence of the second tumour antigen found 
in SV40 transformed cells, small T (Livingstone and Bradley,
1987) .
(ii) Polyoma Virus T Antigens.
Three T antigens, large, middle and small T, are 
expressed by integrated polyoma virus sequences in 
transformed rodent cell lines (Ito, 1980). Like its SV40 
counterpart, polyoma virus large T antigen is able to bind 
to DNA, exhibits ATPase activity and is required for viral 
DNA replication. Unlike the SV40 protein, however, it is not 
able to transform cells. The transforming
function of polyoma virus is located on a separate protein, 
middle T antigen, which is sufficient to transform 
established culture cells. Middle T antigen cannot, however, 
induce the conversion of primary cells to an "immortalized" 
cell line and this requires the co-operation of large T 
antigen (Fried and Prives, 1986). A tyrosyl-specific protein 
kinase activity is found associated with middle T antigen 
which is due to its association with the cellular
C “ S2TCproto-oncogene product pp60-----  (Courtneidge and Smith,
c — s rc
1983, 1984). The pp60-----  molecules associated with middle
T antigen differ from their non-complexed counterparts by 
the presence of a phosphate free tyrosine at residue 527 
(Cartwright et al., 1986) and a higher tyrosine kinase 
activity (Courtneidge, 1985). Courtneidge (1985) proposed 
that middle T antigen might affect transformation by
prevgn£j.gg phosphorylation of tyrosine 527 as mutants of
pp60 , with a substitution of phenylalanine for tyrosine
at residue 527, readily transform cells whereas wild type
c-src does not (Cartwright et al., 1987). The prevention of
phosphorylation of the tyrosine residue is thought to be
caused by steric hindrance brought about by the binding of
middle T antigen (Cheng et al., 1989).The amino terminal of
middle T antigen is required for its capacity to transform
cells (Murkland and Smith, 1987) and for its ability to
associate with and activate the protein kinase activity of 
c-srcpp60----- . This region was further located to the first four
amino acids of middle T antigen (Cook and Hassell, 1990).
Adenovirus type 12 E1A has been shown to transform rat cells
in transfection assays (Gallimore et al., 1985), however,
such transformation is 30 fold less efficient than with 
virus transformed cells.
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Small T antigen may co-operate in the transformation caused 
by middle T antigen (Ito, 1980).
2.1.2. Transformation by Adenovirus.
Cell lines derived from adenovirus transformed 
non-permissive cells maintain a subgenomic fragment from the 
left-hand 8-12% of the viral genome which contains genetic 
information sufficient for transformation of primary cells 
in culture (Sambrook et al., 1975). This region contains two 
transcriptional units ElA and E1B which are responsible for 
oncogenic transformation (Graham et al., 1974; Gallimore et 
al., 1974). In transformed cells ElA codes for two 
co-terminal mRNAs specifying two related proteins whereas 
E1B codes for one mRNA which is translated into two 
unrelated proteins (Branton et al., 1985).
There is a certain amount of evidence to suggest that 
ElA could take over the cell proliferating function of 
c-myc. Transformation by adenovirus types 5 and 12 is 
accompanied by an inhibition of expression of a number of 
cellular genes, including c-myc (van der Eb et al., 1989). 
Additional to this is the fact that the sequences 
responsible for transformation are also associated with the 
suppression of transcriptional enhancers (Velcich and Ziff, 
1985; Hen et al., 1985). ElA has also been shown to interact 
with pRB which is believed to be involved with the negative 
regulation of cellular proliferation (section A.2.1.1.i).
The proteins encoded by the E1B gene region play a 
cooperative part in the transformation process and cannot, 
by themselves, induce alterations in cell growth or 
morphology (reviewed by Stillman, 1986). One of its encoded 
proteins has been shown to bind to p53 (reviewed by Levine,
1990) whereas the other protein localizes to membranes of 
the nuclear envelope, cytoplasm and the cell surface in 
transformed cells.
It has been suggested that ElA gene promotes the 
establishment of immortalized non-tumorigenic clones 
(Houwelling et al., 1980) while E1B produces the transformed 
phenotype.
2.1.3. Transformation by EBV.
EBV is a human herpesvirus that is causally associated
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with several malignancies including nasopharangeal 
carcinoma, African Burkitts lymphoma and lymphoproliferative 
disorders in immunosupressed patients (Miller, 1985). In 
vitro, EBV infects human B-cells and immortalizes between 10 
and 100% of them (zur Hausen, 1981). The genes required to 
initiate and/or maintain the transformed state in vitro have 
not been identified. However, at least 8 viral genes are 
transcribed in B-cells that have been immortalized in vitro 
and circumstantial evidence exists that several of these 
gene products will be required for this process (Knutson and 
Sugden, 1988). Of the 8 proteins, 6 are nuclear proteins 
(EBNAs or Epstein-Barr virus nuclear antigens) and 2 are 
membrane proteins (LMPs, latent membrane proteins). BNLF-1, 
which is an LMP, induces established rodent cell lines to 
grow in an anchorage-independent fashion in agarose (Wang et 
al., 1985; Baichwal and Sugden, 1988). Most of these 
anchorage-independent clones also grow as tumours in nude 
mice. The product of the BNFL-1 gene contains 6 hydrophobic 
domains which seem to be inserted into the membrane 
(Liebowitz et al., 1986) and which are required to transform 
BALB/3T3 cells (Baichwal et al, 1989). Baichwal et al.
(1989) speculated that this protein is related to 
cell-surface receptors due to its location at the cell 
surface, its rapid turnover, its presence in patches in the 
membrane and its being phosphorylated. If BNFL-1 is related 
to a receptor it is possible that it will function as a 
receptor for some growth factor.
EBNAl is important in the episomal maintenance of the 
viral genome in transformed cells (Reisman et al., 1985). A 
second type of EBNA, named EBNA2, plays a continuing role in 
the expression of the transformed phenotype (Rickinson et: 
al., 1987). Thus, EBV posesses more than one transforming 
function in the same way as SV40, polyomavirus and 
adenovirus.
The above sections show that SV40, polyoma virus, 
adenovirus and EBV all encode multiple transforming 
functions and that the sequences encoding these functions 
are retained by the transformed cell suggesting that their 
continued expression is important for maintenance of the 
transformed phenotype. In many cases the transforming
29
functions may exert their effects by interacting with 
cellular oncogenes and anti-oncogenes.
2.2. Oncogenic Herpesviruses.
The gamma herpesviruses Marek's disease virus (MDV),
EBV, herpesvirus saimiri (HVS) and herpesvirus ateles (HVA) 
all produce tumours in animals. MDV induces malignant 
lymphomas in chickens, the natural host (Kato and Hirai,
1985) , EBV induces lymphomas in marmosets as well as being 
thought to be involved in the aetiology of Burkitts lymphoma 
and nasopharyngeal carcinoma in man (Dambaugh et al., 1986, 
section A.2.1.3.) and HVS and HVA induce lymohomas on 
in Dculation of marmosets, which are not the natural host 
(Melendez et al., 1970; Melendez et al., 1972). In all these 
cases, DNA is maintained in the tumour cells.
HSV and HCMV have been associated with cervical cancer 
but with these viruses the DNA is not present in the 
majority of samples analyzed.
(i ) Herpesvirus saimiri and Herpesvirus ateles.
Herpesvirus ateles causes T-cell lympomas of marmosets 
(see above) and is capable of in vitro transformation of 
peripheral blood T-lymphocytes (Falk et al., 1978). It 
appears to be similar to herpesvirus s amiri on which more 
work has been peformed.
HVS DNA is present in transformed cells as large 
episomal molecules (Kaschka-Dierich et al., 1982; Medveczky 
et al., 1989). HVS-transformed cells are T-lymphocytes of 
the CD-8 class (Kiyotaki et al., 1986), and transformation 
appears to be caused by the left-hand end of the unique 
sequence (L-DNA). This region is extremely variable 
(Medevecsky et al., 1984) and three groups of HVS (A, B and 
C) have been identified on the basis of DNA homology in this 
region. Group A and C strains can transform peripheral blood 
lymphocytes of common marmosets whereas group B strains 
cannot (Desrosiers et al., 1986). Group A and B strains have 
been shown to induce lymphomas in various new world primates 
(Wright et al., 1977). There are contradictory reports about 
the oncogenicity of HVS in rabbits (Daniel et al., 1974; 
Deinhardt et al., 1974), however, recently Medveczky et al.
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(1989) found only group C viruses to be oncogenic in 
rabbits. This group also showed that recombinant B/C 
viruses, constructed by co-transfecting the L-DNA region of 
a C strain virus with virion DNA from a B group virus, was 
also tumourigenic.
Analysis of the DNA from this region of a group A virus 
shows that it contains a reading frame that is required for 
immortalization of marmoset T-lymphocytes and its protein 
product is termed the saimiri transforming protein (STP, 
Murthy et al., 1989). A group C virus did not contain a 
similar protein, however, two further reading frames were 
found in this region of DNA (Biesinger et al., 1989)
(ii) Marek's disease virus.
Several investigators have demonstrated that serial in 
vitro passage of virulent MDV in primary chicken embryo 
fibroblasts resulted in a loss of virion tumourigenicity 
(Churchill et al., 1969; Fukuchi et al., 1985). This loss of 
tumourigenicity correlates with the amplification of a 132bp 
repeat sequence found within the BamHI d and BamHI h 
fragments of the genome (Maotani et al., 1986) and was only 
observed with non-pathogenic strains (Fukuchi et al., 1985). 
A 1.8kb transcript is produced from this region in cells 
infected by a pathogenic strain of MDV but not in cells 
infected with a non-pathogenic strain which suggests that 
this is associated with transformation (Bradley et al.,
1989) .
(iii) Herpes simplex virus and Human Cytomegalovirus.
The alpha herpesvirus, HSV, and the beta herpesvirus,
HCMV, may be involved in cancer of the cervix. Research into 
the epidemiology of cervical cancer has implicated a 
possible multifactorial aetiology. Cervical cancer is 
believed to be a sexually transmitted disease and attention 
has focused on sexually transmitted organisms with oncogenic 
potential. These include HSV-2, HPV (see below) and HCMV.
HCMV is a sexually transmissible cause of cervicitis and 
urethritis (Evans, 1976) and has been shown to transform 
human embryo lung cells (Geder et al., 1976) and human 
endothelial cells (Smiley et al., 1988). Also, mouse 
cervices treated with UV-irradiated HCMV, showed an
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increased level of development of cancer compared to 
untreated controls (Heggie et al., 1986). HCMV DNA, RNA and 
antigens have all been detected in HCMV transformed cells 
and in tumours although there is conflicting evidence 
against this (Macnab, 1987). Transformation studies have led 
to the identification of DNA sequences thought to be 
involved in initiating transformation. Nelson et al. (1983) 
identified a 558bp sequence within the BamHI e fragment of 
HCMV strain AD169 which is capable of transforming NIH3T3 
cells and El Beik et al. (1986) identified a further two 
regions which are capable of transforming NIH3T3 and Rat-2 
cells. The fragments in the latter study do not share 
homology with those of the previous one, however, they do 
show homology with the Bglll c transforming fragment of 
HSV-2 (Jariwalla et al. 1980) . Fletcher et al. (1986) 
detected sequences hybridizing to HCMV DNA in 2/43 biopsies 
taken from patients with cervical intra-epithelial neoplasia 
(CIN). This integrated DNA has been cloned (Fletcher and 
Macnab, 1989) and shows high homology with the Hindlll e 
region of the HCMV genome. The HCMV Hindlll e region 
contains the DNA sequences for the major IE gene which 
encodes a polypeptide with a strong promoter and enhancer 
(Boshart et al., 1985) in addition to the ADl69-transforming 
region (Nelson et al., 1983). The major IE gene has been 
shown to activate transcription of other virus and cellular 
genes (Everett and Dunlop, 1984; Rando et al., 1987), and it 
is conceivable that such activation could involve cellular 
oncogenes during the development of transformed cells, 
although this has not been shown.
Early evidence of a causative role for HSV-2 in cervical 
cancer came from the cervical smears of women with genital 
HSV-2 infection which showed an increased incidence of 
premalignant change (Naib et al., 1966). Further 
seroepidemiological studies showed conflicting results, 
whilst some studies showed that HSV-2 infection may be an 
aetiological agent of cervical cancer (Nahmias et al., 1974; 
Aurelian et al., 1975) results from Vonka et al. (1984) 
disagree with this finding. The association of HSV-2 and 
cervical cancer is discussed in more detail below (sections 
A.2.2.2. and A.2.2.3.).
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2.2.1. The Role of HPV in Cervical Cancer.
A good deal of evidence exists to link human 
papillomavirus (HPV), as well as HSV-2 and HCMV, with 
cervical cancer (reviewed by Baird, 1985; Macnab, 1987) and 
it has been proposed that the viruses may have a synergistic 
effect (section D.2.).
HPV-16 and HPV-18 have been detected in a high 
percentage of genital cancer biopsies (Durst et al., 1983? 
Scholl et al., 1985? Macnab et al., 1986; Murdoch et al.,
1988) and in the majority of cases the HPV DNA is integrated 
into the cellular genome. Integration usually occurs within 
the viral El and E2 ORFs and is often accompanied by 
deletions in this area (Schneider-Gadicke and Schwarz,
1986). The viral early region encoding the E6 and E7 ORFs is 
selectively retained and expressed in cervical 
cancer-derived cell lines (Androphy et al., 1987; Banks et 
al., 1987) and transformation of primary rodent epithelial 
cells requires a functional E7 gene to co-operate with the
c-
activated ras (Phelps et al., 1988; Story et al., 1988,
'   A  — —
1990) or fos (Crook et al., 1988) oncogenes. The E7 gene has 
also been shown to interact with pRB which is believed to be 
involved with the negative regulation of cellular 
proliferation (section A.2.1.1.i). Thus, HPV seems to 
transform cells in a similar manner to other DNA tumour 
viruses in that its DNA is integrated into the genome and 
there is evidence of a transforming protein which may 
interact with a cellular oncogene. However, since current 
evidence suggests that infection with oncogenic types of HPV 
is common, without being transforming (Macnab et al., 1986), 
the identification of other factors which influence the 
expression, persistance and progression of HPV infection may 
be significant (section D.2.).
2.2.2. Evidence of Retained HSV-2 Information in Cervical 
Carcinoma Cells.
HSV-2 DNA sequences have been detected in biopsies of 
cervical carcinomas, in situ (CIN), and invasive cervical 
cancer. Almost all studies reveal the presence of the Bglll 
n fragment sequences in a small proportion (about 10%) of 
tumours (Galloway and McDougall, 1983? Park et al., 1983; 
Macnab et al., 1985b, 1986? Prakesh et al., 1985). The
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detection of HSV DNA in cervical cancer specimens is only 
circumstantial evidence that HSV has an aetiological role 
but significance is added by the fact that it is one of the 
two morphological transforming regions (see below) of the 
HSV-2 genome which is most frequently retained.
RNA which preferentially hybridizes to the R regions of 
the HSV genome and a region with map units 0.07-§.40 has 
been demonstrated in pre-malignant cervical cells but not in 
matched control biopsies (McDougall et al., 1980; E gin et
X
al. , 1981). However, R regions of the HSV genome show 
considerable homology ?o regions of human DNA. Also, 
cellular DNA sequences in tumour cells with homology to the 
plasmid vector pBR322 have been found to undergo 
amplification (Park, 1983; Macnab et al., 1984; Cameron et 
al., 1985). Thus, the detection of RNA homologous to HSV DNA 
in cervical neoplasia does not necessarily indicate the 
persistence of viral sequences in the cell (reviewed by 
Macnab, 1987) .
HSV-2 antigens have also been demonstrated in 60-90% of 
cases of cervical dysplasia, CIN and invasive cervical 
cancer (Royston and Aurelian, 1970). In addition, the major 
HSV-2 DNA binding protein has been detected by monospecific 
antisera in over 30% of cervical tumour specimens and CIN 
biopsies (Dreesman et al., 1980) and the large subunit of 
HSV-2 ribonucleotide reductase (RRl) was detected in 50% of 
similar tissues (Di Luca et al., 1989).
2.2.3. Morphological Transformation of Cultured Cells by 
HSV.
Although no direct link has been established between HSV 
infection and cervical cancer, the fact that abortive 
infections with defective HSV can transform normal rodent 
embryo cells (Galloway and McDougall,
1983; Cameron et al. 1985; Jariwalla et al. 1986) is well 
established. Three regions of the HSV genome which induce 
cellular transformation have been identified in vitro by 
transfection assays.
(i) MTRI.
Camacho and .Spear (1978) identified a transforming 
region, present in HSV-1, which is known as MTRI
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(morphological transforming region of HSV-1) and maps in 
Xbal f^ (0.29 to 0.45 map units) and Bglll i^ (0.311 to 0.415 
map units, Reyes et al. 1979). The sequences for 
glycoprotein B (gB) can at least be transiently expressed 
from this fragment. A mutagenic peptide may also be 
expressed from MTRI (Shillitoe et al., 1986) and this is 
discussed in section A.2.2.5.
(ii) MTRII.
In HSV-2, there are two regions of the genome which have 
been associated with the induction of morphological 
transformation. MTR-II, (morphological transforming region 
of HSV-2), maps in Bglll n (0.58 to 0.62 m.u.? Reyes et al. 
1979; Macnab and McDougall, 1980; Galloway and McDougall, 
1981; Cameron et al. 1985; Figure 4). The minimal 
transforming region of this fragment has been localized to a 
small, putative stem-loop structure of 737bp (737TF), 
bounded by direct repeats, which is found in the left-hand 
region of Bglll n (Galloway et al. 1984), within the gene 
encoding UL41 (Figure 4). Galloway et al. (1984) proposed
that a similar structure, present in HCMV, may induce 
morphological transformation. The stem-loop might be 
important since such structures can also be formed by 
insertion sequences (IS) that are capable of integrating 
into the cellular genome. Three mechanisms of transformation 
were proposed (Galloway et al., 1984), activation of a 
cellular oncogene, function as an enhancer or action as a 
mutagen. The effect of this sequence on random mutagenesis 
remains insignificant in transfection assays (Brandt et al.,
1987) and Pilon et al. (1989) have shown that transformation 
induced by it is not linked with mutagenesis of a cellular 
marker gene. The proposal that the putative stem-loop 
structure may function as an IS is also debatable since this 
737bp sequence does not conform to the standard description 
of an IS; it does not appear to be capable of moving around 
the genome and it does not encode a tranposase (Lewin,
1990). The transposase could be supplied by other regions of 
the genome, but this has not been shown. It should also be 
noted that the significance of such stem-loops is unclear 
since computer scanning has found many such structures 
elsewhere in the HSV genome (Shillitoe, 1988).
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Figure 4. Genome arrangement of HSV-2 showing Bgl II g 
(MTR III) and Bgl II n (MTRII) which encode the large (RR1) 
and small (RR2) subunits of ribonucleotide reductase. The 
positions of the genes UL39, UL40 and UL41 are indicated, as 
are the two transforming fragments 737TF and 486TF.
737TF is the smallest fragment of MTR II required to transform 
rat embryo or NIH 3T3 cells in the focus or anchorage dependent
assay of Galloway et al. (1984). The 486TF (Jones et al.. 1986) is 
the smallest fragment of MTR III required to transform Rat 2 cells 
in the focus assay system of Jariwalla et al. (1986).
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The left-hand end of MTRII also contains the coding 
sequences of RR2 (Figure 4, section A.3.3.) and it was 
proposed that expression of this protein might be involved 
in the induction of the transformed phenotype. However, 
retention and expression of these sequences were not found 
to correlate with transformation (Kessous-Elbaz et al .,
1989) .
Other experiments (Pilon et al. 1989) disagree with 
these findings as it was observed that the left-hand portion 
of Bglll n caused neither transformation nor mutagenesis in 
NIH3T3 cells whereas the right-hand region was transforming 
but not mutagenic.
The topic of transformation caused by MTRII is thus very 
confused at present with no good evidence for a mechanism of 
transformation or a transforming region smaller than the 
original Bglll n fragment.
(iii) MTRIII.
MTRIII (the third morphological transforming region of 
HSV), maps in HSV-2 Bglll c (Peden et al. 1982). The left 
64% of this fragment causes cellular immortalization whereas 
the remaining 30%, BamHI e (0.54 to 0.58 m.u.), acts to 
convert immortalized rat embryo (RE) cells to the 
transformed phenotype (Jariwalla et al. 1986). The minimal 
region of MTRIII that is capable of causing transformation 
has been mapped to a 486bp fragment,486TF, located on the 
PstI c fragment (Jones et al. 1986). The same fragment on 
the HSV-1 genome can also transform cells but with much less 
efficiency (R. J. Jariwalla, personal communication). 
Sequence analysis of this region revealed the presence of 
short ORFs but these were found to have no upstream TATA or 
CAAT boxes so their significance is unclear. PstI c also 
contains a number of repetetive DNA elements that appear to 
be clustered within the 486bp sequence. There are 5 
stretches of alternating purine/pyrimidines compared to only 
one such stretch in the corresponding region of HSV-1. Such 
residues may have the capacity to form Z-DNA which has been 
implicated in homologous recombination and destabilization 
of chromatin structure. The cluster of Z-DNA tracts may be a 
"hot-spot" for recombination and could contribute to a 
transforming function by exerting cis-acting sequences on
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the expression of cellular genes. There are also three 
CCGCCC motifs (again compared to one in HSV-1), one of which 
occurs as an inverted repeat. This sequence is thought to be 
an SPl protein binding consensus (Ishi et al. 1986), and 
recently three copies of the inverted sequence have been 
identified in the strong enhancer of HCMV (Boshart et al.,
1985). Five purine- and three pyrimidine-rich elements, 
which resemble enhancer core sequences, are also present 
within the 486bp fragment, as are a number of possible 
stem-loop structures which could promote transposition or 
insertion in a similar manner to the 737bp sequence 
described previously (see above).
The 486bp transforming region has been shown to function 
as a transcriptional promoter when fused to the bacterial 
CAT gene (Jones, 1989) and it was suggested that the 
fragment may act to alter the expression of a cellular gene. 
A number of cellular genes have been found to be 
differentially expressed in cells transformed by the 486TF, 
namely c-H-ras and p53, which are present in higher levels. 
Regions of p53 were also found to have been amplified. This 
suggests that these genes may be involved in the 
transformation process possibly due to some effect of the 
486TF (Jones et al., 1989). Zhu and Jones (1990) have also 
suggested that the 486TF, in combination with cellular 
factors, triggers unscheduled rounds of cellular chromosomal 
replication resulting in chromosomal abberations which may
Of
ultimatly lead to cellular transformation. Bglll c also
A
contains most of the coding sequences for RRl (Figure 4, 
section A.3.3.), including a region with serine/threonine 
protein kinase activity (Chung et al., 1989, section 
A. 3.3.4.) and although transformation can be established 
with the 486TF alone, the potential role of this in 
transformation has not been ruled out (section A.2.2.5.).
2.2.4. The "Hit and Run” Hypothesis.
In HSV-transformed cell lines the quantity of DNA 
present is always less than one copy per cell and varies 
with passage in culture (Galloway et al., 1980; Cameron et 
al., 1985). It seems unlikely, therefore, that sufficient 
HSV DNA could be retained in order to encode a protein 
responsible for the maintenance of the transformed state.
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This does not exclude the possibility that active 
recombination of HSV sequences into the host cell chromosome 
might be important for oncogenesis (Galloway and McDougall, 
1983). Short HSV sequences might be difficult to detect by 
Southern blotting analysis. Alternatively, HSV sequences may 
act in a "hit and run" mechanism where activation of a viral 
or cellular oncogene might occur before the HSV DNA is 
rapidly excised from the host cell (Skinner, 1976; Galloway 
and McDougall, 1983). Saavedra and Kessous-Elbaz (1985) 
described an experiment where co-transfection of the plasmid 
pAG60 (which confers resistance to the antibiotic G418) with 
the complete Bglll n fragment reduced the overall efficiency 
of colony formation in G418, compared with pAG60 alone, 
suggesting that this sequence is poisonous to cells. The 
whole Bglll n fragment seems to be required for the 
inhibitory effect since sub-fragments of this sequence have 
no effect on colony formation (Kessous-Elbaz et al., 1989).
The failure of HSV-transformed cells in tissue culture 
to retain viral sequences contrasts with the presence of HSV 
sequences in a small but significant proportion of cervical 
cancer and CIN biopsies. The differences observed may 
reflect the fact that cervical cancers are generally of 
epithelial origin whereas the rat cells examined in culture 
are predominantly fibroblastic (Macnab, 1987).
2.2.5. Possible mechanisms of HSV Oncogenesis.
(i) Activation of Cellular Genes; evidence for the 
trans-activation of cellular genes has been presented 
(section A.I.5.2.). Other ways of cellular gene activation 
include reduced methylation and promoter/enhancer insertion. 
In HSV-2 infected and HSV transformed cells, cellular DNA 
shows reduced methylation (J.M. Macnab, ' ( |C^
). This phenomenom leads to increased gene 
expression in experiments with mouse retroviruses (Janner et 
al., 1982). In addition, tumour cells often show reduced 
methylation when compared to normal control cells (Adams and 
Burdon, 1983). As for promoter/enhancer insertion causing 
gene activation, sequences as small as lOObp can induce a 
cellular gene (McKnight and Kingsbury, 1982; Everett, 1983). 
Such sequences would escape detection by the Southern
38
blotting analysis of Cameron et al. (1985). Homologies 
between viral and cellular DNA sequences (Peden et al.,
1982; Gamez-Marquez et al., 1985; Spector et al., 1987) 
could allow viral integration into the host cell DNA by 
homologous recombination.
(ii) Activation of an Endogenous Virus; HSV-infection 
can activate endogenous C-type virus (mux) from a feline 
cell line (F81) transformed by the Moloney strain of murine 
sarcoma virus (Hampar et al. , 1976; Boyd et al., 1980). This 
activation may be due to mutagenesis or integration of an 
HSV promoter/enhancer near to the integrated endogenous 
virus (Macnab, 1987). HSV-1 sequences responsible for this 
map in MTR-1. Boyd et al. (19 80) found that the TK gene from 
MTR-1 is responsible but this is disputed by Shillitoe et 
al. (1986) who found the inducing sequences in MTR-1 to be 
distinct from the TK gene and also from the mutagenic BamHI 
2 fragment (section A.2.2.5.iv) and the DNA polymerase gene.
(iii) Amplification of Cellular Genes; both HSV-1 and
HSV-2 have been shown to amplify integrated SV40 sequences,
hoW
m  an SV40-transformed Chinese hamster cell line (Schle 
et al., 1983) in a similar manner to certain physical and 
chemical carcinogens (Laui, 1981). This effect seems to 
require the DNA polymerase (Matz et al., 1984; Heilbronn et 
al., 1985). Amplified and mutated cellular oncogenes have 
been found in many tumours suggesting that the mutagenic and 
amplifying properties of HSV may at least be partly 
responsible for its oncogenic actions.
(iv) Mutagenesis of Cellular Genes; HSV infection was 
first thought to be mutagenic when chromosomal aberrations, 
including random changes and specific gaps were reported in 
infected cells (Stich et al., 1964). This process does not 
require viral DNA synthesis (zur Hausen, 1967, 1968; Waubke, 
1968) and may be due to the induction of a DNase with 
endonuclease activity by HSV-infection (Morrison and Keir, 
1968) .
An increase in the mutagenic rate of a cellular gene 
encoding the enzyme hypoxanthine-guanine phosphoribosyl 
transferase (HGPRT) was also shown after infection of
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permissive cells with UV-inactivated HSV-1 (Schlehofer and 
zur Hausen, 1982) and infection of non-permissive cells with 
HSV-2 (Pilon et al., 1985). In the latter study, the 
transcription rate and the size of the transcript were 
similar to those in uninfected cells suggesting that the 
mutagenic effect was due to point mutations (Pilon et al.,
1986). Such mutations could have oncogenic effects if they 
activated oncogenes, like c-ras, or inactivated 
anti-oncogenes.
Hwang and Shillitoe (1990) studied the effect of HSV-1 
infection on the mutagenic rate of a marker gene, supF, 
located on the shuttle vector plasmid pZl89 (Seidman et al., 
1985, section C.2.1.1.). The mutation frequency was higher 
in infected cells (0.25%) than in uninfected controls 
(0.06%) or in cells infected with vaccinia virus (0.07%). 
Sequencing revealed that the mutations induced by HSV-1 were 
not only more frequent, but also different, in type to those 
occuring spontaneously. The differences included the 
observations that there was more than one mutation occuring 
in the marker genes in HSV-1 infected cells. There seemed to 
be a "hot spot" for HSV-1 mutations, deletion mutations 
occured at a higher frequency and there were also insertionsA'
which were not present in the spontaneous mutants. These 
differences indicate that there might be some mechanisms 
resulting from HSV-1 infection which determine the type of 
mutations as well as increasing their frequency.
The mechanism by which HSV infection could increase the 
frequency of somatic mutation is unknown, but could be 
related to the activity of various viral proteins. The 
maximum increase in mutation frequency is seen 2-4 hours 
post-infection (Hwang and Shillitoe, 1990) implying that the 
effect is likely to be a function of a structural component, 
or an IE or E protein, particularly one which is involved in 
DNA metabolism, rather than late proteins. Candidate E 
proteins include dUTPase (Caradona and Cheng, 1981; Preston 
and Fisher, 1984), uracil-DNA glycosylase (Caradonna and 
Cheng, 1981; Caradonna et al., 1987), alkaline exonuclease 
(Costa et al., 1983), thymidine kinase (McKnight, 1980), DNA 
polymerase (Ostrander and Cheng, 1980; Gibbs et al., 1985) 
or ribonucleotide reductase (Huzar and Bacchetti, 1983; 
Cohen, 1972).
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HSV DNA polymerase and DNase activity have been proposed 
as having a role in mutagenesis (Galloway and McDougall, 
1983, Matz et al., 1984, 1985) and viruses with mutant DNA 
polymerase activity have been isolated. These viruses show 
reduced mutagenesis of the TK gene implying that the wt DNA 
polymerase may be mutagenic (Hall et al., 1984, 1985). 
However, the HSV DNA polymerase does not appear to be linked 
with mutations that arise in a shuttle vector plasmid in 
HSV-1 infected cells (Shillitoe, personal communication).
In normal cells, intracellular dUTP levels are very low, 
reducing the incorporation of dUTP into DNA (Shlomai and 
Kornberg, 1978; Goulian et al ., 1980a,b). The dUTPase is 
involved in the hydrolysis of dUTP to dUMP (Williams and 
Cheng, 1979) implying a role for an increase in dUTPase 
activity in preventing misincorporation of uracil into DNA. 
Alternativly, increased dUTPase activity in infected cells 
(Caradonna and Cheng, 1981) could cause an accumulation of 
dUMP which would be converted to dTTP by thymidylate 
synthetase. HSV-1 uracil-DNA glycosylase (Caradonna and 
Cheng, 1981; Caradonna et al., 1987) might also function in 
mutagenesis. Error prone editing or repair functions of this 
enzyme could be followed by misincorporation of dUMP and 
deaminated cytosine residues (Friedberg, 1985).
Perturbation of dNTP pools caused by the viral thymidine 
kinase or ribonucleotide reductase may also cause mutations 
and this will be discussed below (section A.2.2.5.).
Expression of the BamHI £ fragment, which lies within 
HSV-1 MTRI, has been shown to increase the reversion rate of 
a frameshift mutation in bacterial cells by up to 39-fold 
(Shillitoe et al., 1986). The effect was only seen when the 
viral DNA was cloned in one orientation and in one reading 
frame and was enhanced when the promoter was induced 
suggesting that the mutagenic effect was dependent on the 
expression of RNA or a peptide encoded at the left end of 
BamHI £. This region lies to the right of the fragment which 
reactivates retroviruses (Boyd et al., 1980) and to the left 
of the virus DNA polymerase which has been suggested as 
having a role in mutagenesis (see above). The mutagenic 
region specifies the 3' terminal portions of 5 RNA species 
(Holland et al., 1984), the functions of which are unknown, 
and expresses a basic (21% arg nine) peptide consisting of
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37 amino acids, 6 of which are encoded by the vector 
(Shillitoe et al., 1986). Recent work (Das and Shillitoe, 
1990) has shown that immune sera directed against the 
peptide reacted with extracts from HSV-1 infected cells more 
strongly than preimmune sera, implying that this reading 
frame appears to be expressed in HSV-1 infected cells.
2.2.6. The Postulated Role of HSV Ribonucleotide Reductase 
in Mutagenesis.
A role for HSV ribonucleotide reductase in 
transformation was first suggested when subfragments of the 
Hindlll a region, which encompasses UL39 and UL40, were 
shown to induce transformation. Supporting this observation 
is the fact that the HSV enzyme lacks the tight allosteric 
control shown by its cellular counterpart (section A.3.3.) 
and may be involved in the destabilization of dNTP pools in 
infected cells (Jamieson and Bjursell, 1976). The effect of 
HSV ribonucleotide reductase on mutagenesis will be 
discussed in more detail below (section A.3.3.5.).
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3. RIBONUCLEOTIDE REDUCTASES.
3.1. Reaction Mechanism.
The enzyme ribonucleotide reductase catalyses the 
reduction of ribonucleoside diphosphates (NDPs) to the 
corresponding deoxyribonucleoside diphosphates (dNDPs). In 
non-growing cells, the concentrations of deoxyribonucleoside 
triphosphates (dNTPs) are very low and the activity of 
ribonucleotide reductase is thus a prerequisite for DNA 
synthesis and cell multiplication.
The mechanism of the reaction involves a direct 
replacement of the hydroxyl-group, at the 2'-position of the 
ribose moiety, by a hydrogen (Thelander and Reichard, 1979, 
Figure 5). NADPH is the ultimate hydrogen donor for the 
reaction but several proteins participate as hydrogen 
carriers. Two hydrogen donor systems have been identified so 
far. These are the thioredoxin system and the glutaredoxin 
system.
3.1.1. The Thioredoxin System.
This system was first discovered in E. coli (Laurent et 
al,1964). Thioredoxin reductase consists of two, probably 
identical, subunits each of which has one tightly bound FAD 
molecule and a redox-active disulphide in its active centre 
(Thelander, 1968; Ronchi and Williams, 1972). It serves to 
reduce another protein, thioredoxin, at the expense of 
NADPH. The E. coli thioredoxin contains two redox-active 
cysteine residues (Holmgren, 1968) located on a protrusion 
of the active centre of the enzyme (Holmgren et al., 1975). 
The reduced form of thioredoxin is an efficient hydrogen 
donor for ribonucleotide reductase.
Mammalian enzymes specify a thioredoxin system similar 
to that of E. coli. Bacteriophage T4 only encodes a 
thioredoxin which seems to be reduced by the host cell 
thioredoxin reductase (Berglund et al., 1969). T4-induced 
thioredoxin can also be reduced by the glutathione system 
(see below) and appears to be a functional hybrid between 
these two hydrogen donor systems (Holmgren 1978).
Attempts to identify the principal hydrogen donor for
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Figure 5 . Reduction of a ribonucleoside diphosphate to a deoxyribonucleoside 
diphosphate by ribonucleotide reductase (RR). RR-(SH)2 and RR-(S)2 
represent the reduced and oxidized forms of ribonucleotide reductase.
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the HSV-1 induced ribonucleotide reductase resulted in the 
purification of a protein, present in both infected and 
mock-infected extracts, which had similar physical 
characteristics to the cellular thioredoxin (Darling^lSSS) 
suggesting that HSV-1 utilizes the cellular enzyme as a 
hydrogen donor. The lack of sequence evidence for the 
existence of a virus-induced thioredoxin supports this idea.
3.1.2. The Glutaredoxin System.
The glutaredoxin system was identified in an E. coli 
mutant which was unable to replicate bacteriophage T7 DNA, 
and failed to express any detectable level of thioredoxin 
without displaying a decreased capacity to reduce 
ribonucleotide diphosphates (NDPs) in vitro (Holmgren,
1976). In this system, glutathione reductase and NADPH 
reduce glutaredoxin which contains two redox-active cysteine 
residues (Holmgren, 1979a) and serves as a hydrogen donor 
for ribonucleotide reductase (Holmgren, 1979b).
The true in vivo hydrogen donor system is presently 
unknown, but both systems possibly substitute for each other 
under different growth conditions.
3.2. Classification of Ribonucleotide Reductases.
Three different classes of ribonucleotide reductases are 
thought to exist. Class 1 enzymes are monomeric and are 
found in several prokaryotes and a few eukaryotes. Class 2 
enzymes are dimeric and are found mainly in eukaryotes and 
animal viruses. Finally, class 3 enzymes resemble those of 
class 2 in structure but differ from them biochemically.
This class of enzyme is found in a number of gram-positive 
bacteria. Class 1 and 2 enzymes will be described in more 
detail below.
3.2.1. Monomeric Ribonucleotide Reductases.
Monomeric ribonucleotide reductases are represented by 
the Lactobacillus leichmanni enzyme which consists of a 
single polypeptide chain of 76,000 molecular weight (Panagou 
et al., 1972; Chen et al., 1974). The enzyme has a single 
regulatory site which binds the deoxyribonucleoside
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triphosphate (dNTP) allosteric effectors (Singh et al., 
1977). It has been proposed that the enzyme's activity is 
only positively regulated as no negative effectors have been 
found (Goulian and Beck, 1966; Vitols et al., 1967; Follman 
and Hogenkamp, 1971). Binding of the positive effectors 
dATP, dCTP, dTTP and dGTP results in the reduction of CTP, 
UTP, GTP and ATP respectively (Vitols et al., 1967). Chen et 
al. (1974) showed that the substrates can bind to the 
regulatory site with an affinity 100- to 1000-fold lower 
than that of the effectors.
It is assumed that the enzyme has a single catalytic site 
which binds the ribonucleoside triphosphate (NTP) substrates 
(Vitols et al., 1967). The activity of the class 1 enzymes 
requires adenosylcobalamine (AdoCbl, Bl2-coenzyme) which 
binds directly to the polypeptide chain and is dependent on 
effector binding to the regulatory site (Singh et al.,
1977). It is thought that AdoCbl functions in a similar 
manner to the class 2 enzyme subunit which contains the iron 
centre and the tyrosyl free radical (see below; Ashley et 
al., 1986) .
3.2.2. Oligomeric Ribonucleotide Reductases.
(i ) The E. coli Enzyme.
The E. coli ribonucleotide reductase is a dimeric enzyme
consisting of two non-identical subunits, Bl and B2 (Brown
and Reichard, 1969a) which are encoded by the nrdA and nrdB
genes respectively (Fuchs and Karlstrom, 1976). The active
enzyme consists of the Bl and B2 subunits weakly bound in a
2+1:1 stoichiometry in the presence of Mg (Brown et al., 
1967; Brown and Reichard, 1969a; Thelander, 1973) .
The Bl subunit has a molecular weight of 160,000 and is a 
dimer of two identical polypeptides (Thelander, 1973). Each 
Bl subunit contains two catalytic sites which bind all four 
NDP substrates (von Dobeln and Reichard, 1976) . Reduction of 
the substrates requires the presence of the active 
sulphydryl groups provided by two cysteine residues also 
located on Bl (Thelander, 1974) and the stable free radical 
provided by B2 (Thelander, 1974; Ehrenberg and Reichard,
1972). The Bl subunit also contains four regulatory sites 
which can be separated into two types based on their
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affinity for dATP binding (Brown and Reichard, 1969b). The 
two h sites have high affinity for dATP whereas the two 1 
sites have low affinity for this effector. The h sites also 
bind ATP, dTTP and dGTP, regulating the substrate 
specificity of the enzyme, whilst the 1 sites bind only ATP 
in addition to dATP and regulate the overall level of enzyme 
activity with ATP binding activating the enzyme and dATP 
binding reducing its activity. Binding of an effector to the 
h sites results in a conformational change of the catalytic 
site leading to the preferential binding of the appropriate 
substrate. It has been proposed that in vivo there are three 
active and one inactive enzymic states (Thelander and 
Reichard, 1979) . When ATP is bound to the 1^ sites, binding 
of ATP, dTTP or dGTP to the h sites will reduce CDP or UDP, 
GDP (and ADP) or ADP (and GDP) respectively. When dATP is 
bound to the 1_ site the enzyme is inactive irrespective of 
effector binding to the h sites.
The B2 subunit is also dimeric, consisting of two 
identical polypeptides. It has a molecular weight of 78,000 
(Thelander, 1973). The B2 subunit has two important 
elements, an iron centre, which is made up of two non-heme 
iron atoms (Brown et al., 1969) and a stable free radical 
(Ehrenberg and Reichard, 1972) which is destroyed by 
hydroxyurea, a powerful radical scavenger. Sjoberg et al. 
(1977) located the radical to a tyrosine, using isotope 
substitution experiments, which was then identified by 
site-directed mutagenesis (Larsson and Sjoberg, 1986) . The 
radical is involved in the transient transfer of the 
unpaired electron from the enzyme to the substrate. Sjoberg 
et al. (1983) proposed a scheme for this reaction (Figure 
6). Firstly, the hydrogen at position C-3 of the ribose 
moiety is abstracted by the tyrosyl radical of B2 resulting 
in the formation of substrate intermediate I. The presence 
of the radical at C-3 destabilizes the ribose moiety which 
facilitates the ejection of OH- from C-2 forming substrate 
intermediate II. C-2 is then reduced by thiols from Bl and 
recapture of the hydrogen atom at C-3 regenerates the free 
radical. It is unusual to find a stable free radical as an 
integral part of an enzyme and it is thought that it is 
generated and stabilized by the iron centre (Atkin et al.,
1973) .
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Figure 6. The Proposed Involvement of the E. coli Ribonucleotide Reductase 
radical in the reduction of a ribonucleoside diphosphate to a 
deoxyribonucieoside diphosphate. The diagram depicts the substitution 
of the 2' OH group of the substrate ribose moiety with a H. The 
balance of electrons (e-) and the radical (*) are shown.
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Apart from being regulated at the level of enzymic 
activity, the E. coli ribonucleotide reductase enzyme is 
also regulated at the transcriptional level since the 
inhibition of DNA synthsis by thymine starvation increases 
the level of transcription of the reductase genes (Hanke and 
Fuchs, 1983b). This appears to be mediated by a positive 
regulatory protein(s) (Hanke and Fuchs, 1984).
Post-transcriptional regulation also appears to exist as a 
report of a truncated form of B2, resulting from limited 
proteolysis of normal B2 by a serine protease and giving 
rise to an inactive enzyme, has been made (Sjoberg et al.,
1987) .
(ii) Bacteriophage-induced Enzymes.
Bacteriophages T2, T4, T5 and T6 induce a novel 
ribonucleotide reductase activity during infection of E. 
coli (Cohen and Barner, 1962; Biswas et al., 1965; Berglund 
et al., 1969; Eriksson and Berglund 1974), whereas T7 and 
lamda do not (Eriksson and Berglund, 1974). The T4 induced 
enzyme has a molecular weight of 225,000 and is composed of 
two subunits, T4B1 and T4B2, which form a tight complex 
(Berglund 1972a).
The T4B1 subunit consists of two identical polypeptides 
which have a molecular weight of 85,000 (Berglund, 1972a, 
1975). The subunit has a single catalytic site and possibly 
two types of allosteric sites. One of these has a low 
affinity for dATP and the other has high dATP affinity and 
also binds ATP, dTTP and dGTP (Berglund, 1972b). The 
allosteric properties of the T4-induced ribonucleotide 
reductase are similar to those of the E. coli enzyme except 
for the fact that high dATP concentrations positively 
regulates the reduction of the pyrimidine substrates instead 
of inhibiting enzyme activity. The lack of negative 
effectors of the T4-induced enzyme may be related to the 
fact that T4 DNA synthesis is not turned off during 
infection but continues until the T4-infected cell lyses.
The T4B2 subunit also consists of two identical subunits 
which have a molecular weight of 34,500 (Berglund, 1972a, 
1975; Cook and Greenberg, 1983). The T4B2 subunit contains 
two non-heme iron atoms per molecule which are essential for 
activity. Their optical and EPR spectra are very similar to
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those of the E.coli B2 iron centre (Berglund, 1972a, 1975). 
The subunit also contains a tyrosine free radical (Berglund, 
1972a; Sahlin et al., 1982) which is similar to that of the 
E. coli enzyme.
(iii) The Mammalian Enzyme.
Ribonucleotide reductase activity has been demonstrated 
in a number of mammalian systems including rat hepatoma 
(Moore, 1977), calf thymus (Engstrom et al., 1979? Eriksson 
et al., 1979; Thelander et al., 1980), rabbit bone marrow 
(Hooper, 1972, 1978) and human tissue culture cell lines 
(Chang and Cheng, 1979) . The mammalian enzyme is again 
composed of two non-identical subunits, Ml and M2.
The Ml subunit consists of two identical polypeptides 
and its molecular weight in calf thymus is 17^000. The Ml 
dimer contains two catalytic sites and two different types 
of allosteric effector binding sites. The allosteric 
effector binding sites are similar to those of the E.coli 
enzyme except for two differences. Firstly, the number of 
sites in Ml is lower than in Bl and secondly, the Ml sites 
show an equal affinity for dATP binding (Thelander et al., 
1980). Allosteric regulation of activity is similar to that 
of the E.coli enzyme (Eriksson et al., 1979) although in the 
case of the mammalian enzyme, control is more strict.
The M2 subunit has a molecular weight of 88,000 in the 
mouse and is a dimer of two polypeptides. M2 contains a 
non-heme iron centre, which is of the same type as the iron 
centre of B2 (Thelander et al., 1985). It also contains a 
free radical, located on a tyrosine (Graslund et al., 1982), 
which, like the E.coli radical, is inhibited by hydroxyurea 
(Engstrom et al., 1979), but to a greater extent. 
Kjoller-Larsen et al. (1982) and Thelander et al. (1985) 
suggested that this was due to different active site 
topologies with the mammalian site being more exposed.
Synthesis of the mouse enzyme is regulated in a cell
Synthetic
cycle dependent manner. Ml activity is constant
throughout Gl, S and G2 phases whereas M2 activity is less 
in Gl compared to S and G2 (Eriksson and Martin, 1981; 
Engstrom et al., 1985). The reduced activity of M2 in Gl is 
due to the de novo synthesis of the M2 protein at the start 
of the S phase and it has been proposed that this regulation
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occurs at the transcriptional level (Eriksson etal., 1984).
(iv) Viral Induced Enzymes.
Several animal viruses including HSV-1 (Cohen, 1972), 
HSV-2 (Cohen et al., 1974; Huzar and Bachetti 1981; Huzar et 
al., 1983), PRV (Lankinen et al., 1982), EHV serotypes 1 and 
3 (Cohen et al., 1977; Allen et al., 1978), EBV (Henry et 
al., 1978), VV (Slaubaugh et al., 1984) and VZV (Spector et 
al., 1987) have been reported to induce a novel 
ribonucleotide reductase activity in infected cells which 
differs from the host cell enzyme.
3.3. The HSV-Induced Enzyme.
Direct evidence for virus-encoded ribonucleotide 
reductase activity has been obtained for HSV-1 in that the 
multiple HSV-1 mutant tsG (Brown et al., 1973) expressed 
reduced levels of ribonucleotide reductase activity at the 
PT while at the NPT no activity was observed.
The HSV-induced enzyme is composed of two non-identical 
subunits, RRl and RR2 (Frame et al., 1985; Cohen et al., 
1985; Bachetti et al., 1986; Ingemarson and Lankinen, 1987) 
both of which are phosphorylated (Bachetti et al., 1984).
RRl has been shown to be a product of the UL3 9 gene by 
marker rescue of the mutant HSV-1 virus ts!207 (Nikas, 1988) 
and has a molecular weight of 136,000 in HSV-1 and 138,000 
in HSV-2 (Marsden et al., 1978).
RR2 has a molecular weight of 38,000 in HSV-1 and 36,000 
in HSV-2 and is a product of the UL40 gene (Preston, V. G. 
et al., 1988). It was first thought to be a component of the 
viral reductase when it was found to exhibit homology with 
the B2 subunit from E.coli (Standart et al., 1985; Sjoberg 
et al., 1985; McLauchlan, 1986^ and was
shown to be the smaller protein species (Preston V.G. et 
al., 1984) that precipitated with RRl after exposure to 
RRl-specific antibodies (Frame et al., 1985). UL39 and UL40 
mRNAs have unique 5'-ends and common 3'-ends (section 
A.l.4.10.). The arrangement of mRNAs at this HSV-2 genome 
locus is shown in Figure 7.
Conclusive evidence for the involvement of the RR2 
polypeptide in enzymic activity was obtained from the HSV-1
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Figure 7. The Ribonucleotide reductase locus of HSV-2 showing the location 
of transcripts ( — ► ) and the coding regions (■ ■ ■  ) of RR1 and RR2 with 
respect to BamHI 1ragments_e and_Land the Xhol and Sst I sites within 
these fragments. The 4.5 kb and 1.2 kb transcripts encode RR1 and RR2 
respectively. The other mRNAs are late transcripts (McLauchlan, 1986).
Also shown ) are the HSV-2 fragments used for the construction of 
the plasmids pCRR1, pCRR2 and pCRR3 (section C.1.). The plasmid pCRRt 
thus contains the sequences encoding RR1, pCRR2 contains the sequences 
encoding RR2 and pCRR3 contains the sequences encoding both RR1 and RRl
49
mutant ts!222 which has a lesion in UL40 and induces 
negligible levels of ribonucleotide reductase activity at 
both the PT and NPT (Preston V.G. et al., 1988).
The active HSV-1 enzyme has a sedimentation coefficient 
of 17S which corresponds to an approximate molecular weight 
of 370,000 (Ingemarson and Lankinen, 1987), which lead to 
the suggestion that the active enzyme is a homodimeric 
complex of the c>c2^ 2 structure. The complex shows tight 
binding (Frame et al., 1985; Ingemarson and Lankinen, 1987), 
similar to that of the T4-induced enzyme (Berglund 1972a).
Unlike the bacterial and mammalian enzymes, the
2+HSV-induced ribonucleotide reductase is inhibited by Mg or
ATP (Averett et al., 1983; 1984; Huszar and Bacchetti 1981;
Ponce de Leon et al., 1977). This effect is reduced in the
2+presence of a Mg /ATP complex, presumably because the 
formation of the complex lowers the concentration of free 
ligands.
The HSV enzymes have similar substrate binding 
properties. Both enzymes utilize NDP substrates which bind 
at a common catalytic site and which compete with the 
reaction products (dNDP's, Averett et al., 1983). Both 
enzymes are also insensitive to inhibition by dNTPs 
suggesting that they are not allosterically regulated 
(Averett et al., 1983, 1984). The same suggestion can be 
applied to the PRV- (Lankinen et al., 1982) and VZV-induced 
ribonucleotide reductase activities (Spector et al., 1987), 
however, the W-induced activity is inhibited by dATP and 
dTTP and is thus thought to be allosterically regulated 
(Slaubaugh et al., 1984).
There is strong conservation of the tyrosine residue and 
its flanking amino acid sequences in the E.coli B2 and HSV-1 
RR2 subunits and this fact along with the observed 
inhibition of the HSV enzyme by hydroxyurea, a radical 
scavenger (Averett et al., 1983; Lankinen et al., 1982), 
suggests that the HSV enzyme contains a tyrosine radical.
The PRV-induced enzyme is also inhibited by hydroxyurea and 
displays an EPR spectrum resembling that of the M2 tyrosyl 
radical (Lankinen et al., 1982) and so also appears to 
contain a tyrosyl radical.
3.3.1. Regulation of HSV Ribonucleotide Reductase Synthesis.
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As described above, HSV ribonucleotide reductase 
activity does not appear to be allosterically regulated. 
Synthesis of RRl and accumulation of enzymatic activity 
behave temporally as E events (O'Hare and Hayward, 1985a), 
however, studies have shown that RRl can also be synthesized 
under conditions that do not allow the expression of other 
such genes (Middleton et al., 1982). Expression from the 
HSV-1 RRl promoter was found to be stimulated by Vmw65 and 
sequence analysis has revealed the presence of three 
elements which show homology to the TAATGARAT element (Wymer 
et al., 1989). This promoter has also been shown to contain 
a potential binding site for the cellular "octomer motif 
binding factor" at position -136 (Nikas, 1988) and fragments 
containing this site are retarded in gels by Vmw65/cellular 
transcription factor complexes. These complexes have similar 
mobilities in gels to those of the IEC complex formed with 
DNA fragments containing the TAATGARAT motif of the 
regulatory region of IE gene promoters. The above findings 
thus indicate that RRl is capable of being expessed as an IE 
gene. The HSV-2 RRl promoter also contains an AP-1 element 
(Wymer et al., 1989) which may be indicative of IE gene 
expression since AP-1 binding factors are consistently 
expressed in most cell systems (Lee et al., 1987).
In contrast to RRl, the RR2 gene is not expressed in the 
absence of functional IE products (Nikas, 1988). However, in 
the presence of functional IE gene products both the RRl and 
RR2 mRNA levels increase compared to the levels observed 
under IE conditions.
3.3.2. HSV Ribonucleotide Reductase is Essential for Virus 
Growth.
Preston V.G. et al., (1984) suggested that HSV 
ribonucleotide reductase is essential for virus replication 
after observing that the HSV-1 mutant ts!207 failed to 
produce any ribonucleotide reductase activity at the NPT and 
that its yield was 100-fold lower than that of the wt virus 
at this temperature. However, three subsequent reports 
questioned this proposal. Firstly, hydroxyurea, which 
reduces ribonucleotide reductase activity to undetectable 
levels, only lowered the HSV-2 yield in proliferating cells 
6-fold (Nutter e t a l . , 1985). Secondly, a significant amount
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of DNA replication occured in the absence of the 
ribonucleotide reductase genes (Wu et al., 1988) as shown 
using the plasmid replication assay developed by Challberg 
(1986). Finally, the enzyme was shown to be dispensible in 
dividing cells at 34°C (Goldstein and Weller, 1988a) using 
the mutant HSV-1 virus hr 3 which expresses the N-terminal 
434 amino acids fused to the^-galactosidase (lacZ) gene.
Later studies confirmed the requirement for HSV 
ribonucleotide reductase in virus replication as the HSV-1 
mutant ts!222 failed to grow in resting cells at the PT 
indicating that the enzyme is essential under these 
conditions (Preston V.G. et al., 1988). In exponentially 
growing cells, at the PT, tsl222 is dependent on the 
cellular enzyme for replication whilst it was suggested that 
at the NPT the mutant fails to replicate due to inactivation 
of the cellular enzyme. Goldstein and Weller (1988b) also 
show that growth and replication of an HSV-1 mutant, 
expressing less than 10% of the RRl DNA coding region, were 
severely restricted in non-dividing cells or at 39.5°C.
Evidence that ribonucleotide reductase is an essential 
HSV function has been obtained from pathogenicity studies of 
the HSV-1 mutants ts!207 and ts!222. The virulence, in mice, 
of both these mutants was reduced by about 1 million-fold 
when compared to that of the parental virus (HSV-1 strain 
17+), (Cameron et al., 1988). Similar results were also 
obtained by Jacobson et al., ( 189) using a mutant containig 
a deletion in RRl.
3.3.3. Ribonucleotide Reductase as a Target for Antiviral 
Compounds.
The HSV-encoded ribonucleotide reductase is an 
attractive target for antiviral compounds since it is
r\turo '
important for^pathogenicity, it is biochemically distinct 
from the mammalian enzyme and an oligopeptide, which 
inhibits activity, has been identified (Dutia et al., 1986; 
Cohen et al., 1986a; McClements et al., 1988).
This peptide, YAGAWNDL, corresponds to the C-terminal 9 
amino acids of RR2 and inhibits the enzyme by blocking 
RR1/RR2 interaction. Exposure of infected monolayers to the 
peptide, however, does not reduce the level of infective 
virus, presumably because it is too large to enter the
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cells. Enzymic activity can be restored by reassociation of 
the two subunits, both in vivo and in vitro, without the 
requirement for any other HSV proteins (Huang et al., 1988; 
Darling et al., 1988). It has also been demonstrated that 
the two subunits exist in a state of dynamic equilibrium 
between the associated and disassociated forms (Dr. A. J. 
Darling, personal communication). These observations will 
pr ove valuable in further characterization of the enzyme 
and in studies with antiviral compounds.
3.3.4. The Additional Amino-terminal Domain of HSV RRl.
Comparison of the HSV ribonucleotide reductase to its 
counterparts in eukaryotic and prokaryotic cells or in other 
viruses has identified an additional amino-terminal domain 
in the HSV RRl, comprising 320 amino acids, which produces a 
50% increase in molecular weight (Nikas et al., 1986; Swain 
and Galloway, 1986). Proteolytic degradation studies have 
associated enzymic activity with the carboxyl two-thirds of 
HSV RRl and further work showed that the amino-terminal 140 
amino acids were not required (Lankinen et al., 1989). This 
lead to the suggestion that the amino-terminal domain unique 
to the HSV protein is functionally distinct (Ingemarson and 
Lankinen, 1987). Consistent with this interpretation are the 
following observations. Firstly, fragments covering only the 
promoter and/or proximal one-third of the HSV-2 RRl coding 
region have transforming potential (Hayashi et al., 1985; 
Jariwalla et al., 1980, 1986; Jones et al., 1986). Secondly, 
the transforming potential of HSV-1 maps at a site distant
(ULV^
from the ICP6^gene (Camacho and Spear, 1978) and the 
HSV-unique amino-terminal domain of RRl shows only 38% 
intertypic homology as compared to 93% for the remaining 
two-thirds (Nikas et al., 1986). Finally, the expression of 
RRl and enzymic activity behave temporally as E genes but 
the promoter has cis-response elements associated with the 
regulation of IE gene expression which may be related to the 
postulated distinct function of the amino-terminus.
The amino-terminal domain of HSV RRl shows less homology 
than the rest of the protein (Nikas et al., 1986) and Chung 
et al. (1989) associated this domain of HSV-2 with a
protein kinase activity, which could
be related to its transforming ability. Recently the
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amino-terminal domain has been shown to transform 
immortalized Syrian hamster embryo cells, as has full-length 
RRl, whereas the carboxy-terminus did not (Wymer et al.,
1990) .
3.3.5. The Effect of HSV Ribonucleotide Reductase Activity 
on the Mutation Frequency in Infected Cells.
As discussed previously (section A.2.2.5.), the lack of 
allosteric control shown by the HSV ribonucleotide reductase 
may have the effect of destabilizing the dNTP pools in 
infected cells. The importance of dNTP concentrations in 
mediating base substitutions and misincorporations has been 
stressed in studies of both prokaryotic (Weymouth and Loeb, 
1978; Fersht, 1979; Hibner and Alberts, 1980) and eukaryotic 
(Kunkel et al., 1982) systems and the disruption of dNTP 
pools in infected cells may cause an increase in somatic 
mutations. This, in turn, could lead to transformation if, 
for example, a cellular oncogene was affected. Further 
evidence that mutant ribonucleotide reductase activity is 
capable of producing an increased mutation rate within the 
cell was gained by Caras et al. (1988) who showed that a 
mutant Ml subunit, deficient in allosteric control, raised 
the cellular mutation rate when expressed in cells 
containing a normally regulated Ml subunit. No difference in 
dNTP pool sizes was detected, however, and this may be 
because the mutator phenotype is mediated by small changes 
which are difficult to measure due to cellular 
compartmentalization. In the cell lines from which the 
mutant Ml was isolated, the pool sizes were disrupted 
(Ullman et a l ., 1980) so it is possible that the wild-type 
Ml is maintaining the dNTP pool balance in the transfected 
cells and the mutant Ml is only exerting a localized effect 
within the replication complex.
There are, however, flaws in this transformation model. 
For instance, the ribonucleotide reductase locus of HSV-1
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does not appear to transform cells and this virus has not 
been associated with human cancer. Since both enzymes are 
similar, if one caused transformation by disturbing dNTP 
pools, then the other would be expected to have the same 
effect. However, transformation appears to be such a 
complicated process, involving numerous factors, that other 
virus functions may well be required. These factors might be 
specific to HSV-2.
Additionally, the minimal transforming regions of HSV-2 
have been mapped to small DNA fragments one of which lies 
within UL39 and the other which lies outside UL40 (section 
A.2.2.3.). However, it has been suggested that two 
transformation mechanisms might exist, one involving the 
minimal transforming regions and the other involving the 
ribonucleotide reductase enzyme (R.J. Jariwalla, personal 
communication). One aim of this thesis is to study the 
effect of HSV-2 ribonucleotide reductase expression on 
mutagenesis as a step in the initiation of cellular 
transformation.
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SECTION B; MATERIALS AND METHODS.
1. MATERIALS.
1.1. Cells.
Baby hamster kidney (BHK-C13) cells (MacPherson and 
Stoker, 1962) were used for growth and assay of virus. Human 
embryo kidney cells transformed by adenovirus type 5 (29 3 
cells, Graham and Smiley, 1977), which encode mRNAs and 
proteins from the early region of the viral genome (Spector 
et a l ., 1980), were used for transient expression assays and 
for the pZl89 mutagenesis assay. These cells were supplied 
by Jill Macfarlen. The use of 293 cells was suggested by Dr. 
M. Seidman (personal communication) as they give a low 
background mutation frequency in the pZl89 mutagenesis 
assay. Chinese hamster ovary (CHO) strain D422 cells 
(obtained from Dr. M. Meuth) which are hemizygous for the 
adenine phosphoribosyl transferase gene (aprt), (Bradley and 
Letavonec, 1982) were used for the aprt mutagenesis assay. 
Mouse fibroblasts (NIH3T3 cells, obtained from Dr. J. Lang) 
were used in the generation of stable cell lines.
1.2. Bacterial Cells.
E. coli K12 strain DHl (recAl, F, endAl, gyrA96, thi-1, 
supE44, Hanahan, 1983) were used as the host in recombinant 
plasmid experiments. E. coli strain MBM7 070 (F-, lacZamCA 
7020, lacYl, hsdR-, hsdM+, ara-Dl39, (araABC-leu)7679, 
galU, qalK, rpsL, thi, Casadaban and Cohen, 1980) which was 
provided by Dr. M. M. Seidman, was used for analysis of 
plasmids in the pZl89 mutagenesis assay.
1.3. Viruses.
HSV-2 wild type (wt) strain HG52, HSV-1 (wt) strain 17+ 
and temperature sensitive HSV-1 mutants tsK, t^l204, ts!222 
and tsl207 were obtained from stocks maintained in the 
Institute by Mary Murphy. The HSV-1 deletion mutant dll403 
(Stow and Stow, 1986) was supplied by E. Stow. The virus 
_inl814 (Ace et al., 1989) was obtained from Dr. C. Preston.
The L-particles^(HSV-1 particles containing the envelope and 
tegument only) were obtained from Gordon McLean. They were 
obtained during a method of virion purification where virus 
pellets were layered onto a 5-15% Ficoll 400 gradient and 
banded (9000rpm/2 hours/4°C). The L-particles were present 
in a band located above the purified virion band, •
1.4. Tissue Culture Media.
(i) BHK-C13 cells were grown in Glasgow Modified Eagle's 
medium (Busby et al., 1964) supplemented with 100 units/ml 
streptomycin, 100 units/ml penicillin, 0.002% (w:v) phenol 
red. The growth medium used (ETC10) consisted of 80% Eagles, 
10% tryptose phosphate and 10% calf serum.
(ii) 293 and NIH3T3 cells were grown in Dulbecco's medium 
(DMEM, Flow laboratories), a modified version of Eagles 
medium supplemented with 20mM glutamine, 100 units/ml 
streptomycin and 100 units/ml penicillin. In addition to the 
above ingredients, growth medium contained 10% foetal calf 
serum.
(iii) CHO cells were grown ino<-minimal essential medium
-5(Gibco) supplemented with 10 M thymidine, 20mM glutamine, 
100 units/ml streptomycin, 100 units/ml penicillin and 5% 
foetal calf serum.
(iv) For washing and removal of cell monolayers the 
following media were used:
(a) PBS, which contained 170mM NaCl, 3.4mM KCl, lOmM 
NaHP04, 2mM KH2PC>4 (pH 7.2).
(b) Versene, which consisted of PBS containing 0.6mM 
EDTA and 0.0015% (w:v) phenol red.
(c) Trypsin, which comprised 25% (w:v) Difco trypsin 
dissolved in Tris-saline. The constituents of 
Tris-saline were 140mM NaCl, 30mM KCl, 280mM Na2HP04, 
lmg/ml dextrose, 25mM Tris HCl (pH 7.4), 0.005% (w:v) 
phenol red supplemented with 100 units/ml penicillin 
and 100 units/ml streptomycin.
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1.5. Bacterial Culture Media.
Bacteria were propagated in L-broth which consisted of 
177mM NaCl, 1% (w:v) Difco Bactotryptone and 0.5% (w:v) 
yeast extract (pH 7.5 prior to sterilization). Solid medium 
for the growth of colonies was agar containing 1.5% (w:v) 
agar in L-broth. These media were supplemented where 
appropriate with ampicillin or kanamycin (Sigma Chemical 
Company).
1.6. Enzymes.
The majority of restriction enzymes were obtained from 
New England Biolabs or Bethesda Research Laboratories (BRL). 
The Klenow fragment of E. coli DNA polymerase and the calf 
intestine phosphatase (CIP) were as supplied by Boehringer 
Corporation Limited and lysozyme, proteinase K, RNase A and 
DNase were supplied by Sigma Chemical Company.
1.7. Radiochemicals.
325[^- P] deoxynucleoside triphosphates were supplied by 
Amersham International PLC at a specific activity of 3,000 
Ci/mMol.
1.8. Chemicals and Miscellaneous Reagents.
Most chemicals of analytical grade were supplied by BDH 
Chemicals or Sigma Chemical Company. Koch-Light laboratories 
supplied acrylamide, bisacrylamide, boric acid and caesium 
chloride, Biorad laboratories supplied ammonium persulphate 
(APS), TEMED (N,N,N,N-tetramethylethylene diamine) and the 
reagents for Western blotting (gelatin, horse radish 
peroxidase congugate and protein A). The DNA sequencing 
primer (51—3 1) was obtained from Pharmacia. Other 
oligonucleotides used for cloning purposes were constructed 
by Dr. J. McLauchlan using a Biosearch 8600 DNA synthesizer. 
The dNTP's were supplied by P-L Biochemicals. Tissue culture 
materials were supplied by Sterilin Limited and Nunc.
1.9. Antibodies.
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Rabbit antiserum 20208 was raised against a peptide, 
RNSQFVALMPTA (RRl posititions 959-970), (Lankinen et al., 
1989). The antiserum 14995 was raised against a peptide, 
YAGAVVNDL (RR2 positions 332-340), (Telford, 1989). Both 
anti sera were supplied by Dr. H. Lankinen.
1.10. Plasmids.
The constructs made during the course of this study used 
the plasmids pBamt and pRRl (obtained from Dr. I. Nikas) and 
pUCet-2 (obtained from S. Simpson).
The plasmid pZl89 (Seidman et al., 1985) was used for 
the mutagenesis assay.
The plasmid pl75 contains the coding sequences for 
Vtnwl75 and was provided by Dr. R. Everett.
The plasmid p61, which contains the neo gene was a gift 
from Dr. J. Lang.
1.11. Some Commonly used Buffers and Solutions.
STET:
TE:
TBE: 
5xLB: 
SSC:
lOOxDHB:
HBS:
ILB:
EB:
TBS:
3xBM:
PEB:
NTB:
50mM Tris HCl (pH 8.0), 50mM EDTA, 8% (w:v) 
sucrose, 5% (v:v) Triton X100. 
lOmM Tris HCl (pH 7.5), ImM EDTA.
90mM Tris, 90mM boric acid, ImM EDTA (pH 9.3). 
lOOmM Tris HCl (pH 7.5), 20mM MgCl2, 20mM DTT. 
150mM NaCl, 15mM sodium citrate (pH 7.5).
2% (w:v) Ficol, 2% (w:v) polyvinylpyrolidone, 2% 
(w:v) BSA, (Denhardt, 1966).
140mM NaCl, 50mM HEPES (pH 7.12), 1.5mM Na2HP04 . 
150mM NaCl, 1.5mM MgCl2, lOmM EDTA, lOmM Tris HCl 
(pH 7.9), 1% (w:v) SDS.
lOOmM NH4A c , lOmM MgAc, 0.1% SDS, ImM EDTA.
20mM Tris, 500mM NaCl (pH 7.5).
10% (v:v) spacing gel buffer, 5% (v:v) 
mercaptoethanol, 10% (v:v) glycerol, 2.25% (w:v) 
SDS, bromophenol blue to colour.
7M urea, 350mM NaCl, lOmM EDTA, lOmM Tris (pH 7.9), 
1% (w:v) SDS.
0.05M Tri s/HCl (pH 7.5) , 0.01M MgSO  ^ 0.01M DTT, 
50ug/ml BSA. 4
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2. METHODS.
2.1. Cell Culture.
Working stock 293, CHO, NIH3T3 and BHK cell cultures 
were kept in 750ml tissue culture flasks or rotating plastic 
850ml culture bottles. For expression and mutagenesis 
experiments, cells were harvested using a method based on 
cell type. For CHO and BHK cells, the monolayer was washed 
once with 20ml versene and once with 20ml trypsin and the 
detached cells were then resuspended in growth medium. 293 
cells, however, were washed twice with 20mls versene before 
detaching the cells by striking the flask sharply.
2.2 Virus Preparation.
BHK cells in 850ml roller bottles were infected with HSV 
at a moi of 0.003 pfu/cell (10 mis per bottle) in 40ml 
growth medium. Virus-infected cells were incubated at 31°C 
for 3-4 days until extensive cytopathic effect (CPE) had 
developed. Cells were then removed by shaking them into the 
medium, and pelleted (1500rpm/10minutes/4°C).
The supernatant medium was further centrifuged 
(12,000rpm/2 hours/4°C) to concentrate cell-released virus 
(CRV) which was sonicated and stored at -70°C. The pelleted 
material from the low-speed centrifugation was sonicated in 
a small volume of medium for recovery of cell-associated 
virus (CAV). Cell debris was then removed by further 
low-speed centrifugation, sonicated, re-centrifuged and 
re-sonicated before the supernatant containing the CAV was 
stored at -70°C.
The CRV and CAV fractions were checked for sterility 
using blood agar plates and titrated on BHK monolayers.
2.3. Virus Titration.
Virus samples were serially diluted in 10-fold dilutions
-9to a final dilution of 10 . Duplicate plates of BHK cells
-4 -9were then infected with lOOul of 10 to 10 dilutions. The
k n
virus was left to a sorb for 1 hour at 37 C before the
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inoculum was removed and the plates were overlaid with 
methylcellulose medium (growth medium containing 1.5% 
methylcellulose) and incubated for 2-3 days at 37°C. Giemsa 
stain was then added to the methylcellulose medium, left for 
1 hour and washed off. The plaques could then be counted and 
the virus titre established.
2.4. Virus Growth Curves.
Tissue culture plates (30mm) were seeded at a density of
5
5x10 BHK cells per plate and incubated overnight. The 
following day, the cells (1x10 /plate) were infected with 5
pfu/cell in a total volume of lOOul. The virus was left to
 ^ oa sorb for 1 hour at 37 C before the medium was removed. The
cells were washed twice with medium (without serum) and
overlayed with 1.5ml growth medium. Plates were harvested at
appropriate times by scraping the cells into the medium with
rubber policemen, dispensing into black capped vials,
sonicating and storing at -70°C.
Each sample was then titrated on BHK monolayers.
2.5. UV-Inactivation of Virus.
Virus was inactivated by dispensing 400ul into 35mm
tissue culture plates and placing 10-20cm underneath a UV
5lamp for 15 minutes. This reduces the virus titre by 10 
and there is no production of IE gene products (Dr. C. 
Preston, personal communication). The method was suggested 
by Dr. C. Preston.
2.6. Standard DNA Cloning Techniques.
(i ) Restriction Enzyme Digests.
Restriction enzyme digests were performed at 37^C unless 
recommended otherwise by the suppliers. Plasmid DNA and 
restriction enzyme were incubated for 2 hours using an 
enzyme specific reaction buffer. For diagnostic purposes, 
digests were generally carried out in 30ul of buffer for 2 
hours using 1 unit of enzyme for every 0.5ug of plasmid DNA. 
For sub-cloning DNA fragments, the enzyme units and 
incubation time varied according to the size and amount of
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the DNA fragment and whether or not the reaction was desired 
to reach completion.
ii) Ligation of DNA Fragments.
DNA fragments, produced by cleavage with restriction 
enzymes, were ligated to a cleaved plasmid vector which 
contained compatible "sticky ends". Vectors and fragments 
were mixed in ligation buffer (LB) at a ratio of 1:10 and 
incubated overnight at 15°C.
In order to prevent reannealing of the linearized 
vector, these were treated with 25 units of CIP (calf 
intestine phosphatase) during the restriction enzyme digest. 
All traces of CIP were removed by phenol/chloroform 
extraction, chloroform extraction and ethanol precipitation.
(iii) Isolation of DNA Fragments.
After restriction enzyme digestion of the starting 
plasmid and separation of the DNA fragments using a 
non-denaturing agarose or acrylamide gel, specific fragments 
could be isolated. In the case of agarose gels, a piece of 
NA 45 membranfilter (Schleicher and Schuell) was inserted 
into the gel directly in front of the fragment so that 
further electrophoresis caused the fragment to become bound 
to the paper. Incubation of the NA 45 filter at 68^C in TE, 
supplemented with 1M NaCl, for 1 hour released the bound 
fragment. Phenol/chloroform extraction, chloroform 
extraction and ethanol precipitation then purified the 
fragment before it was re-suspended in DW.
In the case of acrylamide gels, the fragment to be 
isolated was cut out of the gel and shaken overnight in 
elution buffer (EB). The solution was then phenol/chloroform 
extracted, chloroform extracted and ethanol precipitated 
before being resuspended in DW.
(iv) Filling In DNA "Sticky ends".
After isolation of the digested DNA fragment it was 
incubated for 60 minutes at 37°C in a solution of 0.04M 
dATP, 0.04MdCTP, 0.04M dGTP, 0.04M dTTP, lOmM Tris/HCl (pH 
7.5), 60mM NaCl, lOmM MgCl2, lOOug/ml BSA and 5 units T4 DNA 
polymerase. The fragment was then precipitated with ethanol 
and dissolved in DW.
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(v) Adding Restriction Enzyme Linkers to DNA fragments. 
Restriction enzyme linkers were ligated to blunt-ended DNA 
fragments. The resulting DNA was precipitated and dissolved 
in DW before being digested with an excess of the relevant 
enzyme in order to remove any multiple copies of the linker. 
The digested fragment was then isolated.
2.7. Large Scale Preparation of Plasmid DNA.
Fifty ul of a bacterial glycerol stock (section B.2.8) 
was used to inoculate 8ml of L-broth supplemented with 
lOOug/ml of ampicillin and the culture was shaken overnight 
at 37°C. Half of the resulting culture was then diluted into 
400mls of L-broth containing ampicillin and incubated with 
shaking for a further 6 hours. Then, plasmid DNA was 
amplified by the addition of chloramphenicol to a 
concentration of 50ug/ml and the culture was shaken 
overnight at 37°C.
Isolation of plasmid DNA was essentially performed using 
the method of Holmes and Quigley (1981). Bacteria were 
recovered by centri fugation (8,000rpm/10 minutes) and were 
then resuspended in 25ml of STET followed by the addition of 
3ml of freshly prepared lysozyme (lOmg/ml, Sigma Chemical 
Company). The suspension was brought to the boil using a 
bunsen burner and was then transferred to a boiling water 
bath for a further 40 seconds. After centrifugation, 
(17,000rpm/l hour/4°C) the nucleic acid in the supernatant 
was precipitated by adding an equal volume of isopropanol 
and standing at RT for 20 minutes. The precipitate was then 
pelleted by centrifugation (3,000rpm/20 minutes/4°C). The 
pellet was resuspended in 10.5ml of DW, llg of caesium 
chloride and 0.5ml of ethidium bromide (lOmg/ml) were added, 
and the DNA was banded at 40,000rpm for 72 hours at 12°C.
Two bands of DNA could then be seen, an upper chromosomal 
band and a lower supercoiled plasmid band. The latter was 
removed with a syringe.
The ethidium bromide was removed from the plasmid DNA by 
multiple extractions with water-saturated butan-2-ol. The 
DNA solution was then made up to a volume of 10ml with water
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and was precipitated overnight at -20°C using 2.5 volumes of 
ethanol. This precipitate was then pelleted by 
centrifugation (3,000rpm/20 minutes/4°C) and resuspended in 
lml DW. The DNA was treated with 50ug/ml RNase A for 1 hour 
at 65°C and then with 50ug/ml proteinase K and 0.1% (w/v)
SDS for 1 hour at 37°C. The DNA was phenol/chloroform 
extracted, chloroform extracted and precipitated with 
ethanol. After washing the pellet with 70% ethanol, the DNA 
was lyophilized and resuspended in DW to give a final 
concentration of around lmg/ml. The DNA concentration was 
estimated by running the DNA on an agarose gel alongside 
plasmid standards of known concentration.
2.8. Small Scale Preparation of Plasmid DNA ("Miniprep.").
Two ml of L-broth supplemented with ampicillin 
(lOOug/ml) were inoculated with single plasmid-transformed 
bacterial colonies and were shaken overnight at 37°C. Half 
of the bacterial culture was saved in order to make a 
glycerol stock of the plasmid-transformed bacteria by mixing 
the lml culture with lml of sterile glycerol and storing at 
-20°C. The remainder was poured into a 1.5ml reaction vial 
and centrifuged for 15 seconds in a microfuge. The bacterial 
pellet was resuspended in lOOul of STET and lysozyme 
(lOmg/ml) and heated in a boiling water bath for 45 seconds 
before being centrifuged for 10 minutes in a microfuge. An 
equal volume of isopropanol was then added to the 
supernatant and precipitated nucleic acids were pelleted by 
centrifugation for 10 minutes, washed in 70% ethanol and 
lyophilized. Finally, the pellet was resuspended in 50ul of 
DW and stored at -20°C. When DNA prepared by this technique 
was digested with restriction enzymes, 0.2ul of RNase A 
(lmg/ml) was added to remove RNA thus facilitating band 
visualization following gel electrophoresis.
2.9. Transformation of E.coli.
(i ) preparation of Competent DHl Bacteria.
A 10ml culture of DHl bacteria was shaken overnight at 
37°C. Then 2mls of this were transferred to 100ml of 
pre-warmed media and shaken at 37°C until the OD^qq
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reached 0.3. The culture was chilled on ice for 10 minutes 
and the bacteria were pelleted by centrifugation 
(3,000rpm/10 minutes/4°C). The pellet was then resuspended 
in 40ml of ice-cold lOOmM CaCl2 and incubated on ice for 40 
minutes. The cells were pelleted by centrifugation as before 
and resuspended in a total of 2ml of ice-cold lOOmM CaCl2 . 
The bacterial cells were then kept on ice for a minimum of 1 
hour before use. Maximum efficiency of DNA uptake was 
reached after 3 days of incubation on ice and uptake still
r
occured for up to 5 days.
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(ii) Preparation of Competent MBM7070 Bacteria.
A 10ml overnight culture of MBM7070 bacteria was grown 
in LM (L-broth plus lOmM MgSC>4 and lOmM MgCl2) . Then lml of 
this culture was transferred to lOOmls of LM and shaken to 
ODgoo 0.45. The bacteria were then treated as for DHl 
bacteria (see above) except that the bacterial pellets were 
resuspended in ice-cold lOOmM CaCl2 supplemented with lOmM 
DTT (dithiotreitol) and lOmM MES (2- [N-morpholino] 
ethanesulphonic acid).
(iii) Transformation.
For transformation, l-10ul of DNA was added to lOOul of 
competent bacteria in a 1.5ml reaction vial and held on ice 
for 45 minutes. The bacteria were then incubated at 42°C for 
2 minutes before being spread on L-broth agar plates often 
containing a selective agent (eg. ampicillin) to screen for 
bacteria which had taken up plasmid DNA. The L-broth agar 
plates were incubated overnight to allow colonies to form.
2.10. Transfection of DNA into Tissue Culture Cells.
(i ) The Calcium Phosphate Method.
DNA transfections were performed by the calcium 
phosphate procedure as developed by Graham and van der Eb 
(1973). Cells were seeded at 30-40% confluence 18 hours 
prior to transfection. Then 10-20ug of DNA was dissolved in 
TE to a final volume of 420ul and 60ul of 2M CaCl2 was added 
dropwise to the TE/DNA solution whilst vortexing. The 
DNA/CaCl2 solution was then added dropwise whilst vortexing 
to 480ul of 2xHBS and left at RT for 30 minutes in order for
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a precipitate to form. This suspension was then added 
dropwise to cell monolayers and swirled into the medium 
(10ml). The cells were incubated at 37°C overnight before 
the medium was replaced with fresh medium.
Unless otherwise stated this transfection method was 
used in all experiments.
(ii) Electroporation.
Cells were grown to 70% confluence, harvested and washed
twice with electroporation medium (272mM sucrose, 7mM sodium
phosphate pH 7.4, ImM MgCl~). They were then resuspended in
8the same medium at a concentration of 0.5 to 1.0x10 
cells/ml. Then, 0.8ml of cell suspension was placed in the 
Gene Pulsar cuvette (Bio-Rad) and between 10 and 40ug of 
linearized plasmid was added and thoroughly mixed. The cell 
suspension and plasmid were incubated for 10 minutes on ice 
prior to electroporation. The cuvette containing cells and 
plasmid was then placed in the Gene Pulsar chamber, pulsed 
once with 400 volts and 25uFD capacitor and then returned to 
ice for a further 10 minutes. The cells were then plated and 
allowed 48 hours for recovery before selective medium was 
added. Cell survival was checked by plating 100 cells onto 
duplicate plates and seeing how many formed colonies. About 
50% survival is optimum in electroporation experiments.
2.11. Electrophoresis.
(i ) Miniqels.
Analysis of small amounts of DNA utilized horizontal 
(100mmx70mmx7mm), 0.5% agarose, 20ml gels in TBE buffer plus 
ethidium bromide (0.5ug/ml). DNA samples were applied to the 
gel slots in lxTBE, 10% (w/v) sucrose, 0.02% (w/v) 
bromophenol blue and xylene cyanol in a final volume of 
lOul. The gel was run in TBE buffer at a constant current, 
50mA for 1 hour. Following electrophoresis, the DNA was 
visualized by exposure to UV-light and photographed on 
Polaroid 667 film.
(ii) Large Agarose Gels.
Analysis and preparation of DNA restriction fragments 
utilized horizontal (26 0mmxl60mmx5mm), 1% agarose, 250ml
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gels in TBE buffer plus ethidium bromide (0.5ug/ml). The 
samples were applied as for minigels in a total volume of 
30-60ul and the gel was run at 40mA for 16-18 hours or at a 
maximum voltage of 12V/cm. For gels which were to be used 
for Southern transfer of DNA 0.7% agarose gels were used.
(iii) Non-denaturing Polyacrylamide Gels.
These gels were prepared as described by Maniatis et al. 
(1975) and were used for analysis of DNA fragments of less 
than lkb. Acrylamide stock of 30% (w/v) acrylamide 
(acrylamide:bisacrylamide 29:1, stored at 4°C) was diluted 
to 5% in 75ml of TBE. To this, 0.5ml of 10% (w/v) APS and 
50ul of TEMED were added to initiate polymerization. The 
mixture was poured quickly into a vertical gel kit 
(260mmxl60mmxlmm) and allowed to stand for at least 45 
minutes prior to electrophoresis. Samples were prepared and 
loaded as for agarose gels and the gel was run at a maximum 
voltage of 16V/cm. The gel was stained with ethidium bromide 
(4ug/ml) and then the DNA was visualized as for agarose 
gels.
(iv) SDS Polyacrylamide Gels.
Proteins were separated on vertical 5-12.5% gradient 
polyacrylamide gels in the presence of 0.1% (w:v) SDS using 
the continuous buffer system of Laemmli (1970) modified by 
Marsden et al. (1976). The ratio of acrylamide to 
bisacrylamide was 19:1. The composition of the separating 
gel is shown in Table 2. The buffer used for protein 
separation was resolving gel buffer (1.5M Tris/HCl pH 8.9, 
0.4% SDS). Proteins were loaded onto the gel via a 5% 
polyacrylamide stacking gel the composition of which is 
shown in Table 3. The buffer for stacking gels was 0.5M Tris 
pH6.7, 0.4% SDS.
2.12. RNA Extraction.
(i ) Extraction using ILB.
During this process the cells were kept at 4°C as much 
as possible throughout the procedure until the phenol 
chloroform extraction step.
Cell monolayers were washed with PBS before 4ml of PBS
TABLE 2: SEPARATING GEL COMPOSITION.
Gel concentration 5% 12.5%
Acrylamide (30%) ml 6 15
Resolving gel Buffer ml 9 9
DW ml 21 6.6
Glycerol ml 0 5.4
10% APS ul 225 97.5
TEMED ul 15 15
TABLE 3s STACKING GEL COMPOSITION.
Acrylamide (30%) ml 4
Stacking gel Buffer ml 6
DW ml 14
10% APS ul 200
TEMED ul 10
Tables 2 and 3. The composition of separating and 
stacking gels used for protein separation in 
SDS-poIyacrylamide gel electrophoresis.
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was added to each plate and the cells scraped off using 
rubber-policemen. The cells were then centrifuged 
(2,000rpm/40seconds/4°C) and resuspended in fresh PBS before 
being re-centrifuged under similar conditions. The pellet 
was then resuspended in 0.3mls of isotonic lysis buffer 
(ILB), shaken gently and incubated on ice for 2 minutes. 
Nuclei were then pelleted by centrifugation (3,000rpm/5 
minutes/4°C) and the supernatant was transferred to a 1.5ml 
reaction vial containing 0.3ml phenol extraction buffer 
(PEB) and mixed thoroughly. Three phenol/chloroform 
extractions were then carried out followed by a chloroform 
extraction. RNA was then precipitated twice with ethanol, 
washed in 70% ethanol, lyophilized and resuspended in DW. At 
this stage, the RNA was treated with DNase to remove any 
traces of DNA in the sample. This involved incubating the 
sample in 40mM Tris/HCl (pH 7.5) and 6mM M g C ^  for 30minutes 
at 37°C. The RNA was then phenol/chloroform and chloroform 
extracted, precipitated, washed and lyophilized as before.
(ii) Extraction using the RNAzol method (Biogenesis).
RNA was extracted from animal tissue using this method. 
Tissues were first homogenized in RNAzol (2ml per lOOmg 
tissue). Then, chloroform was added and the samples were 
shaken vigorously and incubated on ice, for 10 minutes, 
before being centrifuged (12,000rpm/15 minutes/4°C). The 
upper aqueous phase (containing the RNA) was transferred to 
a fresh tube and the RNA was precipitated with an equal 
volume of isopropanol for 45 minutes at -20°C. The samples 
were then centrifuged as before to pellet the RNA which was 
washed twice with 75% ethanol by vortexing and subsequent 
centrifugation (12,000rpm/8 minutes/4°C). The pellet was 
then dried and dissolved in 0.5% SDS.
The concentration of the RNA from both extraction 
methods was determined by spectrophotometry l-0=40ug
RNA) .
In order to probe the RNA for specific sequences, 5ug 
was transferred to a nitrocellulose membrane by adding it to 
150ul of 20xSSC and loading onto a well in a slot blot 
apparatus (Schleicher and Schuell). The resulting membrane 
was then air—dried and baked under vacuum at 80 C for 2 
hours.
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2.13. RNA:DNA Hybridization.
The nitrocellulose membrane from the slot blot apparatus 
or from the Northern blot was pre-hybridized and hybridized 
as for Southern transfer hybridizations (section B.2.17.). 
Following hybridization, however, the filter was washed for 
4x30 minutes in O.lxSSC and 0.1% SDS before being air-dried 
and autoradiographed.
2.14. Extraction of DNA.
Minced tissue or pelleted cells were put in a solution 
of 1% (w:v) SDS, 50mM Tris and 50mM EDTA to a total volume 
of 4ml. Then, lOOug of proteinase K was added and the 
tissues were shaken overnight at 37°C. The following day the 
samples were extracted twice with phenol/chloroform and 
twice with chloroform before the DNA was precipitated at RT 
with ethanol. The high molecular weight DNA precipitated as 
soon as the ethanol had been added and this was picked out 
with a pasteur pipette, washed in 75% ethanol, dried briefly 
in air and dissolved overnight in DW.
2.15. Southern Transfer of DNA.
This technique has been described by Southern (1975).
The DNA sample was electrophoresed on an agarose gel which 
was then denatured (1.5M NaCl, 0.5M NaOH) for 1 hour at RT 
with gentle shaking. The gel was then neutralized (1M 
Tris/HCl pH.8, 1.5M NaCl) for 1 hour as above. A strip of 
Whatman 3MM paper was wrapped around a stack of gel plates 
and placed in a tray containing lOxSSC. The gel was placed 
upside-down on the Whatman 3MM paper and covered with a 
sheet of pre-wetted nitrocellulose membrane (Schleicher and 
Schuell). All air bubbles were removed from between the gel 
and the membrane. The nitrocellulose was then covered by two 
sheets of Whatman 3MM paper and a stack of paper towels 
(5-8cm high). The stack was completed with a glass plate and 
a weight (500g). DNA was transferred overnight and the 
membrane was then washed in 6xSSC, dried in air and baked 
under vacuum for 2 hours at 8 0°C.
69
2.16. Hybridization of Southern Filters (DNA:DNA 
Hybridization).
The baked membrane was soaked in 6xSSC and placed in a 
heat-sealable bag with pre-hybridization solution. Roughly
0.2ml of pre-hybridization fluid was added for each cm2 of 
membrane. The bag was then sealed and incubated at 42°C for 
2 hours with gentle shaking. The pre-hybridization fluid was 
then replaced with hybridization fluid and the membrane was 
incubated overnight at 42°C again with gentle shaking. When 
hybridization was complete the nitrocellulose membrane was 
washed in a series of solutions. Firstly it was placed in 
2xSSC and 0.5% SDS at RT for 5 minutes, then 2xSSC and 0.1% 
SDS at RT for 15 minutes and finally it was washed twice (2
hours followed by 30 minutes) in a solution of O.lxSSC and
o0.5% SDS at 68 C. Throughout all the washes the membrane was 
shaken gently. After washing the membrane was air-dried and 
autoradiographed.
2.17. Radioactive Labelling of DNA Probes.
(i) Nick Translation.
32P-labelled DNA was prepared essentially by the method
described by Rigby et al. (1977). A 1.5ml reaction vial was
set up containing 0.25ug DNA in lx nick translation buffer
(NTB), 0.1% BSA, 20nM unlabelled dNTP's (usually dATP and
32dCTP), 50uCi of [oc- P]dNTP's, 0.lug/ml DNase 1 and 1 unit
of E. coli DNA polymerase 1. This was incubated at 16°C for
60 minutes after which time the reaction was stopped by the
addition of EDTA to a concentration of 0.02M. Unincorporated
3 2[oc- p]dNTP's were then removed through a Sephadex G-50 
column.
32(ii) Oligolabelling with P.
DNA was also labelled using an oligolabelling kit 
(Pharmacia). Denatured DNA (50ng) was added to a solution of 
130mM KPO. (pH 7.7), 6.5mM MgCl~, ImM DTT, 32ug/ml BSA and
4 *  32 dpXPi
mixed sequence hexanucleotides, 50uCi PldCTP^and 5
units of Klenow fragment and incubated at 37 C for 60 
minutes. It was not nesessary to remove unincorporated
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dNTP's due to the high level of efficiency of nucleotide 
incorporation.
2.18. Protein Extraction and Western Blotting.
Cells were harvested by removing the medium, washing the 
cell surface with PBS and adding boiling mix (BM, 0.5ml/50mm 
plate). The cells were then left for 10 minutes before the 
boiling mix, containing cells, was transferred to a black 
capped vial, incubated in a boiling water bath for 3 minutes 
and stored at -70°C. The proteins were separated on an 
SDS-polyacrylamide gradient gel as described by Marsden et 
al. (1978).
Once electrophoresis was complete the proteins were 
transferred to a nitrocellulose membrane using a Bio-Rad 
blotting apparatus and blotting in 25mM Tris, 192mM glycine 
and 20% (v:v) methanol for 3 hours at 250mA. After blotting, 
the free protein binding sites in the nitrocellulose 
membrane were blocked by incubating twice for 30 minutes at 
37°C in TBS plus 3% gelatin with gentle agitation. All 
subsequent washings and incubations were carried out with 
such agitation. The membranes were washed twice for 5 
minutes at RT in TTBS (TBS plus 0.05% Tween 20) before being 
incubated with antisera in TTBS plus 1% gelatin for 1-2 
hours at 37°C. Three washes in TTBS for 15 minutes at room 
temperature were then performed followed by incubation of 
the membrane with goat-antirabbit HRP congugate diluted 
1/3000 in TTBS plus 1% gelatin for 1 hour at RT. After 
washing the membrane again for 2x5 minutes in TTBS and 
rinsing twice in TBS, it was subjected to the HRP colour 
development reactions.
Sixty mg of HRP colour reagent in 20ml ice-cold methanol
HtP*
were mixed with 60ul ice-cold 30% and 100ml TBS and 
poured into a light-proof box containing the nitrocellulose 
membrane. This was then left until the protein bands were 
vi sualized.
2.19. Preparation of Partially Purified Extracts for HSV 
Ribonucleotide Reductase Assays.
Cells were infected with 5-10 pfu/cell for 7 hours at
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37°C, harvested by scraping into the medium and pelleted by 
centrifugation (l,000rpm/5 minutes/4°C). They were then 
washed twice with PBS by resuspension and centrifugation and 
the final pellet was drained and the walls of the tube were 
dried. The cell pellet was resuspended in 50mM Hepes (pH 
7.8) and 2mM DTT (Hepes/DTT) and frozen at -70°C (the amount 
of Hepes/DTT used to resuspend the cell pellet was 
equivalent to 150ul/90mm plate). The pellet was thawed, 
sonicated and centrifuged (7,500rpm/15 minutes/4°C).
Then, 0.3ml of 5% streptomycin sulphate in Hepes/DTT was 
added per ml of supernatant in a dropwise manner, with 
constant shaking, and the solution was stirred for a further 
20 minutes on ice before the nucleic acids were pelleted by 
centrifugation (7,500rpm/15 minutes/4°C). Then, 0.82ml of 
saturated ammonium sulphate in Hepes/DTT was added (dropwise 
with constant stirring) per ml of extract and stirred on ice 
for 20 minutes. The extract was centrifuged (7,500/15 
minutes/4°C) and the pellet was taken up in a small volume 
of Hepes/DTT and de-sal ted on a PD 10 G25 column. Fractions 
(0.5ml) were collected and the protein concentration was 
determined using Bradford assays.
2.20. Estimation of Protein Concentration.
Estimation of protein concentration was performed using 
the method of Bradford (1976). Ten ul of protein sample were 
diluted in 90ul of DW and mixed with 1ml of Bradfords 
reagent (0.01% Coomassie brilliant blue G, 0.0003% (w:v)
SDS, 4.75% (v:v) ethanol, 8.5% (v:v) phosphoric acid) and 
left at RT for 10 minutes. The absorbance of the solution 
was then measured, at 595nm, and converted to mg of protein 
by comparison to a standard curve produced using known 
quantities of BSA.
2.21. Ribonucleotide Reductase Assays.
Reaction vials (1.5ml) containing 300ug of partially 
purified extract, 20ul of "special" mixture (161mM Hepes, 
pH8.2, lOmM DTT, lOOuM CDP and luCi CDP) and Hepes/DTT to a 
total volume of 90ul were set up on ice. The solutions were 
mixed well and incubated at 37°C for 1/2 hour. This allows
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the substrate CDP to be converted to dCDP. The samples were 
then boiled for 2 minutes, cooled on ice and 2mg of Crotalux 
adamenteus venom and M g C ^  (to a concentration of 15mM) were 
added before further incubation for 2 hours at 37°C. This 
converts the dCDP reaction product to deoxycytosine (dC) 
which can be analyzed on the HPLC. The extracts were boiled 
again for 2 minutes, cooled and dC was added to a 
concentration of 0.1M. The tubes were then mixed and 
centrifuged 5 minutes before the supernatant was removed and 
loaded onto the HPLC.
2.22. The pZ!89 Mutagenesis Assay.
The plasmid pZl89 (Seidman et al., 1985, Figure 8) 
carries a bacterial tyrosine suppressor tRNA gene (supF) as 
a mutational target and sequences that allow replication in 
both bacterial and mammalian cells. Subconfluent plates of 
293 cells were transfected with pZl89 in combination with 
other plasmid DNAs or viruses using the calcium phosphate 
transfection method. After the transfection medium had been 
replaced, the cells were incubated for a 48 hour replication 
period, in the case of transfected cells, or 12-24 hours in 
the case of virus infected cells. After this period, the 
progeny plasmids were extracted using the Hirt extraction 
procedure. The plasmids were then treated with Dpnl to 
remove any unreplicated forms. The enzyme Dpn only cuts DNA 
that has been methylated by the E. coli dam methylase 
(Hattman et al., 1978) and so all plasmids which had 
undergone a replication cycle in a eukaryotic system would 
escape digestion whereas the incoming DNA would be cleaved. 
MBM7070 bacteria were then transformed with the plasmids. 
This strain of bacteria contains a suppressible (amber) 
mutation in the^-galactosidase gene. Colonies containing 
plasmids which have a mutated supF gene are white when grown 
on L-broth agar plates supplemented with 20mg/ml 5-Bromo-4 
chloro-3-indolyl-/?-D-galactopyranoside (x-gal) and
• and
isopropylthio-^-D-galactoside (IPTG)^in contrast to the blue 
colonies that harbour the wild type plasmid. The white 
colonies were replated in order to confirm their mutant 
phenotype. In some cases, the plasmid DNAs were sequenced. 
The percentage frequency of mutagenesis was calculated by
bla
IG
pZ189
5504ori
T antigen
Figure 8 . The plasmid pZ189 contains an ampicillin resistance gene 
( bla, — ► ), the pBR327 origin, the origin and Tantigen coding region 
from SV40 (double line), the tyrosine suppressor tRNA gene supF 
(hatched box) and the IG region from M13 (solid box).
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the following equation:
mutation = no. white colonies x 100
frequency total no. colonies
2.23. Hirt Extraction Procedure.
Medium was removed from the cells, replaced with Hirt 
extraction buffer (0.5% (w:v) SDS, 0.01M EDTA, pH7.5),
(Hirt, 1967) and incubated at RT for 15-20 minutes. The 
viscous lysate was then scraped from the plates using a 
rubber policeman and transferred to a 1.5ml reaction vial. 
Then, 5M NaCl was added to a final concentration of 1M and 
the solution was mixed gently by inversion. The mixture was 
stored for a minimum of 8 hours at 4°C before being 
centrifuged (17,000rpm/30 minutes/4°C) to pellet the genomic 
DNA. RNase A was then added to the supernatant, which
contains the low molecular weight plasmid DNA, at a
concentration of lOOug/ml and incubated at 37°C for 3 hours. 
It was then phenol/chloroform extracted three times, 
chloroform extracted once and the DNA was precipitated with 
ethanol. The precipitate was washed with 70% ethanol, 
lyophilized and resuspended in 30ul DW.
2.24. The aprt Mutagenesis Assay.
Cultures of CHOD422 cells were mutagenized and then 
grown in non-selective medium for 6 days to allow expression 
of the aprt- phenotype. Mutagenesis in the case of this 
study involved transfection of the cells with plasmids 
designed to express HSV-2 ribonucleotide reductase. The 
cells were plated in medium containing 0.04mM 8-azaadenine 
(AA) and were incubated at 37°C for 2-3 weeks in order for 
the AA-resistant mutants (aprt- ) to form colonies.
The percentage frequency of mutagenesis was calculated by the 
equation:
mutation = mutant colonies x 100
frequency total cells plated x plating efficiency.
The plating efficiency was obtained by plating 100 cells 
in two, 50mm tissue culture plates and determining how many
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proceeded to grow and form colonies.
2.25. Mutagenesis of Plasmid DNA by Hydroxylamine.
Five ug of plasmid DNA was added to a solution of 0.4M 
hydroxylamine, ImM EDTA and 50mM sodium pyrophosphate and 
incubated at 7 5°C for 60 minutes. The DNA was then purified 
through a spin-x/G25 column (Costar).
2.26. Sequencing.
(i) Labelling the 5 '-terminus of DNA restriction fragments. 
The restriction fragment to be labelled was incubated
with lx bacteriophage T4 polynucleotide kinase buffer (0.5M
Tris/HCl pH 7.6, 0.1M MgCl9, 50mM dithiothreitol, ImM
32spermidine and ImM EDTA pH 8.0), 50pmoles of [2f- P]ATP, and 
10-20 units of bacteriophage T4 polynucleotide kinase, for 
30 minutes at 37°C. The reaction was then stopped with 2ul 
of 0.5M EDTA (pH 8.0) and the solution was extracted with 
phenol chloroform before being precipitated with ethanol.
The DNA was then dissolved in 50ul of DW and the labelled 
DNA was separated from the unincorporated nucleotides using 
a sephadex G50 column.
(ii) Sequencing Reactions.
The nucleotide sequences of 5*-end labelled DNA 
fragments were determined by the methods of Maxam and 
Gilbert (1977, 1980). These methods are based on the 
specific modification of DNA bases followed by their removal 
and cleavage of the DNA backbone.
In outline, bases are chemically modified under 
conditions which confer base modification specificity. This 
leads to ring opening and in some cases, base elimination. 
Guanine residues are modified at 20 C by dimethyl sulphate 
(DMS) in a sodium cacodylate buffer (pH 8), adenosine and 
guanosine residues are modified by incubation at 37°C with 
piperidine formate (pH 2). Thymine and cytosine residues are 
modified by hydrazine at 20°C with the cytosine specific 
modification achieved by suppressing the modification of 
thymidine with the addition of NaCl to 1.5M.
Reactions with DMS and hydrazine were stopped and the
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DNA precipitated by the addition of sodium acetate solution 
containing tRNA and ethanol. Reactions with piperidine 
formate were stopped by freezing at -70°C and the piperidine 
formate was removed by two rounds of lyophilization.
Incubation of chemically modified DNA with 1M piperidine 
at 90°C causes cleavage of the DNA backbone at the site of 
modification. Piperidine is removed by three rounds of 
lyophilization.
2.27 Generation of Transgenic Mice.
Transgenic mice were established essentially by the 
method of Hogan et al. (1986). C57xCBA hybrid female mice
were hormonally super-ovulated with pregnant mares serum (51 
units) and human chorionic gonadotrophin (2.5 units). They 
were then mated with C57xCBA hybrid males and fertilized 
1-cell eggs were collected from the oviduct using a fine 
glass tube (120-180um diameter). Cumulus cells surrounding 
the eggs were removed with hyaluronidase (300 units/ml) in 
modified Brinsters medium (Brinster, 1972). The cells were 
then transferred to Brinsters medium modified by 
substituting the Hepes buffer (pH 7.4) with bicarbonate 
buffer. Then, l-2pl of a l-10ug/ml DNA solution consisting 
of DNA dissolved in 5-10mM Tris (pH7.4) and 0.1-0.2mM EDTA 
was injected into one of the pronuclei of a fertilized egg 
using an automated microinjecting system.
Around twenty eggs were transferred to both oviducts of 
a pseudo-pregnant female mouse (the mouse was termed 
pseudo-pregnant after having been mated to a sterile male). 
About 1 in 3 eggs survive the microinjection procedure so 
transferring this number of eggs should result in 7-8 
offspring which is the optimum number for a mouse litter.
Mice were screened for the presence of integrated 
sequences by preparing DNA from the end 1cm of the tail and 
hybridizing this to nick-translated DNA probes using a slot 
blot apparatus or the Southern blotting technique.
2.28. Statistical Analysis of Data.
The probability of a mutation occuring in the marker 
genes of the mutagenesis assays used was assumed to be a 
random event, hence the data for mutation of the genes was
determined by the Poisson distribution (Mather, 1949). The 
Poisson distribution or "law of small probabilities" is 
broadly defined as a set of results that fits into the 
categories defined below;
(i) The data consists of whole number observations, ie. 
counts.
(ii) Each event is a small fraction of the total number at 
risk, ie. the event is rare.
(iii) The events are independent of each other and occur 
randomly.
If a Poisson type of event has occurred rl and r2 times 
there is an appropximate significance test which gives 
values v such that if the smaller of rl and r2 is less than 
or equal to v the null hypothesis that the two results are 
equal should be rejected.
For example; Table 8:
Mock-infected (31°C): 4 white colonies, 8912 total 
HSV-1 (31°C): 17 white colonies, 5101 total
1. Standardize results ie:
Mock-infected (31°C): 4 white colonies, 8912 total 
HSV-1 (31°C): 30 white colonies, 8912 total
2. rl=4 
r2=30
rl+r2=34 v=9 (0.01 level of significance)
3. As rl is less than v the results are significantly 
different.
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SECTION C; RESULTS.
This section outlines the procedures used and documents the 
results for the experiments peformed. Details of the 
materials and methods used can be obtained from SECTION B: 
MATERIALS AND METHODS. The results are also discussed at 
the end of each set of experiments.
1. PLASMID CONSTRUCTION AND POLYPEPTIDE EXPRESSION.
An important goal of the work discussed here was to 
examine the role of HSV-2 ribonucleotide reductase 
expression on the increased somatic mutation rate seen in 
HSV-infected cells. One approach involved the introduction 
of plasmids, designed to express HSV-2 ribonucleotide 
reductase, into cells which were then assayed for the 
mutation rate of a marker gene.
Plasmids were constructed to express RRl and RR2 in 
cultured cells under the control of the inducible mouse 
metallothionein (MT-1) promoter, such that their effect 
could be assessed under expressing and non-expressing 
conditions.
1.1. The MT-1 Promoter.
The MT-1 promoter responds at the transcriptional level 
to heavy metals such as zinc and cadmium (Durnam and 
Palmiter, 1981), to glucocorticoid hormones (Hagar and 
Palmiter, 1981), to an unidentified factor in the 
acute-phase response (Durnam et al., 1984) and to interferon 
(Friedman et al., 1984). The promoter contains 5 metal 
regulatory elements (MREs) situated upstream from the TATA 
box (Stuart et al., 1984, 1985). A consensus MRE sequence 
has been formulated from a number of metallothionein 
promoters including mouse, man, sheep and Drosophila and 
this consists of the 15bp sequence 5 1 —CTNTGCRCNCGGCCC—3 1. 
Several metallothionein genes have been cloned and shown to 
retain their expression and regulation after transfection 
into heterologous cells (Durnam et al., 1984; Searle et al., 
1984; Hamer and Walling, 1982). The MT-1 promoter has also 
been shown to confer metal, steroid and/or inflammatory
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response to a variety of structural genes that were 
transferred into cells or animals (Pavlakis and Hamer, 1983; 
Brinster et al., 1982; Palmiter et al., 1982, 1983; Karin et 
al., 1984a,b; Richards et al., 1984). The MT-1 promoter was 
thus chosen to confer heavy metal inducibility to the HSV-2 
reductase genes.
1.2. Construction of pCRR2.
The plasmid pCRR2 (Figure 9) contains the sequences 
encoding the small subunit of HSV-2 RR2 under the control of 
the MT-1 promoter. The starting plasmid, pUCt (Figure 9a) 
contains the coding sequences of HSV-2 RR2 (Figure 7) on a 
BamHI/XhoI fragment. In order to clone the MT-1 promoter 
into this construct, an oligonucleotide was constructed 
which had BamHI "sticky ends" and internal Kpnl and Bglll 
restriction enzyme sites (Figure 9a). The MT-1 promoter 
could then be inserted on a KpnI/Bglll fragment isolated 
from the plasmid pEE3.8_i (kindly provided by Dr. P. Searle). 
The oligonucleotide was constructed such that the 
translational ATG start codon, which was cut, by BamHI, in 
isolating the BamHI/XhoI subfragment, was recreated (Figure 
9a). A detailed diagram of the sequences cloned in pCRR2 is 
shown in Figure 9b.
1.3. Construction of pCRRl.
The plasmid pCRRl contains the coding sequences for 
HSV-2 RRl under the control of the MT-1 promoter. The 
starting plasmid, pUCet^, (Figure 10a) contains the 
sequences for RRl on an Sstl/BamHI fragment (Figure 7). 
Polyadenylation sequences from the HSV-2 IE gene 5 had been 
cloned into pUCet2 downstream of the RRl sequences as these 
were not present in the Sstl/BamHI fragment.
As with pCRR2, an oligonucleotide was constructed 
(Figure 10a), this time with BstEII "sticky ends", 
containing internal Kpnl and Bglll restriction enzyme sites 
such that the MT-1 promoter could again be inserted on a 
KpnI/BglII fragment. The oligonucleotide was inserted into 
the BstEII site 247 nucleotides upstream of the translation 
start site (Figure 10b), however, as the Sstl/BamHI
RRl-containing fragment contains 2 BstEII sites, linear 
molecules were first isolated after partial digestion with 
BstEII. The oligonucleotide was then ligated into the 
linearized plasmids and resultant plasmids containing the 
oligonucleotide inserted into the correct site were 
determined and isolated. The oligonucleotide was designed to 
take advantage of the redundant recognition sequence of 
BstEII by having "sticky ends" complementary to the correct 
insertion site. BstEII recognizes the heptanucleotide 
sequence GGTNACC and in the correctly situated BstEII site 
N=T whereas in the incorrect site N=G.
The MT-1 promoter was again ligated into the KpnI/Bglll 
sites of the oligonucleotide, however, there is an 
additional Bglll site elsewhere in the RRl coding sequences 
and so linear plasmid molecules again had to be isolated 
after partial digestion with Bglll before cutting with Kpnl 
and ligating in the promoter. Restriction enzyme digests 
were performed on the resultant plasmids so that the ones 
that contained the promoter in the correct site could be 
isolated.
A detailed diagram of the sequences cloned in pCRRl is 
shown in Figure 10b.
1.4. Construction of pCRR3.
This plasmid contains the coding squences for both RRl 
and RR2 (Figure 11). RRl expression is under the control of 
the MT-1 promoter whereas the expression of RR2 is under the 
control of its own HSV promoter.
The starting plasmid, pRRl, (Figure 11) contains the HSV-2 
ribonucleotide reductase coding sequences on a Sstl/Xhol 
fragment (Figure 7). The MT-1 promoter was cloned into the 
BstEII site upstream from the RRl coding sequences in an 
identical manner to pCRRl.
1.5. Detection of HSV-2 Ribonucleotide Reductase RNA in 
Cells Transfected with pCRRl, pCRR2 and pCRR3.
Subconfluent, 50mm plates of 293 cells were transfected 
with pCRRl, pCRR2, pCRR3 and pUCl3 such that 2 plates were 
transfected with each plasmid. The transfection mixture was
Figure 9 . (a) The construction of pCRR2. The starting 
plasmid, pUCt (obtained from Dr. I. Nikas), contains the 
coding sequences for HSV-2 RR2 (open box) present on a 
BamHI/XhoI fragment (Figure 7). This was digested with BamHI 
and an oligonucleotide containing internal KpnI/Bglll sites 
was ligated into the plasmid. The oligonucleotide contains 
an ATG (underlined) to replace the one that was lost during 
BamHI/XhoI digestion in the isolation of the BamHI/XhoI 
frament (Figure 7).
The resulting plasmid was then digested with Kpnl and 
Bglll, and the MT-1 promoter (solid box), present on a 
KpnI/Bglll fragment isolated from the plasmid pEE3.8i^ 
(obtained from Dr. P. F. Searle), was ligated into this.
The location and orientation of the ampicillin •
p
resistance gene (amp ) are indicated.
Construction of pCRR2.
ampl
BamHI
{
HSV-2 RR2
pUCt
5-GATC GGTACC
CCATGG
AGATCT
TCTAGA
ATG
TACCTAG-3
Kpnl Bglll
Kpnl
mmmaL
Bglll
MT-1
Cut with BamHI and ligate in 
oligonucleotide.
KPnl Bglll
HSV-2 RR2
Cut with Kpnl and Bglll and ligate 
in promoter.
MT-1
HSV-2 RR2
Figure 9 (b). Diagram of the sequences present in pCRR2. The 
MT-1 promoter is shown as a shaded box and the TATA box and 
cap site are indicated as are the positions of the MREs 
(metal regulatory elements, single lines above the promoter 
sequences). The HSV-2 RR2 sequences are shown as an open box 
and the ATG and TGA codons are marked. The ATG is provided 
by an oligonucleotide (Figure 9a).
cn
oocn
cr
"D
33
33ro
cr~o
ro
C71
cr
*o
M
T-1
Figure 10. (a) The construction of pCRRl. The starting 
plasmid pUCet^ (obtained from S. Simpson) contains the 
coding sequences for RRl (open box) on an Sstl/BamHI 
fragment (Figure 7) and the poly(A) sequences from HSV-2 IE 
gene 5 (hatched box). This plasmid was partially digested 
with BstEII and an oligonucleotide containing internal 
KpnI/Bglll sites was ligated into the isolated linear 
molecules. The resultant plasmid, with the oligonucleotide 
inserted into the correct site, was partially digested with 
Bglll and again linear molecules were isolated. The MT-1 
promoter (solid box), located on a KpnI/Bglll fragment 
isolated from the plasmid pEE3.8_i (obtained from Dr. P. F. 
Searle), was ligated into the linear molecules.
The location and orientation of the ampicillin 
resistance gene (amp ) are indicated.
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Partially digest with BstEII, isolate linear molecules 
and ligate in oligonucleotide.
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HSV-2 RR1
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Partially digest with Bglll, isolate linear molecules, 
digest with Kpnl and ligate in MT-1 promoter.
Figure 10 (b). Diagram showing the HSV-2 RRl gene sequences 
n pCRRl (top) with the TATA box, the ATG and TAA codons, 
and the 2 BstEII sites marked.
The MT-1 promoter is shown below and its TATA box, cap
site and MREs (dotted lines) are marked. The numbers below
this sequence indicate the number of nucleotides a site is
away from the MT-1 RNA CAP site.
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Figure 11. The plasmid pCRR3 containing the coding sequences 
r HSV-2 RRl and RR2 (open box) located on an Sstl/Xhol 
vment (Figure 7) with RRl under the control of the MT-1 
promoter (solid box) and RR2 under the control of its own 
promoter.
The starting plasmid pRRl (obtained from Dr. I. Nikas) 
is also shown. The cloning procedure is the same as that for 
the construction of pCRRl (Figure 10).
The location and orientation of the ampicillin 
resistance gene (amp ) are indicated.
Plasmids pRR1 and pCRR3.
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left on the cells for some 18 hours before being removed and 
replaced with fresh medium. One of each set of 2 plates was 
then left in ordinary growth medium whilst the other plate 
was subjected to growth medium supplemented with lOOuM zinc 
sulphate. The zinc sulphate was added to stimulate 
transcription from the MT-1 promoter and the concentration 
of lOOuM was chosen since this had been used successfully in 
other studies (Searle et al., 1985). The cells were then 
incubated at 37°C for a further 24 hours before cytoplasmic 
RNA was extracted. The RNA was treated with DNase to remove 
all traces of DNA and then 5ug of RNA from each sample was 
transferred to a nitrocellulose membrane using a slot blot 
apparatus. The nitrocellulose membrane was incubated 
overnight with a nick-translated DNA probe under 
hybridization conditions. The probe used was a BamHI/Hindlll 
subfragment isolated from pCRR2 (Figure 12). To check that 
any hybridization was due to RNA, a duplicate of each sample 
was treated with RNase before loading it onto the slot blot 
apparatus. Following hybridization the membrane was washed, 
air-dried and autoradiographed (Figure 13).
The amount of radioactive product was quantitated using 
a Joyce-Loebl scanning densitometer and the areas under the 
peaks of the densitometer tracing were measured by a DEC PDP 
11/44 computer linked to a digitizing tablet.
The results show that pCRR2 produces HSV-2 RR2 RNA in an 
inducible manner with a 25-fold increase in RR2 RNA levels 
on induction with lOOuM zinc sulphate. The hybridization is 
a result of the probe hybridizing to RNA since on treating 
the extract with RNase no hybridization was observed. In the 
case of pCRR3, where the coding sequence of HSV-2 RR2 was 
under the control of its own HSV-2 promoter HSV-2 RR2 RNA 
was seen in transfected cells. In most experiments, the 
amount of RR2 RNA observed is roughly the same in cells 
transfected with pCRR3 irrespective of induction, and was 
around 6-fold lower than that seen in induced cells 
transfected with pCRR2. A small amount HSV RR2 RNA was also 
seen in non-induced cells transfected with pCRR2. As 
expected, pCRRl and pUCl3 transfected cells did not produce 
HSV-2 RR2 RNA since these plasmids do not contain the coding 
sequences for this gene. A positive control consisting of 
5ug of RNA isolated from cells that had been transfected
(a) Xhol Xhol1 1
pCRRl-------------] I MT-1 I HSV-2 RR1
RR1 probe 
(KDOObp)
RR1
BamHI Hindlll
«  \  1
pCRR2 \ mt-1 | HSV-2 RR2------------------ I----
RR2 probe 
(185abp)
RR2
Figure 12. Linear representations of the plasmids pCRRl (a) 
and pCRR2 (b) showing the regions from which the DNA probe 
sequences were isolated for nick-translation. The DNA probe 
for RRl was a lOOObp Xhol fragment and the probe for RR2 was 
a 1850bp BamHI/Hindlll fragment. The reading frames of RRl 
and RR2 are marked as solid lines.
pCRRl -* •
t T
Nl ! RNase
Figure 13. Slot blot analysis of the production of FISV-2 RR2 RNA 
in 293 cells transfected with the plasmids pCRRl, pCRR2, pCRR3 
and pUC13. The amount of RR RNA per 5ug of total cell RNA 
produced in cells induced with 100uM zinc sulphate (I) is compared 
to the amount produced in cells that were not induced (Nl). RNA extracts 
that had been treated with RNase are also shown (RNase). The slot 
labelled (+) denotes RNA from pUC13 transfected cells treated with RNase 
and spiked with 0.005ug of unlabelled DNA probe.
pCRR2
pCRRl
pCRR3
pUC13
Nl
Figure 14. Slot blot analysis of the production of HSV-2 RR1 RNA 
in293celts transfected with the plasmids pCRRl, pCRR2, pCRR3 
and pUC13. The amount of RR1 RNA/5ug of total cell RNA produced 
in cells induced with zinc sulphate (I) is compared to the amount 
produced in cells that were not induced (Nl).
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with pUCl3 spiked with 0.005ug of probe sequence DNA is also 
shown on this autoradiograph.
The experiment was repeated, this time using a 
nick-translated DNA probe isolated from the internal Xhol 
fragment of the RRl gene (Figure 12). In this case, HSV-1 
RRl RNA was seen in pCRRl- and pCRR3-transfected cells 
(Figure 14). Both these plasmids contain the HSV-2 RRl gene 
under the control of the MT-1 promoter. The RNA was 
inducible using lOOuM zinc sulphate with the increase in RNA 
levels being 15-fold with pCRR3 and 19-fold with pCRRl on 
induction. Again, there was RNA produced from the MT-1 
promoter without induction. No HSV-2 RRl RNA was seen in 
cells transfected with pCRR2 or pUCl3 neither of which 
contain the coding sequences for the RRl gene.
Results from other experiments mainly gave induction 
increases of between 15- and 25-fold for the MT-1 promoter 
treated with lOOuM zinc sulphate.
Further experiments in this study mainly involve pCRRl 
and pCRR2 as these plasmids have the HSV-2 ribonucleotide 
reductase genes under the control of the MT-1 promoter and 
are thus both inducible.
1.6. The Effect of Time on the Transient Expression of HSV-2 
Ribonucleotide Reductase RNA from pCRRl and pCRR2.
These experiments were performed in order to determine 
at what time following induction an increase in RNA 
production could be detected and for how long this increase 
was maintained.
Twelve, 50mm plates of subconfluent 293 cells were 
transfected with pCRRl. After 18 hours, the transfection 
mixture was washed off and replaced with fresh medium. Then 
lOOuM zinc sulphate was added to half the plates and RNA was 
extracted from one induced and one non-induced plate at 0,
6, 12, 24, 36 and 48 hours after induction. After treating 
the RNA extracts with DNase, the RNA was compared by 
transferring 5ug to a nitrocellulose membrane using a slot 
blot apparatus and hybridizing the membrane with a 
nick-translated DNA probe isolated from pCRRl (Figure 12). 
The membrane was autoradiographed (Figure 15) and the amount 
of radioactive product was assessed using a Joyce-Loebl
0Hours after 
induction.
293 pCRR1 pCRR1 
+  —
Figure 15. Slot blot analysis of the production of HSV-2 RR1 RNA 
with respect to time in 293 cells transfected with the plasmid pCRR1 
and induced with 1 0 0 uM zinc sulphate. The autoradiograph shows the 
RR1 RNA levels/5ug of extracted RNA at 0, 6 , 12, 24, 36 and 48 hours
after induction for untransfected 293 cells (293) and for cells that 
had been transfected with pCRR1 under induced (+) or non-induced (-) 
conditions.
N.B. The lack of any signal for the non-induced sample at 48 
hours is suprising and may be due to an error in loading.
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Figure 16. Graphical representation of the effect of time on the production of 
HSV-2 RR1 and RR2 RNA from the MT-1 promoter in pCRR1 and pCRR2 following 
transfection of 293 cells and induction with 100uM zinc sulphate.
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Figure 17 Slot blot analysis of the production of HSV-2 RR2 RNA with . 
respect to time from 293 cells transfected with the plasmid pCRR2 and 
induced with 100uM zinc sulphate. The autoradiograph shows the RR2 
RNA levels/5ug total cell RNA at 0, 6 , 12, 24, 36 and 48 hours after 
induction for cells that had not been transfected (293) and for pCRR2 
transfected cells under induced (+) and non-induced (-) conditions.
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scanning densitometer as before (section C.I.5.).
The results show that the increase in HSV-2 RRl RNA in 
cells transfected with pCRRl was apparent 6 hours after 
induction of the MT-1 promoter with lOOuM zinc sulphate, was 
maximal between 12 and 24 hours post-induction and was 
beginning to drop after 36 hours (Figure 16). The induced 
level of RRl RNA was 15-fold greater, at its maximum level, 
than the non-induced level in pCRRl transfected cells.
The experiment was repeated with pCRR2 and using a 
nick-translated DNA probe isolated from pCRR2 (Figure 11). 
Again, induction of RNA was apparent 6 hours after 
induction. RNA levels appear to reach maximum levels between 
24 and 36 hours after induction in this experiment (Figure 
17), which is slightly later than the for maximum induction 
level from the MT-1 promoter in other experiments. The 
average induction from the MT-1 promoter with respect to 
time is shown graphically in Figure 16.
1.7. The Effect of Zinc Concentration on the Induction of 
the MT-1 Promoter in pCRRl and pCRR2.
This experiment was performed to determine the optimum 
concentration of zinc sulphate to use for induction of the 
MT-1 promoter.
Subconfluent, 50mm plates of 293 cells were transfected 
with pCRR2 and left for 18 hours before the transfection 
medium was removed. Medium containing various concentrations 
of zinc sulphate (0, 25, 50, 75, 100, 125 and 150uM) were 
added to the plates and RNA was extracted 24 hours later.
The RNA was then screened for HSV-2 RR2 RNA using a slot 
blot apparatus as in previous experiments. The resulting 
filter was autoradiographed (Figure 18) and the amount of 
radioactive product was assessed using a Joyce-Loebl 
scanning densitometer as before (section C.I.5.).
The experiment was repeated with pCRRl and the RNA was
screened for HSV-2 RRl RNA (Figure 19).
The results show that the amount of HSV-2 RRl RNA 
transcribed from pCRRl and the amount of HSV-'l RR2 RNA
transcribed from pCRR2 increased as the concentration of
zinc sulphate was raised (Figure 20). At a concentration of 
125uM, however, the cells start to die and become detached
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Figure 18. Slot blot analysis showing the effect of zinc concentration 
on the induction of the MT-1 promoter in pCRR2. 293 cells were 
transfected with pCRR2, induced with zinc sulphate at concentrations 
of 0, 25, 50, 75, 100, 125 and150uM and RNA harvested 24 hours later 
was screened for the presence of HSV-2 RR2 RNA by loading 5ug 
of extracted RNA onto a slot blot apparatus and hybridizing the filter 
with a DNA probe.
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Figure 19. Slot blot analysis of the effect of zinc concentration 
on the induction of the MT-1  promoter in pCRRl 293 cells were 
transfected with pCRRl, induced with zinc sulphate at concentrations 
of 0, 25, 50, 75, 100, 125 and 150 uM and RNA harvested 24 hours 
later was screened for the presence of HSV-2 RR1 RNA by loading
5ug of extracted RNA onto a slot blot apparatus and hybridizing the 
filter with a DNA probe.
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Figure 20.
Graphical representation of the effect of zinc concentration on the production of 
HSV-2 RR1 and RR2 RNA from the MT-1 promoter in pCRRl and pCRR2 after being 
transfected into 293 cells. The effect of zinc sulphate concentrations of 0,25, 50
75, 100 and 125uM are shown.
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from the plate and inductions are variable according to the 
rate of cell death. Results given here show that induction 
from the MT-1 promoter in pCRRl gives the greatest value at 
125uM whereas in pCRR2 the level of induction is beginning 
to drop at this concentration. At a zinc sulphate 
concentration of 150uM the cells were all detached from the 
plate before RNA was harvested.
Because of the cell death at 125uM zinc sulphate, lOOuM 
zinc sulphate was chosen for subsequent transient expression 
experiments in order to obtain maximum induction without 
decreasing cell viability. In experiments where the cells 
were to be in contact with the zinc sulphate for more than 
48 hours, the concentration was dropped still further to 
75uM.
1.8. The Production of HSV-2 Ribonucleotide Reductase 
Proteins in Cells Transfected with pCRRl, pCRR2 and pCRR3.
Subconfluent, 100mm plates of 293 cells were transfected 
with pCRRl, pCRR2 and pCRR3 such that 4 plates were 
transfected with each plasmid. Two plates of cells were left 
non-transfected to act as controls. Following transfection,
2 plates out of each set of 4 were induced with lOOuM zinc 
sulphate whilst the remaining 2 were left non-induced. After 
24 hours, proteins were harvested by removing the medium, 
washing with PBS and then adding BM (0.5ml/plate). The 
extracts from the identically treated plates were then 
pooled, incubated in a boiling water bath for 3 minutes and 
stored at -70°C.
SDS-polyacrylamide protein gels were loaded in duplicate 
with lOOul of sample/track of each of the protein extracts. 
An HSV-2-infected cell extract was also loaded to act as a 
positive control. The gels were run overnight at 11V each 
and then the separated proteins were transferred to a 
nitrocellulose membrane by Western blotting. One membrane 
was then exposed to antibody directed against HSV-2 RRl 
(14995) and the other to antibody directed against HSV-2 RR2 
(20208). Both antibodies were kindly supplied by Dr. H. 
Lankinen. The proteins were then visualized using the horse 
radish peroxidase (HRP) technique.
The results show that antibody raised against HSV-2 RRl
Figure 21. The production of HSV-2 RRl in 293 cells 
transfected with the plasmids pCRRl, pCRR2 and pCRR3. 
Proteins were harvested after 24 hours, separated on an 
SDS-polyacrylamide gel, transferred to a nitrocellulose 
filter by the Western blotting technique and screened for 
the presence of HSV-2 RRl using the antibody 20208 (supplied 
by Dr. H. Lankinen). The protein produced from each plasmid 
under induced (lOOuM zinc sulphate) and non-induced 
conditions was compared. Also shown on the gel is a HSV-2 
infected cell extract and an extract taken from 
non-transfected 293 cells.
M=HSV-2 (wt) infected cell extract.
l=pCRR3-transfected 293 cells, induced.
2=pCRR3-transfected 293 cells, non-induced.
3=pCRRl-transfected 293 cells, induced.
4=pCRRl-transfected 293 cells, non-induced.
5=pCRR2-transfected 293 cells, induced.
6=pCRR2-transfected 293 cells, non-induced.
7=non-transfected 293 cells.
RR1-**
Figure 22. The production of HSV-2 RR2 in 293 cells 
transfected with the plasmids pCRRl, pCRR2 and pCRR3. 
Proteins were harvested after 24 hours, separated on an 
SDS-polyacrylamide gel, transferred to a nitrocellulose 
filter by the Western blotting technique and screened for 
the presence of RR2 using the antibody 14995 (supplied by 
Dr. H. Lankinen). The protein produced from each plasmid 
under induced (lOOuM zinc sulphate) and non-induced 
conditions was compared. Also shown on the gel is an HSV-2 
wt) infected cell extract and an extract taken from 
non-transfected 293 cells.
l=non-transfected 293 cells.
2=pCRR3-transfected 293 cells, induced. 
3=pCRR3-transfected 293 cells, non-induced. 
4=pCRRl-transfected 293 cells, induced. 
5=pCRRl-transfected 293 cells, non-induced. 
6=pCRR2-transfected 293 cells, induced. 
7=pCRR3-transfected 293 cells, non-induced. 
M=HSV-2 (wt) infected cell extract.
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recognize a protein, presumably RRl, which had similar 
mobility in induced cells transfected with pCRRl, pCRR3 and 
in cells infected with wt HSV-2 (Figure 21). In this 
experiment, no HSV-2 RRl protein was detected in non-induced 
cells transfected with pCRRl or pCRR3, nor in cells (either 
induced or non-induced) transfected with pCRR2 or pUCl3. The 
antibody also recognizes several proteins in the transfected 
cell extracts that do not co-migrate with the protein seen 
in infected cells. This recognition probably represents 
non-specific binding.
Antibody raised against HSV-2 RR2 recognises a single 
protein, presumably RR2, which had similar mobility in 
induced cells transfected with pCRR2 and in cells infected 
with HSV-2 (Figure 22). No protein was detected in 
non-induced cells transfected with pCRR2 or in cells (either 
induced or non-induced) transfected with pCRRl, pCRR3 or 
pUCl3.
1.9. HSV-2 Ribonucleotide Reductase Activity from Cells 
Transfected with the Plasmids pCRRl, pCRR2 and pCRR3.
To check that the HSV-2 ribonucleotide reductase 
proteins produced in cells transfected with pCRRl, pCRR2 and 
pCRR3 were enzymatically active, activity assays were 
performed. Plates were transfected with one of the plasmids 
pUCl3, pCRRl, pCRR2 and pCRR3. A further 2 plates were 
co-transfected with pCRRl and pCRR2. For controls, 2 plates 
were left untransfected and 1 plate was infected with HSV-2. 
After 18 hours, the transfection mixture was removed and 
replaced with fresh medium. To 1 plate from each pair, lOOuM 
zinc sulphate was added and all the transfected plates were 
incubated for 24 hours at 37°C. Partially purified HSV 
ribonucleotide reductase extract from the infected plate; 
wcks made at this time. After further incubation of the 
transfected plates, more partially purified HSV 
ribonucleotide reductase extracts were made from the 
transfected plates. The extracts were then subjected to 
ribonucleotide reductase assays. The results show that in 
the assay used, enzyme activity was obtained from induced 
cells co-transfected with pCRRl and pCRR2 (Figure 23) and in 
HSV-2-infected cells. No activity was seen in non-induced
Figure 23. HSV ribonucleotide reductase activity from 293 
cells co-transfected with the plasmids pCRRl and pCRR2. 
Partially purified enzyme extracts from the transfected 
cells were prepared and subjected to ribonucleotide 
reductase assays. The Figure shows the HPLC traces from 
nzyme assays performed on, (a) a pCRRl/pCRR2 co-transfected 
extract from cells that had been induced with zinc sulphate,
(b) an HSV-2 infected cell extract and (c) untransfected 293 
cells.
The top traces is the UV-absorbance and shows the 
position of the cytosine (substrate) and deoxycytosine 
(product) markers. The bottom trace is the eluted 
scintillation trace and the peaks of the labelled cytosine 
and deoxycytosine are indicated. There is no deoxycytosine 
peak in the untransfected extract.
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cells that had been similarly transfected or in cells 
(either induced or non-induced) transfected with pUCl3f 
pCRRl, pCRR2 or pCRR3 alone (data not shown), or in 
untransfected cells. No activity would be expected with 
cells transfected with pCRRl or pCRR2 alone since the whole 
enzyme would not be present nor in cells transfected with 
pUCl3 or untransfected cells since neither subunit would be 
present.
1.10. Discussion I .
The results presented above describe the construction of 
three plasmids which express the HSV-2 proteins RRl and RR2. 
The plasmid pCRRl contains the coding sequences for RRl 
under the control of the inducible MT-1 promoter, pCRR2 
contains the coding sequences for RR2 under the control of 
the MT-1 promoter and pCRR3 contains the coding sequences 
for RRl and RR2. In pCRR3, RRl is under MT-1 control and RR2 
is under the control of its own HSV promoter.
Experiments to determine the optimum conditions of MT-1 
stimulation found that around lOOuM zinc sulphate produced 
the most HSV-2 ribonucleotide reductase RNA. This is in 
agreement with other studies (Searle et al., 1985). 
Concentrations of zinc sulphate above this level were found 
to be toxic to the cells and for longer-term exposure to 
zinc treament the concentration of zinc sulphate was dropped 
to 75uM.
Where the HSV-2 ribonucleotide reductase genes were 
under the control of the MT-1 promoter, treatment with lOOuM 
zinc sulphate solution increased the level of RNA production 
by 15-25-fold. Searle et al. (1985) found the MT-1 promoter 
to confer a similar amount of induction to the HSV TK gene; 
the amount of TK induction was measured at the level of 
enzyme activity and was found to be 18-fold.
RNA produced from the MT-1 promoter was apparent at 
around 6 hours post-induction, was maximal around 12-24 
hours and then began to decrease. Other studies, performed 
in vivo have shown that induction from the MT-1 promoter is 
apparent much sooner, 30 minutes after induction (Durnam ^t 
al., 1984; Durnam and Palmiter, 1981), however, the fact 
that these experiments were performed on the endogenous gene
86
might account for this effect. In experiments where HSV TK 
gene expression from the MT-1 promoter is monitored, 22 
hours ^as been used as a time period to allow protein 
expression (Brinster et al., 1982; Stuart et al., 1981).
This is in agreement with the production of RNA and protein 
in this study.
HSV-2 ribonucleotide reductase RNA was present at low 
levels in transfected cells under conditions of 
non-induction. This may be due to the basal level of 
activity from the MT-1 promoter or to some stimulus of the 
promoter from the growth medium. Recent experiments suggest 
that a lower basal level of transcription from the MT-1 
promoter can be obtained using charcoal-stripped serum, 
though this varies with different batches of serum (Dr. J. 
McLauchlan, personal communication).
HSV-2 RR2 RNA was also produced from the HSV promoter in 
pCRR3-transfected cells. The amount of RNA was similar in 
induced and non-induced cells and was around 6-fold less 
than the amount obtained from an induced MT-1 promoter. The 
production of HSV-2 RR2 RNA from the HSV promoter, which is 
normally activated by IE gene products, is in agreement with 
findings of Nikas (1988).
HSV-2 ribonucleotide reductase proteins were detected in 
cells that had been transfected with the plasmids. Protein 
was produced in detectable amounts when the relevant gene 
was under the control of an induced MT-1 promoter. The 
presence of protein in cells that were not induced cannot be 
ruled out as a small amount of RNA is present, however, the 
amounts were not detectable with this assay.
Enzyme activity was only found in induced cells that had 
been co-transfected with pCRRl and pCRR2. The detection of 
activity would only be expected in cells transfected with 
pCRR3 or co-transfected with both plasmids since both 
subunits are required and there is no evidence that one 
subunit from the HSV enzyme can interact with a cellular 
subunit. No activity was seen in non-induced co-transfected 
cells or in cells that were transfected w ,i*h pCRR3 (either 
induced or non-induced). This may be because the assay is 
not sensitive enough to detect this, as small amounts of 
HSV-2 ribonucleotide reductase RNA were found in these 
cells.
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2
. THE EFFECT OF HSV-2 RIBONUCLEOTIDE REDUCTASE EXPRESSION
ON MUTAGENESIS.
The experiments in this section describe effects of 
HSV-2 RRl and RR2 expression on mutagenesis. Three 
mutagenesis assay systems were used. One system assayed the 
mutagenesis of a marker gene located on a shuttle vector
plasmid and the other systems assayed the mutagenesis of the
cellular aprt gene.
The effects of the HSV-1 mutants ;tsl207 and tsl222 which
have ts lesions in the genes encoding RRl and RR2
respectively, were also assessed.
2.1. The pZ!89 Mutagenesis Assay System.
2.1.1. Introduction.
Shuttle vector plasmids that can replicate in both 
eukaryotic and prokaryotic cells are powerful tools for the 
study of rearrangement and mutagenesis of DNA in mammalian 
cells. Plasmids carrying bacterial marker genes can be 
exposed to mutagenic agents in a eukaryotic environment, 
recovered and used to transform an appropriate bacterial 
host. The integrity of the marker gene can then be 
determined quickly and easily using standard microbiological 
procedures.
Studies where shuttle vectors have been cycled through 
mammalian cells and then screened for mutations in bacteria 
have, however, revealed a high frequency of spontaneous 
mutation (Calos et al., 1983; Razzaque et al., 1983, 1984; 
Lebkowski et al., 1984). The mutant plasmids contained 
deletions, insertions of cellular DNA and point mutations. 
The majority of plasmids found in one study were of the 
deletion/insertion type (Razzaque et al., 1983) which 
probably resulted from the introduction of double-stranded 
breaks early in infection (Razzaque et al., 1984).
Additional breaks, followed by recircularization, would 
produce deletions while ligation of cellular DNA would 
produce insertions. The actual frequency of the spontaneous 
mutant plasmids recovered would be a function of the size of 
the marker gene and its proximity to sequences necessary for 
plasmid selection and replication. Seidman et al. (1985)
88
designed a plasmid, pZ189 (Figure 8), to minimize the. 
recovery of spontaneous mutants and which also facilitated 
the characterization of the induced mutants. The plasmid 
contains the bacterial tyrosine suppressor tRNA gene (Brown 
et al., 1979), supF, whose gene product can be quickly 
screened in bacteria (see below) and whose sequence can be 
easily determined. The tRNA gene is small (150bp) and lies 
between two essential functions of the plasmid; the 
ampicillin resistance gene and the DNA replication origin of 
the plasmid, which minimizes recovery of the spontaneous 
mutational events described above. The plasmid also contains 
the replication origin and early gene region from SV40 virus 
and replicates as efficiently in permissive cells as 
wild-type SV40 viral DNA.
The pZ189 mutagenesis assay (section B.2.2.3.), employs 
the use of the E. coli strain MBM7070 which carries the lacZ 
amber mutation. In the presence of IPTG, X-Gal and 
ampicillin, this E. coli strain forms blue colonies if it 
contains a plasmid with an active supF gene and white 
colonies if the gene is inactive.
The experiments described below (section C.2.2.2.) use 
the pZl89 mutagenesis assay to detect any increase in the 
mutation frequency of pZl89 within cells that were also 
transfected with plasmids expressing HSV-2 RRl and RR2. 
Firstly, however, the plasmids pCRRl and pCRR2 had to be 
modified for use in this assay system.
2.1.2. Modification of pCRRl and pCRR2 for use in the pZl89 
Mutagenesis Assay.
The plasmids pCRRl and pCRR2 express the RRl and RR2 
subunits of HSV-2 ribonucleotide reductase as described 
previously (sections C.1.2. and C.I.3.). Unfortunately, in 
the pZl89 mutagenesis assay, the mutagenic frequency is 
obtained by counting the number of white colonies (which 
contain plasmids with an inactive supF gene) as opposed to 
blue ones (which contain plasmids with an active supF gene). 
Misleading data would result from this assay if pCRRl or 
pCRR2 escaped the Dpnl enzyme treatment (which digests DNA 
that has not been replicated in eukaryotic cells, section
B.2.2.3.) and were introduced into the MBM7070 bacteria
0>ne
since these plasmids^would
Figure 24. Construction of the plasmids pCKRRl and pCKRR2. 
The starting plasmids pCRRl and pCRR2 contain the coding 
sequences for the HSV-2 RRl and RR2 proteins (open boxes) 
under the control of the MT-1 promoter (solid box). In 
addition pCRRl contains the polyadenylation (polyA) signals 
from the IE5 gene.
The kanamycin resistance gene (kanR, hatched box) was 
ligated into an EcoRI digest of these plasmids and the 
resulting construct were digested with XmnI, which cuts 
within the ampicillin resistance gene (ampR, arrow). Bal31 
digestion (indicated by dotted arrows) then removed part of 
the ampR genes before the plasmids were religated to form 
the plasmids pCKRRl and pCKRR2.
The Construction of pCKRRl and pCKRR2.
EcoRI EcoRI
MT-1
2EP-R ( pCRRl HSV-2 RR1
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appear as ampR white colonies. To eliminate this effect, the 
R
amp gene in pCRRl and pCRR2 was inactivated and replaced by 
a kanamycin resistance marker (kanR ). This meant that 
bacteria transformed with pCKRRl or pCKRR2'would not grow on 
the mutagenesis selection plates which contain ampicillin.
The strategy for the modification of pCRRl and pCRR2 is 
shown in Figure 2 :. The first step was to ligate in a kanR 
gene. The plasmids were digested with EcoRI and the kanR 
gene (located on an EcoRI fragment isolated from the plasmid 
pUC4K) was ligated into the linearized plasmids. The ampR 
gene was then inactivated. This was achieved by digesting 
the plasmids with Xmnl (which cuts once within the ampR 
gene), isolating the linear molecules and then subjecting 
the linear molecules to Bal31 digestion for 30.seconds. This 
enzyme (Lau and Gray, 1979) catalyzes the progressive 
removal of nucleotides from both the 5'- and 3'-termini of 
double-stranded DNA and thus removes nucleotides from the 
ends of the linearized plasmid. Plasmids containing the kan 
gene were then selected by ligation of the Bal31-digested 
ends and transformation into DHl bacteria which were grown 
on L-broth agar plates containing kanamycin (50ug/ml). The 
inactivation of the amp gene was checked by replica plating 
the kanamycin-resistant bacteria on L-broth containing 
ampicillin. The integrity of the remaining plasmid sequences 
was determined by restriction enzyme digests of mini-prep 
DNA and by checking that they were still capable of 
producing HSV-2 RRl and RR2. The resultant plasmids were 
called pCKRRl and pCKRR2.
2.1.3. The Effect of HSV-2 Ribonucleotide Reductase 
Expression from the Plasmids pCKRRl and pCKRR2.
Subconfluent 90mm plates of 293 cells were 
co-transfected with pZl89 and one of the plasmids pCKRRl, 
pCKRR2, pi75 and pUC13 such that 2 plates were transfected 
with pZ189 plus one other each plasmid. Two additional 
plates were transfected with pZl89, pCKRRl and pCKRR2. Ten 
ug of each plasmid was used for the transfections and the 
total amount of DNA was kept equal (30ug) using calf thymus 
DNA. As controls, 2 plates were transfected with pZl89 alone 
and 2 plates were transfected with pZl89 that had been 
subjected to treatment with the chemical mutagen
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hydroxylamine. This mutagen can directly cause a change in 
base-pairing by causing a tautomeric shift. It can react 
with A, C and U but the reaction with C is most common 
leading to the replacement of the amino group by a 
hydroxyamino group. This leads to the C residue behaving 
like a U (Singer and Kusmierek, 1982) resulting in a GC to 
AT transition.
After 18 hours, the transfection mixture was removed and 
one plate out of each pair was induced with lOOuM zinc 
sulphate whilst the other was left in non-inducing medium. 
The plates were incubated for 48 hours then plasmid DNA was 
recovered using the Hirt extraction procedure. Unreplicated 
DNA was removed by treatment with Dpnl and E. coli strain 
MBM7070 was transformed with the remaining plasmid DNA. The 
bacteria were spread on L-broth agar plates containing IPTG, 
X-Gal and ampicillin and incubated overnight at 37°C. The 
resulting blue and white colonies were then counted.
The experiment was repeated three times (twice in the 
case of pl75) and the pooled data for the numbers of 
colonies counted is shown in Table 4. Results were assessed 
for their significance at the 1% level using the statistical 
analysis outlined in section B.2.28. The frequency of 
mutagenesis of pZl89 in non-induced cells co-transfected 
with pZ189 and pUCl3 was taken as the control mutation 
frequency ie. the frequency to which the other mutation 
frequencies was compared.
The mutation frequency of pZl89 shuttled through 293 
cells and screened in bacteria was found to be 0.04%. This 
is similar to the findings of Hwang and Shillitoe (1990). 
When cells, containing pZl89, were subjected to treatment 
with lOOuM zinc sulphate the mutation frequency was not 
affected implying that zinc treatment per se has no effect 
on mutagenesis. Co-transfection of the control plasmid pUCl3 
with pZ189 also did not affect the mutation frequency of 
pZ189 from that observed by transfecting pZl89 alone either 
in cells induced with zinc sulphate or in non-induced cells. 
This suggests that the addition of a second plasmid to the 
mutagenesis assay does not affect mutagenesis.
The plasmid pl75 appears to have no effect on 
mutagenesis of the supF gene when transfected into cells 
together with pZl89. This plasmid contains the gene encoding
Table 4. Effect of expression ^ of HSV-2 RRl and RR2 from the 
plasmids pCKRRl and pCKRR2 under lOOuM zinc-induced (+) and 
non-induced (-) conditions on the mutation rate of the supF 
gene in the pZl89 mutagenesis assay. The Table shows the 
combined colony numbers from three experiments where the 
riasmids pCKRRl, pCKRR2, pUCl3 and pl75 were transfected 
into 293 cells. The total number of colonies counted, the 
number of white (mutant) colonies and the % mutagenesis are 
listed. As a positive control, pZl89 DNA that had been 
treated with the chemical mutagen hydroxylamine (pZl89*) was 
included in the experiment.
Transfected 
plasmid(s)
Induced Colonies
counted
Whites %
Mutagenesis
pZ189 - 9333 4 0.04
pZl89 + 8234 4 0.05
pZl89+pUCl3 - 6786 4 0.06
pZ189+pUC13 + 8238 4 0.05
pZl89+pl75 - 10002 3 0.03
pZ189+pl75 + 6300 4 0.06
pZl89+pCKRR2 - 5625 4 0.09
pZ189+pCKRR2 + 4217 4 0.09
pZ189+pCKRRl
—
5339 5 0.09
pZl89+pCKRRl + 4511 5 0.11
pZl89+pCKRRl 4024 4 0.10
+PCKRR2
pZl89+pCKRRl + 3092 3 0.11
+pCKRR2
pZ189* - 5462 16 0.30
N.B. Any mutations occuring in the T antigen region may not 
allow replication of the plasmid and would not score in the 
assay. Thus, the number of mutations in the supF gene may 
have been underscored.
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Vftiwl75 and was used to determine whether any mutagenesis 
resulting from pCRRl- and pCRR2- transfection was specific 
or whether other HSV-2 genome regions were mutagenic.
Co-transfection of pCKRRl with pZl89 raises the mutation 
frequency of pZl89 to 0.09% with non-induced cells and 0.11% 
with zinc-treated cells. These values were not found to be 
statistically significant compared to the level of 
mutagenesis in cells co-transfected with pZl89 and pUCl3. A 
similar effect is seen in cells co-transfected with pCKRR2 
and pZl89. The plasmid pCKRR2 raises the mutation frequency 
of pZ189 to 0.09% in both induced and non-induced cells. 
Again this increase is not significant.
Transfection of both pCKRRl and pCKRR2 together with 
pZl89 raises the mutation frequency to 0.11% for induced 
cells and 0.1% for non-induced cells. Although these figures 
are the highest obtained in the transfection experiments 
involving pCKRRl and pCKRR2 they were not found to be 
significantly different from the figures obtained following 
co-transfection of pZl89 and pUCl3 using statistical 
analysis.
Treatment of pZ189 with a chemical mutagen 
(hydroxylamine) increases the mutation frequency of pZl89 by 
7-fold. This value was significantly different (at the 1% 
level of significance) from the mutagenic frequency of the 
supF gene in cells co-transfected with pZl89 and pUCl3.
2.2. The aprt mutagenesis assay system.
2.2.1. Introduction.
This mutagenesis assay involves the use of a cellular 
gene, the adenine phosphoribosyltransferase gene, (aprt) for 
monitoring mutagenesis.
Adenine phosphoribosyltransferase is a purine salvage 
pathway enzyme that catalyzes the conversi on of adenine to 
adenosine 5 1-monophosphate. The enzyme is encoded by an 
autosomal gene locus (Taylor et al., 1979, 1985) which is 
constitutively expressed throughout the cell cycle (Hordern
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and Henderson, 1982). Mutants that do not express the enzyme 
can be readily isolated by selection with adenine analogues, 
such as 8-azaadenine (AA), which block the salvage pathway. 
Since both aprt alleles are normally expressed in Chinese 
hamster ovary (CHO) cells (Meuth and Arrand, 1982; Simon et 
al. , 1982, 1983; Adair et al., 1984), direct selection of 
aprt- mutants from wt populations is impractical, however, a 
hemizygous cell line D422 has been isolated on the basis of 
its partial deficiency of enzyme activity (Bradley and 
Letovanec, 1982). This cell line permits single-step 
selection of fully AA-resistant (aprt- ) mutants at 
frequencies comparable to the X-linked hypoxanthine-guanine 
phosphoribosyltransferase (hgprt) locus (Adair et al., 1980; 
Carver et al., 1980; Thompson et al., 1980; Adair and 
Carver, 1983). Phenotypic expression kinetics for 
AA-resistance are more rapid than for thioguanine-resistance 
(hgprt-), making the aprt locus advantageous (Carver et al., 
1980; Thompson et al., 1980; Adair and Carver, 1983). The 
gene is also an attractive mutagenesis marker since it is 
less than 2.5kb in length (Lowy et al., 1980) and its 
sequence is known (Nalbantoglu et al., 1986).
The mutagenesis assay (section B.2.2.5.) involves 
exposing the CHOO^1-. cells to a mutagenic agent, growing the 
cells in a non-selective medium for 3-6 days to allow 
expression of the aprt- phenotype and then plating the cells 
in selective medium containing AA. Any aprt- colonies can be 
seen after about 2-3 weeks. The experiments described below 
show the effect of HSV-2 RRl and RR2 expression from the 
plasmids pCRRl and pCRR2 on the mutagenesis of the CHO o ^ 2 
aprt gene.
2.2.2. The Effect of HSV-2 Ribonucleotide Reductase Suborn!: 
Expression from the Plasmids pCRRl and pCRR2.
Subconfluent 90mm plates of CHO cells were transfected 
with the plasmids pUCl3, pCRRl and pCRR2. One plate was also 
co-transfected with pCRRl and pCRR2. Ten ug of each plasmid 
was used for the transfections and the total amount of DNA 
was kept constant (20ug) using calf thymus DNA. Control 
plates of CHO cells were also used, one of which was 
untransfected and the other was subjected to a 
mock-transfection procedure with no DNA. After 18 hours, the
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transfection mixture was removed and the cells from each 
plate were split between two, 750ml flasks. The cells in one 
flask from each pair were grown in medium containing 75uM 
zinc sulphate whereas in the other flask the cells were 
grown in non-inducing medium. The cells were incubated at 
37°C for 6 days to allow expression of the aprt- phenotype. 
After this time, the cells from each flask were harvested, 
counted and plated in AA-selective medium at a density of
5
1.5x10 cells/90mm plate. The plates were then incubated at
37°C for 2-3 weeks until aprt- colonies appeared on the
plate. These were counted and the % mutation frequency was
calculated. Unfortunately, the experiment was only performed
once due to many problems with contamination.
The plating efficiency for each transfection was
obtained by plating 100 cells in non-selective medium in
two, 50mm plates and assessing the percentage survival.
Effects on mutagenesis by the pCRRl and pCRR2 plasmids were
also calculated as compared to the level obtained in
non-induced cells transfected with control plasmid (pUC13)
DNA. The significance of the results was assessed using the
statistical test outlined in section B.2.28.
Results from this experiment are shown in Table 5.
Untransfected cells gave a spontaneous mutation frequency of 
-41.40x10 % which is much lower than the spontaneous mutation
frequency seen in the pZl89 mutagenesis assay system.
Mock-transfection of the cells did not significantly 
raise the mutation frequency from the level seen in 
untransfected cells. This agrees with Brandt et al. (1987) 
who showed that mock transfection had no effect on 
mutagenesis of the hgprt gene.
Zinc treatment of untransfected or mock-transfected 
CHOD422 cells did not significantly alter the aprt mutation 
frequency in agreement with the pZl89 mutagenesis assay 
where the mutagenic frequency of the supF gene was not 
affected by treating the cells with zinc sulphate (section C
2.1.3.).
Cells transfected with pUCl3 DNA increased the mutation
-4frequency of the aprt gene (2.5x10 %) compared to
untransfected cells. This was not a significant increase, 
which also agrees with results from the pZl89 mutagenesis 
assay.
Table 5 . Effect of expression of HSV-2 RRl and RR2 from the 
plasmids pCRRl and pCRR2 under zinc-induced (+) and 
non-induced (-) conditions on the mutation rate of the aprt 
gene. CHOD422 cells were transfected with the plasmids 
pUCl3, pCRRl or pCRR2 or were co-transfected with pCRRl and 
pCRR2 (pCRRl/pCRR2). Plates of cells were also 
mock-transfected (mock) or left untreated (control). They 
were then grown in conditions of induction (lOOuM zinc 
sulphate) or non-induction and then plated in medium 
supplemented with AA. The Table shows the number of cells 
plated, the plating efficiency of the cells, the number of 
AA-resistant (mutant) colonies and the % mutagenesis for 
each transfection. The final column shows the enhancement of 
each result compared to pUCl3-transfected cells. ND 
indicates that the enhancement calculation was not done.
rH
rH
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Neither pCRRl- nor pCRR2-transfected cells showed a
statistically significant increase in the mutation frequency
of the aprt gene above that observed with pUCl3 transfected
cells. Similarly, inducing the plasmids with 75uM zinc
sulphate solution did not produce a significant effect.
Cells that had been co-transfected with pCRRl and pCRR2 (and
hence had the potential ability to express HSV-2
ribonucleotide reductase activity) gave an aprt gene
mutation frequency of 4.9xl0_4% in non-induced cells and 
-45.1x10 % m  induced cells. These increases were also not
found to be statistically significant.
The alteration in mutation frequencies produced by the 
plasmids expressing RRl and RR2 in both assays is very low 
and was found to be insignificant in all cases. The fact, 
however, that the highest mutation frequencies obtained for 
both assays were those of cells transfected with plasmids 
expressing both RRl and RR2 may indicate some effect of 
enzyme activity. The low level of mutagenesis may be due to 
the inefficiencies of the transfection procedure, and the 
transient expression of RRl and RR2 may not be sufficient to 
have an effect on mutagenesis via dNTP pool imbalances. The 
cellular ribonucleotide reductase is also present in the 
cells to counteract any dNTP pool changes brought about by 
the viral enzyme. In order to overcome these problems 
experiments were performed to establish cell lines that 
stably express the viral ribonucleotide reductase genes 
(section C.2.3.4.). It is also possible that other 
virus-associated factors, not present in transfected cells, 
co-operate in increasing the mutation frequency in infected 
cells. To further study the effect of the virus 
ribonucleotide reductase on the mutation frequencies in 
infected cells the HSV-1 mutants tsl207 and tsl222, which 
have temperature sensitive lesions in the genes encoding RRl 
and RR2 respectively, were employed.
2.3 The Effect of Stable Expression of HSV-2 Ribonucleotide 
Reductase on Mutagenesis.
The generation of cell lines which stably express the 
HSV-2 RRl and RR2 proteins would be useful for studying the
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effect of these proteins on mutagenesis. In order to achieve 
this, a gene (neoR), conferring resistance to the antibiotic 
G418, was cloned into pCRRl, pCRR2 and pCRR3. The plasmids 
were transfected into cells which were selected for 
G418-resistance. Such cells might be expected to contain an 
integrated copy of the transfected plasmids, including the 
genes encoding RRl and RR2, and could be screened for 
mutagenesi s.
2.3.1. Construction of the Plasmids pCNRRl, pCNRR2 and 
PCNRR3.
The plasmids pCNRRl, pCNRR2 and pCNRR3 were derived from
pCRRl, pCRR2 and pCRR3 by the addition of the gene encodng
£
G418 resistance, neo .
The construction of pCNRR2 and pCNRR3 was
straightforward since the neo gene was available on a
Hindlll fragment isolated from the plasmid p61 (obtained
from Dr. J. Lang). This Hindlll fragment could easily be
placed into the Hindlll site located downstream of the RR2
sequences in these plasmids (Figure 9) by ligating it into a
Hindlll restriction enzyme digest of these plasmids. In the
case of pCNRRl, the Hindlll site had been used to clone the
IE5 termination sequences and so was unavailable. The 
£
neo -containing fragment was therefore isolated and its 
"sticky ends" were filled in prior to the ligation of EcoRI 
linkers. This fragment was then ligated into the EcoRI site 
situated immediately upstream of the RRl sequences in pCRRl 
(Figure 10).
2.3.2. The Effect of HSV-2 Ribonucleotide Reductase 
Expression in the aprt Mutagenesis Assay.
The expression plasmids pCNRRl and pCNRR2 and a control 
plasmid, pUCl3, were transfected into CHOD422 cells using 
the electroporation method. A further control plasmid, p61
p
(which contains the neo gene), was also used for 
transfection. The plasmids pCNRRl and pCNRR2 were 
co-transfected in a similar manner. The transfected cells 
were then plated in 50mm tissue culture plates at a density 
of 0.5xl05 cells/plate and allowed to recover and express
n
the neo phenotype for 3 days before being plated at a 
density of 1 . 0 x l 0 * V 5 0 m m  tissue culture plate in growth
Mutation
sulphate
frequency after exposure to zinc
Days exposure 0 1 2 3
N7 0.6 <0.5 <0.5 0.5
1/2.2 1.7 0.5 0.5 4.5
1/2.10 3.3 <0.5 <0.5 2.0
Table 6 . Mutation frequency of the aprt gene in 
G418-resistant cell lines derived from co-transfecting 
CHOD422 cells with the plasmids pCNRRl and pCNRR2 (1/2.2 and 
1/2.10). The Table shows the mutation frequencies after 0,
1, 2 and 3 days exposure to lOOuM zinc sulphate. The Table 
also gives the mutation frequencies observed with N7 (a cell 
line derived from the transfection of a control plasmid, 
p61, containing the neoR gene). All mutation frequencies are 
xlO-6.
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medium supplemented with 8 00ug/ml G418. The cells were then 
incubated for 2-3 weeks until G418-resistant colonies were 
visible. These colonies (which might be expected to contain 
an integrated copy of the transfected plasmid) were then 
isolated and grown up individually.
Three of the G418-resistant cell lines obtained were
grown up in growth medium supplemented with 8 00ug/ml G418.
These were N7 (derived from the p61 transfection) and 1/2.2
and 1/2.10 (which were both cell lines derived from
co-transfection of pCNRRl and pCNRR2). The cells were
exposed to growth medium containing lOOuM zinc sulphate for
periods of 0 to 3 days. After this time, they were placed in
non-selective medium for 3 days to recover and express the
aprt- phenotype. The cells were then plated in medium
containing 0.04mM AA and allowed to form colonies over a 2-3
week period. The number of AA-resistant colonies obtained is
shown in Table 6. The cell line N7 shows a mutation
-4frequency of 0.6x10 % with no exposure to zinc treatment.
On exposing the cell line to zinc sulphate, no increase in 
the number of AA-resistant colonies was observed indicating 
that zinc treatment does not affect mutagenesis. This was 
also found in previous experiments (sections C.2.1.3. and
C.2.2.2.). With cell lines 1/2.2 and 1/2.10 there was no 
accumulation of mutants with increased exposure to zinc 
sulphate and the mutation frequencies are in line with those 
obtained for N7 which also suggests that these G418 
resistant cell lines (obtained by the co-transfection of 
pCNRRl and pCNRR2) do not increase the mutation frequency of 
the aprt gene.
The cell lines used in this experiment were tested for 
RRl and RR2 protein expression by the Western
blotting procedure. Results were negative and other cell 
lines will be tested for the production of these proteins 
and the experiment repeated.
2.3.3. The Effect of the HSV-2 Ribonucleotide Reductase 
Expression on the Transformation of NIH3T3 Cells.
NIH3T3 cells were also used to establish cell lines 
which containing integrated copies of the genes encoding 
HSV-2 ribonucleotide reductase.
The focus forming transformation assay in NIH3T3 cells
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has been used in transformation studies involving the 
morphological transforming regions of HSV (Galloway and 
McDougall, 1981; Galloway et al., 1984). Transformation is 
often accompanied by the presence of an activated oncogene 
particularly of the ras gene family (reviewed by Weinberg, 
1989). The ability of transfected ras genes to become 
transforming in recipient cells can occur in 2 ways. The 
amino acid sequence may be altered by mutation in one or 
more codons within functional domains of the protein 
necessary for transformation (Reddy et al., 1982? Taparowsky 
et al ., 1982) or the normal proto-oncogene may be 
over-produced (Chang et al., 1982). The activation of ras in 
tumour cells involves point mutations which can result in 
the substitution of residues 12 (Reddy et al., 1982? 
Taparowsky et al., 1982) or 61 (Taparowsky et al., 1983). 
Activation of H-ras has also been demonstrated following in 
vitro modification of the proto-oncogene by chemical 
carcinogens, yielding mutations at codons 10 or 11 (Marshall 
et al., 1984? Vousden et al., 1986) or 61 (Vousden et al., 
1986) .
The morphological transformation of NIH3T3 cells thus 
appears to reflect the occurrence of point mutations within 
oncogenes, usually of the ras gene family. Cellular 
mutagenesis could, therefore, be monitored by looking for 
this type of phenotypic change. In the NIH3T3 cell 
morphological (focus forming) transformation assay, normal 
untransformed cells can be fairly easily distinguished from 
transformed cells which show dense growth with cells piling 
up and overlapping.
Subconfluent, 50mm tissue culture plates were 
transfected with pCNRR2, pCNRR3 or p61. The transfection 
mixture was removed after 18 hours and the cells were 
allowed to recover and express the neo phenotype for 48 
hours. After this time, the cells were transferred to 750ml 
flasks containing growth medium supplemented with G418 
(800ug/ml) to select for the neo^ gene. The cells were 
incubated for 2-3 weeks until G418-resistant colonies 
appeared which might be expected to contain integrated 
copies of the transfected plasmids. Transfection resulted in 
the generation of around 200 G418-resistant colonies, for
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each plasmid, which were pooled. Each set of pooled cells 
was then divided into two. One half was incubated in growth 
medium supplemented with zinc sulphate (75uM) and G418 
(800ug/ml) while the other half was incubated in medium 
supplemented with G418 alone. The flasks were observed for 
the occurrence of morphologically transformed cells over a 
2-3 week period.
The only population of cells that gave rise to 
morphological transformants was the pCNRR3-transfected 
population which had not been induced with zinc sulphate. 
This cell population gave rise to 2 transformed foci. The 
fact that no transformed cells were seen when the cells were 
induced (and might be expected to express more enzyme 
activity) suggests that HSV-2 ribonucleotide reductase 
activity does not increase the cellular mutagenic frequency.
To assess whether the G418-resistant cell lines did 
indeed contain the genes encoding HSV-2 RRl and RR2, DNA was 
extracted from the cells and probed for the presence of 
these sequences using the Southern blotting procedure. DNA 
(lOug) extracted from cells transfected with pCNRR3 (C-RR3 
cells) was digested with EcoRI (100 units) and DNA extracted 
from cells that had been transfected with pCNRR2 (pC-RR2) 
was digested with Hindlll (100 units). Lambda DNA digested 
with Hindlll was used as size markers. The separated DNA was 
transferred to a nitrocellulose membrane and probed for the 
presence of RR2 sequences using a labelled DNA probe (Figure 
12). The membrane was then autoradiographed and this is 
shown in Figure 25.
Digestion of C-RR2 DNA with Hindlll should give rise to 
a DNA fragment of around 5150bp if the entire plasmid was 
integrated into the genome. A band of this size was seen. 
Similarly, in the case of C-RR3 DNA, EcoRI digestion should 
give a band of 10300bp if the entire plasmid has integrated. 
Again this band was seen. The plasmids therefore appear to 
have integrated into the cellular genome yet do not appear 
to affect mutagenesis or transformation. Like the aprt- cell 
lines these G418-resistant cells require to be tested for 
RRl and RR2 expression.
2.4. The Effect of ts!207 and ts!222 on Mutagenesis in the 
PZ189 Mutagenesis Assay.
kbp 
q /i — i-sJ. r 
6.6 — >
2.3
2.0
Figure 25. Detection of HSV-2 RR2 sequences in cellular DNA extracted 
from the cell lines C-RR3 (track 1) and C-RR2 (track 2). Ten ug of DNA 
from C-RR3 (digested with EcoRI) and C-RR2 (digested with Hindlll) was 
probed with a labelled RR2 DNA probe. The sizes of the relevant DNA 
fragments are shown to the right of the gel and DNA size markers are on 
the left.
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To further study the effect of HSV ribonucleotide 
reductase activity on mutagenesis, HSV-1 temperature 
sensitive mutants were used. The mutant virus ts!207 has a 
mutation in the gene encoding RRl and fails to induce
activity at the restricted temperature (Preston V.G. et al.,
1984). The mutant phenotype is due to the substitution of an 
asparagine for the wt serine at RRl position 961 (Nikas et 
al., in press). A comparison of the amount of enzyme 
activity and growth between wt HSV-1 and tsl207 is shown in 
Table 7. The HSV-1 mutant t_sl222 has a single base pair 
deletion at the 3'-end of the gene encoding RR2 which alters
the translational reading frame such that the codons of all
but 1 of the C-terminal 15 amino acids are changed and the 
termination codon is removed. No enzyme activity can be 
detected at either 31°C (PT) or 39.5°C (NPT). The virus 
replicates as efficiently as wt at 31°C but is ts at 39.5°C 
suggesting that enzyme activity is required at high 
temperatures but is dispensible at lower temperatures 
(Preston V.G. et a l ., 1988, Table 7). These virus mutants 
have been previously discussed (section A. 3.3.2.). Use of 
the viruses t_sl207 and ts!222 in this study allowed the 
assessment of the role of the viral ribonucleotide reductase 
in mutagenesis during infection.
For each experiment, eight, subconfluent 50mm plates of
293 cells were transfected with the plasmid pZl89. After 18
hours, the transfection mixture was removed and replaced
with fresh medium. The cells were allowed to recover for 6
hours at 37°C prior to infection with the viruses ts!207,
jtsl222 or wt HSV-1 at lOpfu/cell. The amount of virus
inoculum used was lOOul. Two plates were also mock-infected, 
b
After a sorption one plate of cells from each pair was kept 
at 31°C^whereas the other plate was kept at 39.5°C. All 
medium used was also kept at the respective temperature and 
the plates were incubated overnight. After this time, the 
pZl89 plasmid was harvested and used to transform MBM7070 
bacteria in the pZl89 mutagenesis assay as previously 
described. The experiment was repeated and the pooled 
results are shown in Table 8. ^
The results show that mock infection of cells does
A
not affect the mutation frequency of pZ189 and the level of
Virus Temperature % RR 
activity
Growth (yield 
after 24 hours)
wt 31°C 100 +
tsl207 31°C 14.7 +
tsl222 31°C 0 +
wt 39.5°C 80 +
tsl207 39.5°C 0 —
tsl222 3 9.5 °C 0 —
Table 7. Ribonucleotide reductase activity and growth of 
tsl207 and tsl222 as compared to wt HSV-1 at 31 and 
39.5°C (taken from Preston V. G. et al., 1984, 1988).
Vi rus Temp.
°C
Colonies
counted
Whites %
mutagenesis
Increase
mock 31 8912 4 0.05 1.0
mock 39.5 4640 2 0.05 1.0
wt HSV-1 31 5101 17 0.34 6.8
wt HSV-1 39.5 4020 13 0.33 6.6
tsl207 31 1972 6 0.31 6.2
tsl207 39.5 2559 8 0.31 6.2
tsl222 31 3374 10 0.31 6.2
tsl222 39.5 2581 8 0.33 6.6
Table 8 . Effect of wt HSV-1 and HSV-1 mutant viruses ts!207 
and ts!222 on the mutagenesis of the supF gene in the pZ189 
mutagenesis assay. The effect was studied in 293 cells at 
temperatures 31°C (PT) and 39.5°C (NPT). The Table shows the 
pooled results from two experiments and lists the total 
number of colonies counted, the number of white colonies 
obtained and the % mutagenesis. The final column shows the 
increase of each result compared to mock infected cells at 
31°C.
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mutation (0.05%) is roughly the same as for untreated cells 
(0.04%, section C.2.I.3.). HSV-1 infection at 31°C had the 
effect of increasing the mutation frequency of pZl89 to 
0.34% (around 7-fold). This was statistically different at a 
1% level of significance. Raising the temperature to 39.5°C 
did not alter the increase in mutagenesis seen in 
HSV-infected cells, giving a mutagenic frequency of 0.33%.
The HSV-1 mutant tsl207 increases the mutation frequency 
of the supF gene to 0.31% at 31°C and 39.5°C. These figures 
are not significantly different either from each other or 
from those obtained with wt virus.
Similar results were obtained with the mutant tsl222. At 
31°C, this virus increases the mutation frequency of the 
supF gene to 0.31% at 31°C and 0.33% at 39.5°C. As with 
tsl207, these figures are not significantly different from 
each other or from those obtained with wt HSV-1. These 
results suggest expression of that HSV ribonucleotide 
reductase is not mutagenic in infected cells.
2.5. Discussion II.
2.5.1. A Comparison of the pZ!89 and the aprt Mutagenesis 
Assays.
The pZl89 assay, studies the mutagenic frequency of a 
marker gene, the supF gene, located on the shuttle vector 
plasmid pZl89 whereas in the aprt mutagenesis assay, the 
aprt marker gene is chromosomal. This difference in location 
of the marker gene is reflected in the different spontaneous 
mutation frequencies of the two assay systems. In the aprt 
mutagenesis assay, the spontaneous mutation frequency is 
1.4x10”^% which is much lower than the spontaneous mutation 
frequency of the supF gene in the pZl89 assay (0.04%). This 
could be because pZl89 will be subject to mutations that are 
acquired by plasmid DNA entering cells by the transfection 
procedure (Calos et al., 1983? Razzaque et al., 1983, 1984; 
Lebkowski et al., 1984? section C.2.1.1.). Also, the plasmid 
may be affected by the phenomenon that transfection of 
plasmid DNA is mutagenic via some mechanism of 
plasmid-induced DNA damage (Lau et al., 1982). Plasmids are 
capable of integrating into the host genome (Kucherlapati, 
1982) and may induce DNA endonucleolytic cleavage. Finally,
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the marker gene in pZl89 may be being replicated more 
rapidly than the cellular marker gene. A higher rate of 
replication might be expected to increase the mutation 
frequency if mutations are occuring during replication 
(misincorporations) or simply because a mutation is being 
replicated.
Results for the effect of pUCl3 transfection on 
mutagenesis are similar for the two systems with an increase 
in mutagenesis of 1.5-fold compared to the spontaneous level 
which was not found to be significant (section C.2.I.3.).
The two mutagenesis assays thus appear comparable in 
their response to transfected plasmids although they differ 
in the spontaneous mutation frequency of their marker genes.
2.5.2. The Effect of Expression of HSV-2 RRl and RR2 on 
Mutagenesis in Transfection Experiments.
Both the pZl89 and the aprt mutagenesis assays show 
similar results with the transient expression of HSV-2 RRl 
and RR2 from transfected plasmids. Transfection of plasmids 
containing the genes for HSV-2 RRl or RR2 under the control 
of an inducible promoter did not significantly increase the 
mutation frequency of the supF gene in the pZ189 mutagenesis 
assay as compared to the mutation frequency obtained from 
transfection of the control plasmid. A significant increase 
in the mutation frequency of the aprt gene in the aprt assay 
was also not found. Induction of the RRl or RR2 genes had no 
effect in either assay.
Induction of individual plasmids did not affect the 
mutation frequency in transfected cells as would be expected 
if enzyme activity was the cause of an increase in 
mutagenesis in HSV-infected cells and there is no evidence 
to suggest that the individual virus enzyme subunits can 
interact with the cellular Ml and M2 to produce activity. 
Also, even if this were possible, only RRl would be expected 
to alter the mutation frequency according to the proposed 
mutation model of dNTP pool imbalances since it is the 
cellular Ml that is responsible for allosteric control of 
the cellular enzyme. Possibly, expression of RRl alone in 
cells could affect dNTP pool sizes and hence cause 
mutagenesis as this subunit has the ability to bind dNDPs 
but the results presented here would not support that idea.
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Transient expression of both RRl and RR2 together using 
the pZ189 and the aprt mutagenesis assays enzyme does not 
significantly increase the level of mutation from that 
obtained with a control plasmid. Zinc-induction of the RRl 
and RR2 genes also has no effect using these assays. This 
suggests that enzyme activity is not causing the mutagenic 
effect.
Although the experimental results were not significant 
in both the pZl89 and the aprt mutagenesis assays the 
highest mutation frequencies obtained were those in induced 
cells expressing both RRl and RR2. These cells would be 
expected to have the highest levels of HSV-2 ribonucleotide 
reductase activity arid it could be argued that the lack of a 
statistically significant result might be due to the 
inefficiencies of the transfection procedure and the 
transient nature of the assays. The cellular enzyme will 
also be present and may counteract any changes in dNTP pool 
sizes brought about by the viral enzyme. To avoid the
c
problem of the inefficieny of transient transfection
A-
procedures CHO and NIH3T3 cells were transfected with the 
plasmids pCNRRl and pCNRR2 (section C.2.3.I.). These 
plasmids contain a G418 resistance marker and allow 
transfected cells to be selected for integration of plasmid 
DNA.
The G418-resistant cell lines generated by the
transfection of pCNRR2 and pCNRR3 into NIH3T3 cells did not
show an increased level of mutagenesis even though these 
lines contained integrated plasmid sequences. Similarly, 
G418-resistant cell lines generated by co-transfection of 
the plasmids pCNRRl and pCNRR2 did not appear to alter the 
mutation frequency of the aprt gene with or without exposure 
to zinc sulphate. The cell lines generated in both these 
experiments, however, may not express RRl or RR2, hence 
conclusions as to the effect of prolonged enzyme expression 
on mutagenesis require that further cell lines be checked
for expression and the experiment repeated.
The fact that the plasmid constructs do not cause 
mutagenesis is interesting irrespective of HSV 
ribonucleotide reductase activity since the plasmid pCRRl 
(and pCKRRl) contains the 486TF (Jones et al., 1986, section 
A.2.2.3.) and the putative kinase activity of the N-terminal
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domain of RRl (Chung et al., 1989, section A.3.3.5.) both of 
which have been implicated as having a possible role in 
transformation. The 486TF contains putative stem-loop 
structures and one proposed method of transformation was 
mutagenesis resulting from the fragment integrating into the 
genome in a similar manner to an insertion sequence. Subject 
to the sensitivity of the assays, results presented here 
would not support the suggestion that transformation brought 
about by the 486TF is due to random insertion into a 
cellular gene. The possibility that the 486TF integrates 
into the cellular genome at some other, more specific locus, 
is not, however, ruled out. The other putative stem-loop 
structure in the HSV-2 genome associated with transformation 
(737TF from Bgllln, Galloway et al., 1984, section A.2.2.3.) 
has also been used in mutagenesis studies; this fragment did 
not increase the mutagenic frequency of a cellular marker 
hgprt gene (Brandt et al., 1987).
2.5.3. The Effect of wt HSV-1, ts!207 and ts!222 Infection 
on Mutagenesis in the pZ!89 Mutagenesis Assay.
Infection of 293 cells with HSV-1 increases the mutation 
frequency of the supF gene in the pZl89 mutagenesis assay by 
around 7-fold. This figure is in agreement with other 
studies. Pilon et al. (1985) found that infection of 
non-permissive cells with HSV-2 lead to an increase in the 
mutation frequency of the hgprt gene of 2.5-10-fold and 
Hwang and Shillitoe (1990) showed that HSV-1 infection leads 
to an increase in mutation rate of 3.6-fold using the pZl89 
mutagenesis assay.
The HSV-1 mutant tsl207, at 39.5°C and 31°C, shows the 
same effect on mutagenesis as the wt virus. As the levels of 
mutagenesis obtained with this virus are similar at the NPT 
(when the virus is not expressing ribonucleotide reductase 
activity) and at the PT (where the virus is expressing 
enzyme activity) this suggests that HSV-1 ribonucleotide 
reductase activity does not represent the mutagenic agent 
being assayed here. This suggestion is supported by the 
results obtained with ts!222. Again, no difference in 
mutagenesis is seen either at 39.5°C or 31°C compared to the 
wt virus. It is interesting to note that at 39.5°C the ts 
viruses do not grow (Preston V. G. et al., 1988; Preston
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V.G. et al., 1984) and there is still a mutagenic effect 
suggesting that viral replication is not required for this 
process. This is supported by results from previous studies 
with UV-inactivated HSV-1 which was found to increase the 
mutagenesis of a cellular (Schelofer and zur Hausen, 1982) 
and a plasmid borne (Hwang and Shillitoe, 1990) marker gene.
105
3. EXPERIMENTS TO DETERMINE THE MUTAGENIC FACTOR IN HSV-
INFECTED CELLS.
To identify the mutagenic function of HSV in infected 
cells, a number of experiments were performed which are 
described below. The experiments involve studying the 
mutagenic effect caused by HSV-1 and a range of HSV-1 mutant 
viruses, UV-inactivated HSV-1 and incomplete HSV-1 virus 
particles.
3.1. The Growth of HSV-1 in 293 Cells.
This experiment was performed as the growth rate of
HSV-1 in 293 cells is not well documented. A one-step growth
/
curve of HSV-1 would allow the time that the mutagenic 
effect is seen to be compared with the state of virus 
infection at that time.
Twentyfour, 30mm tissue culture plates were seeded with
5 o5x10 293 cells/plate and incubated overnight at 37 C. The
plates were then infected with 5 pfu/cell of HSV-1 in an
b
inoculum of lOOul. The virus was allowed to a .sorb for 1 
hour before the inoculum was removed. The plates were washed 
with medium containing no serum, overlayed with 1.5ml growth 
medium and incubated at 31°C.
At 0, 2, 4, 6, 8, 12, 18 and 24 hours post-infection the 
virus was harvested from 2 plates by scraping the cells into 
the medium, dispensing into black-capped vials and 
sonicating for 1 minute. The samples were titrated on BHK 
monolayers and a one-step growth curve was established 
(Figure 26a). A similar one-step growth curve for HSV-1 in 
BHK cells was also constructed. From the two growth curves, 
it is apparent that the growth of HSV-1 is somewhat slower 
in 293 cells than in BHK cells, however, after 24 hours the 
yield is roughly the same with around a 15-20 fold increase 
in virus titre after 24 hours.
At each time point, protein was also harvested from a 
plate of cells by removing the growth medium, washing the 
cells with PBS and adding BM (0.5ml/plate). After 10-15 
minutes the BM/cell mixture was transferred to a 
black—capped vial and incubated in a boiling water bath for 
3 minutes. The samples were then run on a protein gel,
virus yield (log pfu/10 cells)
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EigjiE2-2£, (a) Single step growth curve of HSV-1 in 293 (— ) and BHK 
(—  ) cells infected with 5pfu/cell.
24 18 12 8 6 4 2 0 M
RR1
Figure 26 (b). Production of RR1 in HSV-1 infected293cells. The tracks 
labelled 0, 2, 4, 6, 8,12, 18 and 24 indicate the number of hours post 
infection that the extracts were made. The track labelled M contains
a positive control. The antibody used was 20208.
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transferred to a nitrocellulose membrane by the Western 
blotting technique and probed for the presence of RRl using 
the antibody 20208 (provided by Dr. H. Lankinen). The 
resulting membrane is shown in Figure 26b.
The production of RRl in infected 293 cells is apparent 
4 hours post-infection and its level gradually increases 
until the final time point at 24 hours post-infection. RRl 
has predominantly early kinetics in infected cells and so 
would be expected to reach maximum levels 4-6 hours 
post-infection. However, the slower growth rate of the virus 
in 293 cells would account for the somewhat delayed 
appearance of RRl.
3.2. Time Course of the Mutagenic Effect of HSV-1 in 
Infected Cells.
Subconfluent 50mm tissue culture plates of 293 cells 
were transfected with pZl89. After 18 hours, the 
transfection mixture was removed and replaced with fresh 
medium. The cells were allowed to recover for 6 hours before 
half of the plates were infected with lOpfu/cell of HSV-1 in
lOOul inoculum. The rest of the plates were left uninfected
b
as controls. After a.'.sorption for 1 hour, the inoculum was 
removed and replaced with growth medium and the cells were 
incubated at 37°C. At time points 0, 2, 4, 6, 8, 12, 18 and 
24 hours post-infection, the pZl89 plasmid was harvested 
from one infected and one non-infected plate of cells and 
assayed as described previously. The results are shown in 
Table 9 and graphically in Figure 27.
The mutagenic frequency of the plasmid pZl89 in infected 
cells increases above the level in uninfected cells almost 
immediately after infection. The level of mutagenesis 
becomes constant after 8 hours. From the previous 
experiment, it was established that the production of RRl (a 
predominantly E protein) is apparent 4 hours post-infection 
and so the mutagenic effect seems to be occurring around, or 
slightly before, the time of E gene expresion. This is in 
agreement with the results from the experiments with ts!207- 
and tsl222-infected cells (section C.2.4) where the 
mutagenic effect is still present at the NPT when there is 
no viral replication and suggests that the mutagenic effect
Hours post 
Infection
Infected Colonies Whites %
Mutagenesis
0 HSV-1 5010 2 0.04
mock 2996 2 0.05
2 HSV-1 2222 2 0.09
mock 1670 1 0.06
4 HSV-1 2043 3 0.15
mock 6664 2 0.03
6 HSV-1 1108 2 0.18
mock 2004 1 0.05
8 HSV-1 1572 3 0.19
mock 4286 3 0.07
12 HSV-1 1768 3 0.17
mock 3330 2 0.06
18 HSV-1 2100 4 0.19
mock 4996 2 0.04
24 HSV-1 1996 4 0.20
mock 2012 1 0.05
Table 9. Time course of the mutation frequency of the supF 
gene in the pZl89 mutagenesis assay performed in HSV-1 
infected 293 cells. The Table shows the times post infection 
at which the plasmid extracts were taken, the total number 
of colonies counted in the assay, the number of white 
(mutant) colonies and the % mutagenesis at each time point 
for HSV-1 and mock-infected cells.
% mutagenesis
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Hours post infection.
Figure 9.1. Effect of HSV-1 infection on the mutagenesis of the supF 
gene in the pZ189 mutagenesis assay. The graph shows the increase in 
mutagenesis with respect to time.
—  HSV-1 infected cells
—  mock infected cells
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may be caused by a structural component or an E or IE gene 
function. Results of Hwang and Shillitoe (1990) also suggest 
that the mutagenic effect occurs around this time (2-4 hours
post-infection) in COS-1 cells.
3.3. The Effect of HSV-1 Mutants and Incomplete Viruses on
the Mutagenic Frequency of pZ!89 in Infected Cells.
Use of HSV mutant viruses provides a further means of 
examining the effect of specific viral genes on mutagenesis. 
From the experiments described so far, the mutagenic 
function appears to act early in infection. Mutant viruses 
used in an attempt to localize this effect are described 
below.
(i) tsK : The virus tsK has a _ts lesion in Vmwl75 and 
produces only four functional IE polypeptides WiwllO, Vwm68, 
Vmw63 and Vftiwl2 as well as a non-functional Vmwl75, and 
Vinwl36 (Marsden et al., 1976) at the NPT.
(ii) dll403 : This virus contains a 2kb deletion within 
both the TRt and IR copies of the VmwllO gene. The deletion
L  Ls
is manifest primarily at low moi and can be overcome by 
increasing the virus dose (Stow and Stow, 1986).
(iii) inl814 : This virus contains a 12bp insertion in 
the gene encoding the transinducing factor Vtnw65. The 
insertion abolishes the ability of Vtnw65 to induce IE gene 
expression at low multiplicities of infection and in vivo.
At high multiplicities of infection the function appears to 
be redundant (Ace et al., 1989).
(iv) tsl204 : The virus ts!204 contains a single 
mutation that affects the ability of the mutant to penetrate 
tissue culture cells and to assemble functional capsids at 
the NPT (Addison et al., 1984). Analysis of virus induced 
polypeptides in tsl204 infected cells grown at the NPT gives 
results similar to those of mock-infected cells except that 
some inhibition of host polypeptide synthesis is observed 
which could be caused by a virion polypeptide (Fenwick and 
Walker, 1979).
(v) L-particles : These are incomplete virus particles 
that contain virus envelope and tegument proteins but no 
capsid proteins or DNA. Preparations of L-particles contain 
L-particles and complete virions in a ratio of 500:1 whereas
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in normal virus preparations a ratio of around 1:1 is seen.
a
(vi) UV-inactivated virus : Virus particles were 
UV-inactivated according to a method suggested by Dr. C. M. 
Preston which results in no activation of E gene promoters 
ie. no expression of IE gene products.
Subconfluent, 50mm tissue culture plates of 293 cells 
were transfected with lOug of the plasmid pZl89. After 18 
hours, the transfection mixture was removed and replaced 
with fresh growth medium. The cells were allowed to recover 
for 6 hours before being infected with virus. Two plates of 
cells were infected with the viruses HSV-1, HSV-2, 
UV-inactivated HSV-1, tsK, tsl204, dll403, inl814 and the 
incomplete virus L-particles. Two plates were mock-infected 
as negative controls. One of each of the plates infected 
(lOpfu/cell) with Ad5, HSV-1, HSV-2, tsK, and ts!204 and one 
of the plates that had been mock-infected were incubated at 
31°C after a ^ sorption and the other plates were incubated at
O
39.5 C. All medium used was also kept at the relevant 
temperature. In the case of the virus mutants _inl814 and 
dll403, one plate was infected with a high moi (lOpfu/cell) 
and the other plate was infected with a low moi 
(0.5pfu/cell). Control plates were also set up with HSV-1 
infection at low and high moi. Cells infected with 
L-particles and UV-inactivated HSV-1 were incubated at 31°C 
only. Cells infected with L-particles were infected with 10 
particles per cell and cells infected with UV-inactivated 
HSV-1 were infected with virus that had been lOpfu/cell 
before UV-inactivation. After 12 hours, pZl89 was harvested 
from the cells and assayed as before. The experiment was 
repeated and the combined results are shown in Table 10. The 
significance of the results, compared to those obtained with 
mock-infected cells, was calculated using the statistical 
analysis outlined in section B.2.28.
Mock-infection of 293 cells has no effect on the
mutagenesis of the supF marker gene in the pZl89 mutagenesis
assay at either 31°C or 39.5°C with the level of mutagenesis
obtained being the same as for uninfected cells.
Results for infection of the virus ts!204 also show that 
the procedure of infection does not produce the mutagenic
Table 10. Effect of infection with HSV-1, HSV-2 and various 
HSV-1 mutants and incomplete virions, under different 
conditions of infection, on the mutagenic rate of the supF 
gene in the pZl98 mutagenesis assay performed in 293 cells. 
The Table shows the pooled results from two experiments and 
lists the total number of colonies counted, the number of 
white (mutant) colonies and the % mutagenesis. The final 
column shows the increase in mutagenesis compared to 
mock-infected cells at 31°C.
EXPERIMENT 1 EXPERIMENT 2
Virus Conditions Colonies Whites Colonies Whites
of infect. counted counted
mock 31°C 2684 2 3142 1
39.5°C 3188 1 4140 2
HSV-1 31°C 1008 2 1384 5
39.5°C 1222 4 436 1
HSV-2 31°C 1874 6 934 3
39.5°C 1752 4 1368 5
tsK 31°C 984 2 431 2
39.5°C 1564 4 506 2
HSV-1/UV 31°C 996 2 846 3
tsl204 31°C 1228 4 1426 3
39.5°C 2456 1 4420 2
L-particles 31°C 2854 3 2910 2
HSV-1 Low moi 778 1 565 2
inl814 Low moi 1668 3 990 3
High moi 620 2 1628 4
dll4 03 Low moi 686 0 728 3
High moi 2014 5 764 3
Virus Conditions
of
infection
Colonies
counted
Whites Mutagenesis
(%)
Incre­
ase
mock 31°C 5826 3 0.05 -
mock 39.5°C 7328 3 0.04 0.8
HSV-1 31°C 2392 7 0.30 6.0
HSV-1 39.5°C 1658 5 0.30 6.0
HSV-2 31°C 2808 9 0.32 6.4
HSV-2 39.5°C 3120 9 0.29 5.8
tsK 31°C 1415 4 0.29 5.8
tsK 39.5°C 2070 6 0.29 5.8
UV- 31°C 1842 5 0.27 5.4
inactivated
tsl204 31°C 2654 7 0.27 5.4
tsl204 39.5°C 6676 3 0.05 1.0
L-particles 31°C 5764 5 0.09 1.8
HSV-1 low moi 1314 3 0.23 4.6
inl814 low moi 2658 6 0.20 4.0
in!814 high moi 2248 6 0.27 5.4
dll403 low moi 1414 3 0.21 4.2
dll403 high moi 2778 8 0.29 5.8
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effect seen in infected cells since at the NPT, when the 
virus does not enter the cell, the mutagenic frequency of 
the supF gene is the same as for mock-infected and 
uninfected cells at 0.05%. At the PT, when infection 
proceeds as normal, the mutation frequency is raised to 
0.27% which is significantly different from the value seen 
in mock-infected cells and is similar to the figure obtained 
on HSV-1 infection (see below).
Both HSV-1 and HSV-2 have the same effect on mutagenesis 
in infected 293 cells, increasing the mutagenic frequency of 
the supF gene to around 0.3% which is 6-fold higher and 
significantly different from the spontaneous mutation 
frequency of the plasmid in mock-infected cells. This is 
slightly lower than the increase in mutagenesis seen in 
cells infected with adenovirus type 5 (0.4%). The mutagenic 
effect seen with HSV-1 and HSV-2 is the same at 31°C and 
39.5°C. Infecting the cells with a low moi reduces the 
mutation frequency (to 0.23%) from that found in cells 
infected with a high moi (0.31%) although this was not found 
to be a significant reduction.
The HSV-1 mutant tsK was as mutagenic as wt HSV-1 virus 
at 31°C (PT) and at 39.5°C (NPT), significantly raising the 
mutation frequency from the level found in mock-infected 
cells to 0.29%. This indicates that expression of the genes 
VmwllO, Vmw68, Vmw63 and Vmwl2 is enough to cause the 
mutagenic effect.
The effect can be further characterized using the 
mutants d!1403 and in!814. At high moi, these viruses show a 
level of mutagenesis similar to that obtained with wt HSV-1 
(0.29 with d!1403 and 0.27% with inl814). At low moi, when 
these viruses exhibit their mutant phenotype, the mutation 
frequency is reduced from that seen at high moi (to 0.21% 
for d!1403 and 0.27% with _inl814) . The differences between 
the mutation frequencies seen in cells infected with a high 
or low moi of dll403 or in!814 are not significant and the 
reduction observed at low moi is similar to the reduction 
observed when the moi of HSV-1 is similarly lowered. Thus, 
when the lower moi has been taken into account these viruses 
seem to be equally mutagenic in 293 cells both at low and 
high moi.
The effect of UV-inactivated HSV-1 also appears to be
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similar to that observed with fully active virus, the 
mutagenic frequency of the supF gene in infected cells being 
0.27%, which is significantly different from the value 
obtained with mock-infected cells.
L-particles are not as mutagenic as wt HSV-1 and do not 
significantly increase the mutation frequency in infected 
cells (0.09%) from that found in mock-infected cells 
(0.05%). A slight increase is seen which may be caused by 
the small proportion of complete virions in the L-particle 
preparations.
3.4. The Effect of HSV DNA on Mutagenesis.
The results described above suggest that viral gene 
expression is not required for the mutagenic effect. The 
introduction of HSV DNA into cells might itself be 
mutagenic. This possibility was investigated by transfecting 
viral DNA into 293 cells alongside pZl89 and observing the 
mutation frequency of the supF mutagenesis marker gene.
Six, subconfluent 50mm tissue culture plates of 293 
cells were co-transfected with 5ug of HSV-1 DNA and 5ug of 
pZl89 plasmid DNA. Two, plates of cells were transfected 
with intact viral DNA, another 2 with BamHI-cleaved DNA and 
the remaining plates with Xbal-cleaved DNA. Two plates of 
293 cells were also transfected with pZl89 alone. The cells 
were incubated overnight at 37°C before the transfection 
mixture was removed and replaced with fresh growth medium. 
The cells were then incubated for a further 24 hours at 37°C 
before pZl89 was harvested from 1 plate of cells from each 
transfection, digested with Dpnl and used to transform 
MBM7070 bacteria. The resulting blue and white colonies were 
counted. The remaining cells were incubated at 37°C for a 
further 48 hours in order to establish whether or not the 
transfected DNA was infectious. The experiment was repeated 
and the combined results are shown in Table 11. The results 
were assessed for their significance using the statistical 
test described in section B.2.28.
HSV-1 DNA is mutagenic in transfected cells. Uncleaved 
HSV-1 DNA significantly increases the mutation frequency of 
the supF marker gene to 0.25% from the spontaneous mutation 
frequency of 0.0 6%.
Transfected Colonies Whites % Increase
DNA counted Mutagenesis
HSV-l+pZl89 3492 8 0.23 4.6
HSV-1(BamHI) 3032 8 0.26 5.2
+PZ189
HSV-1(Xbal) 2256 5 0.22 4.4
+PZ189
pZ189 5834 3 0.05
Table 11. Effect of transfection of intact HSV-1 DNA and 
HSV-1 DNA cleaved with BamHI (Bam) and Xbal (Xba) on the 
mutagenesis of the supF gene in the pZl89 mutagenesis assay. 
The Table shows the pooled results from two experiments and 
lists the total number of colonies counted, the number of 
white (mutant) colonies and the % mutagenesis. Also shown is 
the increase in mutagenesis shown by each transfection 
compared to the spontaneous mutation frequency of pzl89.
Transfected Infectious
DNA
HSV-1 +
HSV-1 (BamHI)
HSV-1 (Xbal)
Table 12. The effect of transfection of intact HSV-1 DNA and 
HSV-1 DNA cleaved with BamHI and Xbal on infection in FG 
cells. Extensive CPE after 48 hours is indicated by (+) and 
no CPE by (-).
This may be of significance since some oncogenes, including 
p53, contain such rearrangements and large alterations in 
transformed cells.
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HSV-1 DNA cleaved with BamHI or Xbal, similarly 
increases the mutation frequency to 0.28% and 0.23% 
respectively. These cleaved DNAs were not found to be 
infectious whereas the intact viral DNA produced extensive 
CPE after 48 hours (Table 12).
3.5. Determination of the Type of Mutations occurinq 
following HSV-1 Infection.
To establish the nature of the mutations induced by
{'5eic3rvi£neV_£'.
HSV-1 in the supF gene of pZl89, restriction enzyme digestsA
were performed on mutant plasmid DNA obtained in the pZl89 
mutagenesis assay.
Mutant (white) colonies arising in the assay were picked 
and retransformed into MBM7070 bacteria to check their 
phenotype. Overnight cultures were then set up. DNA was 
harvested from these using a large scale preparation method. 
The plasmid DNAs were then digested with the enzymes BamHI 
and Hindlll before being electrophoresed on an agarose gel. 
An example of such a gel is shown in Figure 28. The mutant 
plasmid DNAs were run alongside a wt plasmid that had been 
similarly digested, and DNA marker digests. The DNA marker 
digests used were pAT (digested with Hinfl) and lambda DNA 
(digested with EcoRI and Hindlll). This method of analysis 
allowed the detection of large structural changes and 
rearrangements in the plasmids. The results showed that 
roughly 30% (7 out of 20) of mutations occuring in pZl89 
following the use of HSV-1 in the pZl89 muagenesis assay 
were due to such changes which is somewhat lower than the 
figure of 56% that has been reported by Hwang and Shillitoe 
(1990). *
To determine the nature of the mutations in the supF 
gene of plasmids that did not show altered gel mobility, 
future work will include the sequencing of these DNAs. In an 
attempt to initiate this work an 8 50bp EcoRl/Bglll fragment 
containing the supF gene of wt pZ189 has been sequenced and 
found to be in agreement with the known sequence (M.
Seidman, personal communication).
3.6. Discussion III.
wt mutant
p Z 189 pZ189
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Figure 28. An agarose gel showing Bam Hl/Hind III digests of the 
plasmid pZ189 isolated from white (mutant) and blue (wt) colonies 
obtained in the pZ189 mutagenesis assay following HSV-1 infection.
The gel shows digested (D) and undigested (U) DNA from 3 mutant and 1 
wt plasmid. The tracks labelled M1 and M2 show the positions of DNA 
markers. The sizes of the predicted fragments from Bam Hl/Hind III 
digestion of wt pZ189 are marked (on the left), as are the sizes of the 
DNA markers (on the right).
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The experiments described in this section attempt to 
identify the mutagenic factor in HSV-infection. Both HSV-1 
and HSV-2 are equally mutagenic in cells, raising the 
spontaneous mutation frequency of the supF gene in the pZl89 
mutagenesis assay by around 6-fold, suggesting that the 
mechanism of action of both viruses is similar. Roughly 30% 
of these mutations involve large structural changes, the 
rest presumably being caused by small changes and point 
mutations. Preliminary results also suggest that adenovirus 
is mutagenic in the pZl89 mutagenesis assay. This mutagenic 
effect has been shown in previous studies using a different 
assay (Marengo et al., 1981; Paraskeva et al., 1975).
The timing of the mutagenic effect suggests that an IE 
or E protein may be involved and that viral replication is 
not required for the effect.
The virus tsK was mutagenic at the PT and at the NPT, 
when only the four IE genes VtnwllO, Vmw68, Vmw63 and Vtnwl2 
are expressed, indicating that expression of these genes is 
sufficient for mutagenesis. Further characterization of the 
mutagenic effect using the the mutants d!1403 and in!814 
revealed that neither VfttwllO expression or Vmw65 
transactivation was required for mutagenesis. Since Vmw65 
transactivates IE gene expression, the results suggest that 
no viral gene expression is required for the mutagenic 
effect. Results using UV-inactivated virus support this, as 
UV-inactivated virus, which does not express IE proteins 
(Dr. C. Preston, personal communication), is mutagenic.
Use of the virus ts!204, which fails to penetrate cells 
at the NPT, shows that penetration is required for 
mutagenesis and so the mutagenic effect appears to be part 
of the incoming virion, perhaps a structural component or 
the viral DNA itself. L-particles, which do not contain 
viral DNA or capsid proteins were found to be significantly 
less mutagenic than wt virus suggesting that the mutagenic 
effect may be caused by one of these components.
Both intact and cleaved, non-infectious HSV-1 DNA is 
capable of increasing the mutagenic frequency in transfected 
cells. This finding along with the observation that viral 
gene expression is not required raise the possibility that
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the viral DNA itself may be the mutagenic agent. The 
mechanism by which HSV DNA could induce mutations is 
discussed in section D.1.1. ^
No attempt has been made i this study to assess the 
effect of capsid proteins on mutagenesis and further work 
might include such studies.
It would also be useful to assay for mutagenesis after 
transfection with restriction fragments of the HSV genome in 
to try to localize the muatagenic effect.
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4. THE GENERATION OF TRANSGENIC MICE CONTAINING THE GENES
ENCODING RRl AND RR2.
The production of transgenic animals provides a further 
way to study the effect of the HSV-2 ribonucleotide 
reductase genes in eukaryotic cells. Transgenic animals 
provide a good system for the expression of exogenous genes 
since the introduced DNA is stably integrated into the host 
cell genome (Brinster et al., 1981; Constantini and Lacey, 
1981; Gordon and Ruddel, 1981) and as integration normally 
occurs at the one-cell stage (Constantini and Lacey, 1981) 
all the cells should contain copies of the microinjected 
sequence. Transgenic animals containing the genes encoding 
HSV-2 RRl and RR2 would also allow the effect of these genes 
to be assessed in an animal model system.
4.1. Generation of Transgenic Lines 47-8 and 58-1.
Eggs from two C57xCBA hybrid female mice (47 and 58) 
were microinjected with a KpnI/Hindlll fragment isolated 
from pCRR3. This fragment contains both the genes encoding 
the HSV-2 enzyme ribonucleotide reductase (Figure 29). The 
gene encoding RRl is under the control of the mouse MT-1 
promoter whereas the gene encoding RR2 is under the control 
of its own HSV-2 promoter.
4.1.1. Transgenic Line 47-8.
Microinjection of eggs from mouse 47 resulted in the 
production of 11 offspring. Three of these mice were found 
to contain the HSV-2 ribonucleotide reductase genes by 
preliminary sceening by Dr. P. F. Searle, however, only 1 
transferred the genes to the next generation. This female 
mouse was termed 47—8. Mouse 47—8 was mated with a C57xCBA 
hybrid male resulting in 8 offspring, 4 of which were 
positive for the RRl and RR2 genes. Unfortunately the 47-8 
transgenic mother died after giving birth and attempts to 
foster the offspring were only successful with 2 of the 
litter. The surviving 2 mice, one of which was positive for 
the presence of the viral reductase genes, were mated 
together producing offspring of which 1 in 2 were 
transgenic.
Scale
f t r t f p b
S K B  P p p B Ba
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MT-1 P
microinjected fragment
£taure.29. Diagram of the microinjected fragment containing the HSV-2 RR1 
and RR2 genes with RR1 being under the control of the MT-1 promoter ( fenl )
The restriction enzyme sites for Sstl (S), Kpnl (K), Bglll (B), Pstl (P), BamHI (Ba) 
and Hindlll (H) are marked.
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4.1.2. Transgenic Line 58-1.
Microinjection of eggs from mouse 58 resulted in the 
production of 3 offspring, 1 of which was positive for the 
HSV-2 ribonucleotide reductase genes. This positive male 
mouse was mated with a C57xCBA female and half the offspring 
from this mating were transgenic for the genes encoding RRl 
and RR2.
/frc»r>^ <-riP^lon
4.2. Detection of HSV-2 Ribonucleotide Reductase L . 
in Transgenic Lines 47-8 and 58-1.
IWo mice that had been found positive on preliminary 
screening for the presence of HSV-2 ribonucleotide reductase 
sequences (47-8.29 and 58-1.27) were subjected to an 
injection of zinc sulphate (0.1ml of a 3mM ZnSO^ 
solution/lOg of mouse) and were then left for a period of 6 
hours. This treatment should stimulate of the RRl
gene from the MT-1 promoter (Dr. P. Searle, personal 
communication). The mice were then sacrificed and the 
tissues were removed and homogenized in 4mls RNAzol. RNA was 
then prepared by the RNAzol method. Isolated RNA was treated 
with DNase in order to remove any contaminating DNA.
DNA was also prepared from tail, kidney and liver tissue 
in order to check that the mice were indeed positive for the 
viral genes and so that the integrity of the genes could be 
studied in more detail since only slot-blot analysis had 
been performed.
4.2.1. Detection of HSV-2 Ribonucleotide Reductase DNA in 
Transgenic Lines 47-8 and 58-1.
Three separate aliquots of lOug of DNA prepared from 
tail tissue of mice that had been identified as containing 
HSV-2 ribonucleotide reductase sequences (47-8.29 and 
58-1.27) were cut with 100 units of the restriction enzymes 
PstI, BamHI and Bglll/BamHI. The digests were incubated at 
37°C overnight. The DNA was then separated on a 0.7% agarose 
gel alongside BamHI-digested samples from a non-transgenic 
control mouse. Four aliquots of lOug of control tail tissue 
DNA were cut with BamHI and to these, unlabelled RR2-probe 
DNA was added after digestion so that a control sample
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Figure 30 . Detection of HSV-2 RR sequences in cellular DNA 
extracted from the tails of transgenic mice 58-137 and 47-829.
The tracks show 10ug of DNA digested with the restriction 
enzymes Pstl (P), BamHI (B) and BamHl/Bglll (B/Bg) and probed 
with DNA probes isolated from the RR1 and RR2 genes (Figure 12) 
The sizes of the relevant fragments (bp) are marked to the right of the 
gel and DNA size markers (kb) are marked to the left. The 4 left-most 
tracks show DNA from a control mouse digested with BamHI and
"spiked” with RR2 probe DNA equivalent to 0, 1,10 and 50 copies 
per cell.
5 9 6 5
3395
2070
A B C
Figure 31. Detection of HSV-2 RR1 sequences in DNA isolated 
from kidney (top), liver (middle) and tail (bottom) tissue from mice
58-1.27 and 47-829. Five ug of DNA was loaded onto the slot blot
apparatus and screened for the presence of RR1 sequences with a 
DNA probe (Figure 12). Column B contains 0.005ug of probe sequence 
DNA.
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contained probe DNA equivalent to 50, 10, 1 and 0 
copies/cell. A marker track containing lambda DNA digested 
with Hindlll was run alongside the experimental samples. 
After running the gel the DNA was transferred to a 
nitrocelullose membrane by the Southern blotting procedure. 
The resulting membrane was incubated with nick-translated 
DNA probes isolated from the RRl and RR2 genes (Figure 12) 
under hybridizing conditions. It was then washed, air-dried 
and autoradiographed (Figure 30).
The autoradiograph shows that DNA isolated from the mice 
58-1.27 and 47-8.29 and cleaved with BamHI gives a major 
band of around 6000bp. This band corresponds to the 
microinjected fragment (5965bp) containing the RRl and RR2 
genes. The appearance of a band representing the full size 
of the microinjected fragment suggests that the DNA has 
integrated in a head to tail configuration which is 
consistent with the results of other groups (Brinster et 
al., 1981; Constatini and Lacey, 1981).
Cutting the DNA with BamHI and Bglll should give 3 bands 
assuming that the DNA has integrated in a head-to-tail 
configuration, 1 band of 3395bp, 1 of 2070bp and 1 of 500bp. 
The 2 larger bands from this digest are present on the 
autoradiograph. The smaller band is not present and would 
have run off the bottom of this gel.
The gel shows 
that the PstI enzyme did not cut properly and so no 
conclusions can be drawn from the digest with this enzyme.
The gel also shows dilutions of probe DNA representing 
0, 1, 10 and 50 copies/cell allowing an estimation of the 
number of copies of the HSV-2 ribonucleotide reductase 
sequences present per cell in the transgenic mice. These 
genes appear to be present in a copy number of greater than 
50 copies per cell.
4.2.2. Are the HSV-2 Ribonucleotide Reductase Sequences 
Present in all the Mouse Tissues?
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To check that HSV-2 ribonucleotide reductase DNA was 
present in all the mouse tissues, 5ug of the DNA prepared 
from liver, kidney and tail was loaded onto a slot blot 
apparatus and screened for the presence of the RRl gene 
using a nick-translated DNA probe as before. The resulting 
membrane (Figure 31) shows that HSV-2 DNA appears to be 
present in all the tissues screened. This was to be expected 
since the microinjected DNA generally integrates at the 
one-cell stage (Constantini and Lacey, 1981) and so all the 
cells of the mouse would be expected to contain HSV-2 
ribonucleotide reductase sequences.
4.2.3. Detection of HSV-2 Ribonucleotide Reductase RNA in 
Transgenic Lines 47-8 and 58-1.
Five ug of RNA isolated from two mice that had been 
shown to contain HSV-2 ribonucleotide reductase DNA 
sequences (47-8.29 and 58-1.27, see above) and subjected to 
injections of zinc sulphate (0.1ml of a 3mM ZnSO^ 
solution/lOg of mouse), were bound to a nitrocellulose 
membrane using a slot blot apparatus. RNA isolated from a 
mouse that contained the HSV-2 sequences but which had not 
been subjected to zinc-induction (58-1.15) and RNA isolated 
from a mouse that had not been microinjected (control) was 
also bound to the nitrocellulose membrane. In all the mice, 
RNA was isolated from a number of tissues. In order to 
ensure that any hybridization was due to RNA and not to any 
contaminating DNA, 5ug of each isolated RNA was treated with 
RNase A before loading onto the slot blot kit. The membrane 
was hybridized overnight to a nick-translated DNA probe 
isolated from the HSV-2 RRl gene (Figure 12). It was then 
washed, air dried and autoradiographed (Figure 32). The 
experiment was repeated using a probe isolated from RR2 
(Figure 33).
The results for the expression of RRl RNA in the 
transgenic mice show that RRl RNA can be detected in all the 
tissues screened from mice that contain the HSV-2 
ribonucleotide reductase sequences. The amount of RRl RNA 
appears to be the same whether or not the animals are 
subjected to zinc-induction even though the RRl gene is 
under the control of the MT-1 promoter. No HSV-2 RRl RNA is 
detected in the mice that did not contain HSV-2 sequences.
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Figure 32. Detection of HSV-2 RR1 RNA in RNA isolated from the 
transgenic mice 58-1.27, 58-1.15 and 47-8.29. Mice 58-127 and 47-8.29 
were treated with zinc sulphate before the DNA was extracted 
whereas mouse 58-1.15 had not been similarly treated. Five ug 
of RNA isolated from the tissues indicated was loaded onto the slot 
blot apparatus (column A) and probed with a DNA probe (Figure 12)
RNA extracted from a control mouse is also shown. Column B shows 
identical samples treated with RNase before being loaded. Column C 
shows control mouse RNA "spiked" with 0.0025 and 0.005ug of probe DNA.
47-8.29
58-1.27
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kidney 
brain ■ 
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Fiaure33, Detection of HSV-2 RR2 RNA in RNA isolated from the 
transgenic mice 58-1.27, 58-1.15 and 47-8.29. Mice 58-1.27 and 
47-8.29 were treated with zinc sulphate before the RNA was extracted 
whereas mouse 58-1.15 had not been similarly treated. Five ug of RNA 
from the tissues indicated was loaded onto the slot blot apparatus 
(columns A and C) and probed with an RR2 DNA probe (figure 12). 
RNA from a control mouse is also shown The 2 unlabelled slots 
show control mouse RNA "spiked" with probe DNA.
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There was some variation in the amount of HSV RNA in the 
extracts loaded but this may be due to some form of 
differential expression or^isolation between tissues. RNA 
that was treated with RNase A before loading onto the slot 
blot apparatus did not hybridize to the RRl probe indicating 
that any hybridization occuring was due to RNA.
Similarly for RR2, RNA is apparent in all the tissues 
from mice which contain HSV-2 sequences. As expected, 
induction of the RR2 promoter with zinc does not have any 
effect on RNA levels. Again, no RR2 RNA is seen in cells 
that do not contain HSV-2 sequences.
4.2.4. The Presence of HSV-2 Ribonucleotide Reductase 
Proteins and Activity in Transgenic Lines 47-8 and 58-1
Liver, kidney, intestine and brains from 3 mice that had 
been shown to contain the HSV-2 ribonucleotide reductase 
sequences were homogenized in 1ml BM using a Wheaton 1ml 
Dounce tissue grinder. The mice were offspring of the 
transgenic mouse 58-1. One mouse (58-1.55), which was 
positive for ribonucleotide reductase DNA, had been 
subjected to zinc treatment for 8 hours before its tissues 
were removed, another mouse (58-1.3) which also contained 
these sequences had not been treated with zinc and the final 
mouse did not contain HSV-2 DNA.
The samples were boiled and stored at -70°C before 
separating the protein on a gel. The proteins were 
transferred to a nitrocellulose membrane using the Western 
blotting technique, incubated with antibodies directed 
against RRl (20208) and RR2 (14995) and visualized by the 
HRP method.
The resulting membrane did not show the presence of 
HSV-2 RRl or RR2 in any of the samples. Ribonucleotide 
reductase activity assays, performed on partially purified 
extracts from tissues, were also negative.
4.3. Discussion IV.
The results in this section describe the generation of 
two lines of transgenic mice, 47-8 and 58-1, which contain 
the genes encoding the HSV-2 proteins RRl and RR2. The HSV-2 
sequences are present at over 50 copies per cell and are
3* Many problems were encountered in the generation of 
transgenic mice. The litter sizes were smaller than normal 
and some of the offspring had developmental abnormalities.
It is possible that the HSV ribonucleotide reductase 
sequences are causing problems in the developing embryos 
and it may be that the mice that have survived the 
microinjection may have survived because the reductase genes 
were not being expressed.
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integrated in a head-to-tail array which is consistent with 
studies involving other microinjected sequences (Brinster et 
al. , 1981; Constantini and Lacey, 1981). The transgenic mice 
transmit the RRl and RR2 genes to their offspring in the 
expected ratio for a dominant gene, ie. one out of two 
offspring contains the HSV-2 sequences if one parent is 
transgenic. The DNA is contained in all tissues of the 
transgenic mice indicating that it integrated at the 
one-cell stage which is normal for microinjected sequences 
(Constantini and Lacey, 1981).
RNA is present in all the screened tissues in the 
transgenic mice. The amount of RNA present does not appear 
to be affected by induction with zinc even though the RRl 
gene is under the control of the MT-1 promoter. This may be 
because integration into the genome affects stimulation of 
the MT-1 promoter rendering it insensitive to induction by 
zinc.
Although RNA appears to be present in the mouse tissues 
no evidence of protein expression is apparent either by 
screening cell extracts with antibodies or by activity 
assays. This could be because the protein is not being made 
in enough quantity to be detected by these methods 
(detection of protein may not be as sensitive as detection 
of RNA) or that the protein is not being made at all due to 
some block in the translational process of the 
ribonucleotide reductase RNAs. This lack of protein 
expression in transgenic animals that express RNA has also 
been seen with papilloma virus sequences and it has been 
suggested that translation may not occur due to the lack of 
introns within the virus genes (Dr. p. Searle, personal 
communication). If protein is being expressed, be it in 
small amounts, this appears to have little effect on the 
mi ce. t.
Although there is some doubt about the expression of the 
RRl and RR2 proteins in the transgenic mice, the presence of 
HSV-2 ribonucleotide reductase DNA is not in dispute. This 
DNA contains the 486TF which has been shown to cause 
transformation of tissue culture cells (Jariwalla et al., 
1986) and the region encoding the N-terminal domain of RRl 
which may have protein kinase activity (Chung et al., 1989), 
neither of which appears to cause ill-effects in the mice.
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SECTION D: FINAL DISCUSSION.
1.1. The Mutagenic Effect of HSV-Infection.
Many tumour viruses can also act as mutagens. This has
»nric?l-o.lrlC3rv£>
been determined by studying the frequency of^the
cellular hgprt gene in both SV40- (Marshak et al., 1975) and 
adenovirus- (Marengo et al., 1981; Paraskeva et_al., 1983) 
infected cells. In addition, mutations in loci encoding 
glutamine and methionine synthesis and drug resistance have 
been reported after infection with SV40 (Marshak et al., 
1975? Thiele et al., 1976; Varshaver et al., 1977). The DNA 
viruses VZV (Aula, 1963), adenovirus type 12 (Stich et al., 
1964) and papillomavirus (Prunerias et al., 1974) have also 
been shown to induce chromosomal aberrations in infected 
cells.
HSV has been found to cause chromosomal breaks (Hampar 
and Ellison 1963? Stich et al., 1964), and amplification 
(Schlehofer et al., 1983) and rearrangement (Bejcek and 
Conley, 1986) of chromosomal DNA, as well as increasing the
mol-a!hon 5 if*
. j frequency of ^.cellular- and plasmid-based marker 
genes by around 2-10-fold (Schlehofer and zur Hausen, 1982; 
Pilon et al., 1985; Hwang and Shillitoe, 1990; section 
A.2.2.5.). Such mutagenic effects can all be produced by 
chemical carcinogens which lead to the proposal that many 
mutagens also function as carcinogens (McCann et al., 1975). 
HSV-2 may have a role in the development of cervical cancer
fe^ioAs
and certain " of both the HSV-1 and HSV-2 genomes can
transform tissue culture cells (section A.2.) thus the study 
of HSV mutagenesis is important, since it may reveal a 
mechanism of transformation.
The mechanism by which HSV causes cellular mutations is 
unknown, however, its occurence early in infection (Hwang 
and Shillitoe, 1990, section C.3.2.), implies that a 
structural component, or the expression of an IE or E 
protein may be involved. There is some evidence of a 
mutagenic peptide which is encoded within HSV-1 MTRI 
(Shillitoe et al., 1986, section A.2.2.5.), and which may 
have a counterpart in HSV-2 MTRII (Das and Shillitoe, 1990), 
however, further work is needed to determine the 
significance of this.
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E proteins, paticularly those involved in DNA 
metabolism, are also candidates for causing mutations in 
infected cells (section A.2.2.5.) and the work presented 
here studies the role of the HSV-2 enzyme ribonucleotide 
reductase in this process.
The HSV-2 enzyme ribonucleotide reductase was first linked 
with transformation after subfragments of the Hindlll a 
region, which spans the RRl and RR2 genes, were found to be 
transforming in tissue culture cells (section A.2.2.3.). 
Further work on t h i s o f  the genome, however, located 
two transforming regions, MTRII and MTRIII (section A
2.2.3.), neither of which is capable of encoding the entire 
enzyme. The minimal transforming regions of MTRII and MTRIII 
have now been shown to be two small regions of DNA which 
have the potential to form stem-loop structures and thus 
resemble insertion sequences. The first of these, 486TF 
(Jones et al., 1976), maps within UL39 (which encodes RRl, 
Nikas, 1989) and the second, 737TF (Galloway et al., 1984), 
maps downstream of UL40 (which encodes RR2, Preston V. G. et 
al., 1988). The fact that these two regions of DNA are 
transforming but are unable to encode the ribonucleotide 
reductase proteins suggests that transformation of tissue 
culture cells does not require enzyme activity. However, the 
possibility that another mechanism of transformation exists, 
involving HSV-2 ribonucleotide reductase activity, is still 
under discussion (Dr. R. J. Jariwalla, personal 
communication).
HSV-2 ribonucleotide reductase activity has the 
potential to cause mutations within cells since it does not 
appear to be subject to the tight allosteric control shown 
by its cellular counterpart (Averett et al., 1983, 1984) and 
may play a role in the destabilization of dNTP pools in 
HSV-infected cells (Jamieson and Bjursell, 1976). Such 
imbalances in dNTP pools have been shown to be mutagenic in 
both prokaryotic (Weymouth and Loeb, 1978; Fersht, 1979; 
Hibner and Alberts, 1980) and eukaryotic (Kunkel et al., 
1982) systems.
The initial experiments described in this thesis were 
designed to evaluate the role of the HSV-2 enzyme 
ribonucleotide reductase in the increased mutagenic 
frequency seen in infected cells. Plasmids expressing HSV-2
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RRl and RR2 under the control of the inducible MT-1 promoter 
were not found to significantly increase the r— *-
A*
: marker genes in the mutagenesis assays used (section 
C.2.). Results from the transfection experiments were 
consistently negative when the plasmids were transfected 
separately (when no activity would be expected) or together 
(when activity would be expected) under both non-induced and 
induced conditions.
Also presented, are results assessing the mutagenic 
frequency of a marker gene in cells infected with the HSV-1 
mutant viruses ts!207 (Preston V. G. et al., 1984) and 
ts!222 (Preston V. G. et al., 1988), which have
. lesions in RRl and RR2 respectively, and which do 
not express enzyme activity at the NPT. These viruses were 
found to be as mutagenic as wt HSV-1 at both the PT and the 
NPT (section C.2.4.).
These two sets of data imply that ribonucleotide 
reductase activity is not the cause of increased mutagenesis 
in HSV-infected cells.
In the transfection experiments referred to above, the 
highest mutation frequencies were obtained in induced cells 
that had been co-transfected with plasmids expressing RRl 
and RR2 in both the pZ189 and the aprt mutagenesis assays. 
These conditions would be expected to give the highest 
levels of enzyme activity. The lack of statistical 
significance of this result might be explained by the 
inefficiencies of the transfection procedure, the low level 
of induction from the MT-1 promoter and the presence in the 
transfected cell of an endogenous ribonucleotide reductase 
activity (section C.2.2.2.), and it may be that a greater 
level of expression may indeed have some effect on 
mutagenesis. Caras et al. (1988) showed that a plasmid 
expressing a mutant Ml subunit that was lacking in 
allosteric control conveyed a mutator phenotype when 
transfected into mammalian cells. In this case, however, 
cells were primarily selected for the stable expression of a 
second plasmid-based gene which would indicate the 
integration of the plasmid into the host cell DNA. These 
cells would be expected to give higher levels of expression 
than those obtained using a transient transfection 
procedure. In order to increase the amount of viral
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ribonucleotide reductase expression CHO D422 and NIH3T3 
cells were transfected with the plasmids pCNRRl and pCNRR2 
(section C.2.2.1.) which contained the G418-*resistance gene 
neoR. These cells were selected for resistance to G418 which 
would imply integration of the plasmid. The selected cells, 
did not show increased mutagenesis, however, they were later 
found not to express the viral ribonucleotide reductase 
proteins and more lines will now be tested before the 
experiments are repeated.
The possibility still remains that HSV ribonucleotide
o(r m u M i o f i 5
reductase activity might raise the , frequency in
transfected cells although it does not appear to be required 
to induce the mutator phenotype seen in HSV-infected cells, 
since the viruses tsl207 and tsl222, which do not express 
this enzyme at the NPT, are mutagenic (section C.2.4.).
It is interesting to see that cells transfected with 
sequences encoding RRl which encompass both the 48 6TF (Jones 
et al., 1986; section A.2.2.3.) and the region encoding the 
putative kinase activity (Chung et al., 1989), do not show 
an increase in > and transgenic mice containing
these sequences do not show any ill-effects. These regions 
have been implicated as having a role in transformation. The 
486bp fragment contains a number of repetetive DNA elements 
which have been implicated in homologous recombination, 
destabilization of chromatin structure and promoter/enhancer 
function (Jones et al., 1986, section A.2.2.3.). It can also 
act as a promoter for the bacterial CAT gene and it was 
suggested that the 486TF might act to alter the expression 
of cellular genes by insertion of cis-acting regulatory 
elements into the cellular genome (Jones, 1989) . 
Transformation caused by other DNA viruses often appears to 
involve interaction with cellular oncogenes and 
anti-oncogenes (section A.2.1.) and two cellular genes, p53 
and c-H-ras, were subsequently found to be differentially 
expressed in cells transformedp Jb^ e the 486TF DNA fragment 
(Jones et al., 1989). It is ; that their increase in
expression was due to some effect of insertion and/or 
enhancement by the 486TF. The fact that this sequence does 
not appear to cause mutagenesis is similar to the results 
obtained by Brandt et al. (1987) who showed that the 7 37bp 
transforming region (Galloway et al., 1984, section
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A. 2.2.3.) was not mutagenic in transfected cells. These 
transforming fragments have the potential to form putative 
stem-loop structures, thus resembling insertion sequences, 
and may be capable of insertion into the cellular genome 
(Galloway et al., 1984). Such integration may not, however, 
occur in a random manner, in which case the increase in
rooWiHopS
frequency of^marker genes would be no indication 
of integration of the fragment at a specific site elsewhere 
in the genome.
The evidence that the 486bp and the 737bp transforming 
DNA fragments are similar to insertion sequences is slim, 
only involving the fact that they have the potential to form 
stem-loop structures and the possibility that they can 
integrate into the cellular genome in a similar manner to 
these DNA elements. There is no evidence that they are 
mobile or that they encode a transposing function, which is 
the normal requirement for such DNA elements. It is possible 
that the transposing function may be supplied by other 
regions of the HSV or cellular genome, but there is no 
evidence for this.
Since ribonucleotide reductase activity appears not to 
be the mutagenic factor in HSV-infected cells, experiments 
were performed to determine the nature of this effect. The 
mutagenic effect was found to occur early in infection
(section C.3.2.) in agreement with the results of Hwang and
Shillitoe (1990), and experiments using a range of mutant 
viruses (tsK, ijil814 and dll403) suggested that no virus 
gene expression was required (section C.3.3.). This 
observation is consistent with the finding that 
UV-inactivated HSV is also mutagenic (Hwang and Shillitoe, 
1990; Schlehofer and zur Hausen, 1982? section C.3.3.).
Increased mutagenesis does, however, appear to require 
virus penetration since 1isl204 is not mutagenic at the NPT 
when it does not enter cells (section C.3.3.). Infection 
with HSV-1 L-particles, which do not contain viral DNA or 
capsid proteins (Dr. F. Rixon , personal communication,
section C.3.3.), are also not mutagenic implying that the
mutagenic agent is caused by one of these factors (section 
C.3.3.). The observation that both intact, and 
non-infectious, cleaved DNA was found to be mutagenic in 
transfected cells suggests that it may be HSV DNA that is
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the mutagenic agent (section C.3.4.). Experiments using HSV 
capsid proteins to try to increase cellular mutagenesis were 
not performed and it would be worthwhile to try this in 
future studies.
HSV DNA could cause mutations in host cell DNA by the 
integration of small regions of DNA into the cellular genome 
which may disrupt the integrity of cellular genes. Small DNA 
fragments might easily go undetected using the Southern 
blotting analysis of Cameron et al. (1985) who was unable to 
find stably integrated sequences in the genome of 
transformed cells. Such DNA fragments might also contain 
promoter/enhancer elements which could affect the expression 
of cellular genes. Studies by Pilon et al. (1986) and Hwang 
and Shillitoe (1990), however, suggest that the majority of 
mutations in the hgprt gene within HSV-2 infected cells are 
due to point mutations rather than integration of viral DNA 
sequences. The same effect is also apparent with adenovirus 
type 2-induced mutagenesis (Raphs et al., 1982). These 
observations point to a mechanism of mutagenesis seemingly 
independent of the integration of specific viral sequences 
and may explain why many viruses appear to be mutagenic.
An alternative mutational mechanism might involve the 
induction of cellular DNA repair. Several investigators have 
debated whether HSV has single stranded nicks or gaps in its 
DNA (Kieff et al., 1971; Wilkie, 1973; Gordin et al., 1973, 
Hirsch and Vonka 1974) which could act as sites of DNA 
repair. Kolber (1975) observed repair replication of viral 
DNA in an in vitro system containing nuclei isolated from 
HSV-2 infected human cells, Hyman et al. (1977) described 
the in vitro repair of isolated HSV-1 DNA and Nishiyama and 
Rapp (1981) found that native DNA which accumulated in 
infected cells was repairable without requiring incision 
implying that it did contain nicks or gaps and was thus 
capable of inducing cellular DNA repair. Some repair 
synthesis of cellular DNA has also been detected in HSV-2 
infected human cells under conditions restrictive for viral 
DNA replication (Kucera and Edwards, 1979). This appeared to 
occur early in infection (Nishiyama and Rapp, 1981) and by 
14 hours post-infection cells suffer extensive strand 
breaking. These results are consistent with those of Hwang 
and Shillitoe (1990) who showed that HSV infection produced
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mainly point mutations early in infection but that larger 
mutations, including insertions and deletions, were seen at 
later times. Most types of repairable DNA damage is both 
mutagenic and carcinogenic (Hanawalt et al., 1979) and hence 
the mutagenic effect of HSV DNA could act to promote 
transformation of cells giving rise to alterations that 
eventually result in tumour development.
1.2. The Involvement of HSV and HPV in Cervical Cancer.
A variety of clinical observations and epidemiological 
studies have suggested that several factors and/or sexually 
transmitted infections could play a role in the development 
of cervical cancer (Kessler, 1986) . In particular, the 
viruses, HSV-2 and HPV (types 16 and 18) have been 
associated with this neoplasm.
Many studies have shown that regions of the HSV-2 genome 
can immortalize primary rat cells and transform immortalized 
cells in culture (section A.2.2.3.) and in vitro studies 
have also indicated that HPV may promote immortalization of 
primary cell cultues (Pirisi et al., 1987) or neoplastic
A
transformation of already initiated cells (Yasomoto et al., 
1986). Additionally, as described earlier (section
A.2.2.1.), HPV16 and HPV18 have been detected in a high 
proportion of cervical cancer biopsies (Durst et al., 1983; 
Schull et al., 1985; Macnab et al., 1986; Murdoch et al., 
1988) and in the majority of these cases HPV DNA is 
integrated into the cell genome (Schneider-Gadicke and 
Schwarz, 1986). Integration appears to involve different 
regions of the genome but the E6 and E7 ORFs never seem to 
be disrupted (Lehn et al., 1988). The viral E6 and E7 
proteins are selectively retained and expressed in cervical 
cancer derived cell lines (Androphy et al., 1987; Banks et 
al., 1987) and transformation of primary rodent epithelial 
cells requires a functional E7 gene (Phelps et al., 1988; 
Story et al., 1988, 1990; Crook et al., 1988). The E7 gene 
has also been shown to interact with pRB (section A.2.2.I.). 
Thus, HPV seems to transform cells in a similar manner to 
other DNA tumour viruses (section A.2.1.) in that its DNA is 
integrated into the genome and there is evidence for a 
transforming protein. In the case of HSV-2, although the
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Bgllln fragment has been detected in a small proportion 
(10%) of tumours (Galloway and McDougall, 1983, Park et al., 
1983; Macnab et al., 1985b, 1986; Prakesh et al., 1985; Di 
Luca et al., 1989), there is no evidence of a transforming 
protein. In one study (Di Luca et al., 1989), HSV-2 RRl was 
detected in around 50% of cervical carcinoma tissues but 
this protein has not been shown to be required to cause any 
form of transformation and was used mainly as a marker for 
the presence of BamHI e sequences since protein detection 
appeared to be more sensitive than DNA detection.
The fact that HPV sequences are present in a high 
proportion of cervical cancer biopsies and the evidence of a 
transforming protein makes this virus a likely candidate for 
cervical cell transformation, however, the high prevalence 
(around 50%) of HPV sequences in normal cervical tissue 
(Tidy et al., 1988) suggests that other factors must be 
involved. The observation that HPV specific RNA is only
e p
detected m  a proportion of the ne’ lastic tissues
A
containing HPV DNA agrees with this suggestion and lead Lehn 
et al. (1988) to postulate that HPV may only induce 
neoplastic transformation by synergistic interaction with 
other carcinogens including radiation, cigarette smoking and 
other oncogenic viruses.
The proposal that HPV-infection works as a promoter of 
cervical carcinogenesis and that among the initiating 
factors herpes simplex virus plays a key role was also 
suggested by zur Hausen (1982). Evidence that this could 
indeed be the case was obtained by Iwasaka et al. (1988). 
They showed that HPV-16 or HPV-18 DNA transfected into 
Syrian hamster embryo cells produced morphologically 
transformed foci but that these were not tumorigenic in nude 
mice whereas transfection of AE cells (obtained by 
transfection of the immortalizing sequences of HSV-2 DNA), 
however, produced morphologically transformed foci that were 
tumorigenic. Additionally, examination of cervical carcinoma 
tissues for both HPV and HSV DNA revealed that all the 
genital neoplasias that contained HSV-2 BamHIe or Bgllln 
sequences (around 15%) were also positive for HPV DNA (Di 
Luca et al., 1987, 1989). In the later study no HSV or HPV 
DNA could be detected in healthy tissue which is 
contradictory to results from previous studies (Tidy et al.,
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1988). The idea of one virus augmenting the transforming 
capacities of another has been shown in vitro for HCMV which 
enhances bovine papilloma virus transformation (Goldstein et 
al., 1987) and may increase HPV gene expression and 
transformation efficiency (Kowalik et al.f 1990). It is thus 
quite plausible that HSV has a similar effect on HPV. HSV-1 
TIF and ICPO have also been shown to activate HPV 18 gene 
expression implying that the action of enhancement may not 
be limited to one factor, for example a DNA sequence, but 
may take effect from a variety of virus functions including 
gene expression.
In the majority of neoplastic tissue studied the various 
parameters considered as risk factors for cervical carcinoma 
have been examined independently. More recently, however, Di 
Luca et al., (1989) showed the simultaneous presence of two 
such risk factors (HSV-2 BamHI e and HPV DNA) which supports 
the proposal of Lehn et al. (1988, see above) accounting for 
the fact that a large proportion of people whose cervical 
biopsies contain HPV DNA do not have cancer. It seems likely 
that a number of initiating factors might function to 
enhance the transforming potential of HPV. These factors, 
which have also been tentatively linked with cervical 
cancer, include smoking (Trevathan et al., 1984) and oral 
contraceptive use (Vessey et al., 1983), as well as 
infection by other viruses including HSV. The effect of HSV 
on the enhancement of HPV-transformation may not be limited 
to one factor. HSV TIF and ICPO activate HPV gene expression 
and the BamHI e fragment also appears to have a role in 
HPV-transformation (Di Luca et al., 1989). BamHI e has 
itself been linked to the morphological transformation of 
immortalized tissue culture cells (Jariwalla et al., 1986), 
and its possible involvement in HPV-transformation agrees 
with the proposal of Lehn et al. (1988) who suggested that 
the synergistic action of two carcinogens was required for 
the transformation of cervical cells. If this is the case a 
potential role in HPV transformation for the mutagenic 
potential of HSV must also be considered since, as 
previously discussed (section D.I.), many mutagens also act 
as carcinogens (McCann et al., 1975).
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